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ABSTRACT 
Many loci coding for xenobiotic metabolising enzymes, especially those involved in carcinogen 
metabolism, confer susceptibility to various types of cancers. These genes have been poorly 
investigated in sub-Saharan African populations, where the genetic variation that exists is 
relatively unknown. The primary objectives of the study are to determine the frequency 
variation among 15 loci in sub-Saharan Africans, the level of genetic diversity, and the genetic 
affinities among sub-Saharan Africans. Secondary, the study aims to evaluate the implication of 
these variants in disease susceptibility, especially cancer. 
 
The study population comprised of 1880 unrelated individuals from 18 sub-Saharan African 
populations.  DNA samples were used to examine genetic variation for phase I metabolism 
genes CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP2E1, and phase II metabolism genes GSTM1, 
GSTT1, GSTP1 and NAT2. A single base extension (SBE) method was designed and used to 
genotype single nucleotide polymorphisms (SNP): CYP1A1*2A and *2C; CYP1A2*1C and *1F; 
CYP2A6*7 and *8; CYP2D6*3A (2549delA) and CYP2D6*4(1846G>A); CYP2E1*5B(PstI) and 
CYP2E1*5B(RsaI); GSTP1*Ile105Val and *Ala114Val; and NAT2*14A. To investigate the 
presence of null mutations GSTM1*0 and GSTT1*0 a previously reported multiplex PCR method 
was used. The distribution of mutations in the sample was interpreted and compared with data 
from literature respectively. 
 
Mutations CYP1A1*2A, CYP1A2*1C, CYP1A2*1F, CYP2A6*7, CYP2D6*4 and GSTP1*Ile105Val 
mutations was found in most sub-Saharan Africans, while CYP1A1*2C, CYP2A6*8, CYP2D6*3A 
and GSTP1*Ala114Val mutations were almost non-existent. Both GSTM1*0 and GSTT1*0 
mutations were present in all populations, with GSTT1*0 most frequent. The distribution of 
NAT2*14A confirms previous reports of its exclusive existence in Africans. Hardy-Weinberg 
Equilibrium (HWE) and Tajima’s D statistic tests showed none of the mutations were under 
selection. The genetic affinities of sub-Saharans were analysed. Bantu-speakers were closely 
related with little correlation to their geographic locations. Khoisan-speakers were closely 
related, genetically most distinct and oldest among populations. Pygmies were similarly distinct 
from most populations and one of the oldest surviving populations. The data further supports 
previous reports that the Khwe are descendants of an east African pastoralist group. AMOVA 
analyses revealed language as a major confounder among sub-Saharans. Haplotypes were 
inferred to determine their distribution and to understand their significance in populations with 
respect to their functional relevance.  
iii 
 
 The study has confirmed previous reports of genetic histories of these sub-Saharan African 
populations. In unravelling the distribution of these mutations, the study has added to the 
global picture of these mutations. In doing so, the data may add value to the design of future 
cancer studies and pharmacological studies. The study also highlights the importance of 
elucidating ancestral relations of populations, more specifically linguistic and anthropological 
relationships, and to include in the design of future clinical trials in Africa. 
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CHAPTER 1   INTRODUCTION 
 
Understanding the genetic variability of global populations has been the focus of 
numerous population and evolutionary genetic studies (Cavalli-Sfroza et al., 1994; 
Jorde et al., 1998; Lambert and Tishkoff, 2009; Campbell and Tishkoff 2010; 
Schlebusch et al., 2012). Cavalli-Sfroza et al. (1994) used classical polymorphisms to 
understand variation among global populations. Recent research have unravelled 
the genetic variation that exists on the maternally inherited mitochondrial DNA 
(mtDNA), the paternally inherited non-recombining region of the Y sex-chromosome 
(NRY) and autosomal DNA (Jenkins, 1986; Tishkoff et al., 2007; Behar et al., 2008; 
Naidoo et al., 2010; Schlebusch, 2010a; Schlebusch et al., 2012; Badro et al., 2013; 
Montano et al., 2013). These findings contributed to widely recognised and 
consolidated history of human evolution.  Modern humans evolved about 200,000 
years ago and have lived the longest in Africa. Human migration took place across 
North-East Africa through the Arabian Peninsula and beyond into Asia, Europe and 
finally the Americas. The dispersion of modern humans outside Africa occurred over 
different time periods spanning 80,000 to 15,000 years ago (Campbell and Tishkoff 
2010). This resulted in modern humans emerging today with novel genetic and 
phenotypic adaptations where the genetic variation found outside Africa is a subset 
thereof that exists in African populations. The evolution of humans resulted in large 
global demographic variation, where contemporary populations vary in thousands of 
different languages, ethnicities and cultures (Campbell and Tishkoff 2010). 
 
The demographic history of Africans has been shaped by many fluctuations in 
population size, migration events, admixture and extensive population structure. 
This process would have occurred in contrasting environments where Africans lived 
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in tropical rainforests, swamps, savannas, deserts and mountain highlands. In 
adapting to these niches, African populations have developed a variety of 
subsistence methods in hunter-gatherer, agriculture and pastoral lifestyles. Evolving 
and adapting in Africa for the longest time compared to other global populations, 
Africans display the greatest genetic and phenotypic variability (Campbell and 
Tishkoff 2010). 
  
The global distribution of genetic variants thus could differ from being frequently 
present in some populations to low or absent in others.  This phenomenon could in 
part explain the relative differences in disease susceptibility of cancers globally 
(Parkin, 2004; Soerjomataram et al., 2012; Jemal et al., 2012; Chokunonga et al., 
2013), and the variable incidence rates between continents (Parkin, 2004; Ferlay et 
al., 2010; Soerjomataram et al., 2012; Jemal et al., 2012).  During his work from 1859 
to 1864, August Hirsch noticed this global trend and coined the term “geographic 
pathology” (Beck, 1961). These aspects illustrate the need to identify genetic 
variability within and between populations in elucidating the role of genetic factors 
in diseases. 
 
Genetic variation is present between individuals in a population and between 
populations. The variation is created primarily by mutations due to changes in the 
genetic code at a single nucleotide position (called single nucleotide polymorphism – 
SNP), in short tandem repeats, and in recombination where unequal transfer of 
genetic material can result in insertion deletion mutations (indels) of large sections 
of DNA code or duplication of regions. These mutations could result in altered 
function of genes or non-function of genes or have no effect at all. The prevalence of 
these mutations is the result of successful sexual transmission of the mutation from 
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one generation to the next. Genetic variation can be created further by influences of 
natural selection, population migration events and genetic drift or a combination of 
these factors.   
 
The section that follows describes the histories of populations investigated in the 
study, with an understanding of how populations have been and are classified using 
linguistics, archaeology, anthropology and genetics.  
 
1.1 The sub-Saharan African population history 
 
Scholars have often reported the ethnicity of Africans to correlate with the language 
they speak, which inevitably correlates to the culture followed (Nurse et al., 1985; 
Cavalli-Sfroza et al., 1994; Ehret, 2000; Crawhall, 2006). Language is an expression of 
human culture where it is a medium to communicate with one another. In the past 
aspects of life events, new ideas, changes in technology and climate would have 
resulted in the generation of new words. In time new languages or dialects would 
have evolved as populations grew and ventured into different regions. By tracing 
these changes and identifying similarities in words used by contemporary 
populations, linguists have been able to trace the history of African languages. The 
words used would allow one to highlight aspects of your ‘being’, your heritage, your 
culture; and by this had become an identifier of your ethnicity (Ehret, 2000; 
Crawhall, 2006). For this reason the languages spoken by Africans cannot be treated 
as a discrete entities or countable units that are confined to discrete boundaries like 
the political structures that have been created overtime in defining countries (Ehret, 
2000). 
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Geneticists and archaeologist have used their science to trace the histories of 
humans and the variation that exist among different populations. Similar to linguists, 
archeologists use relics of populations to understand the nature of their cultures and 
examine relations among populations to identify possible relations. Geneticists use 
DNA to trace genetic anitquities that would have been passed on from one 
generation to the next to understand historically the relatedness of populations to 
one another (Ehret, 2000; Crawhall, 2006). Cavalli-Sfroza et al. (1994) describes how 
by mapping the languages of the world and their genetic variation a pattern of the 
dispersal of Man globally can be established. Overtime populations would have 
ventured from a central point leaving behind the parent population and thereby 
creating groups speaking a different language and having acquired a slightly 
different genetic make-up. This theory assumes that people tend to associate more 
with people of their own kind, who speak the same language; and thereby would be 
more attracted to a mate speaking the same/similar language, following the 
same/similar culture and living in the a close proximity. By this populations would 
retain genetic traits acquired overtime since the birth of that population. This theory 
is consistant for most African populations.  
 
In contrast, certain African populations have recently been influenced by the influx 
of populations from other regions within and outside Africa. The unions of the 
indigenous and the migrant groups have resulted in offspring speaking either one of 
the parental languages or a combination of both, and now having a combination of 
genetic traces to these parental populations. In Africa, such interactions have usually 
been unidirectional where the migrant populations have been dominant in asserting 
its language and culture (Nurse et al., 1985; Güldemann and Stoneking, 2008; Henn 
et al., 2011). By assimilation some African populations acquired new language, 
different technology, new methods of subsistence and culture. They have lost their 
13 | P a g e  
 
ancient cultures and languages, and some are now extinct (Nurse et al., 1985; 
Güldemann and Stoneking, 2008; Schlebusch, 2010a).   
 
There are four main language groups or phyla in Africa, namely Khoisan-speakers, 
Niger-Congo, Nilo-Saharan and Afroasiatic (Heine and Nurse, 2000).  Populations in 
the study speak languages that are found in the Khoisan and Niger-Congo phyla. The 
sections that follow describe the history of populations used in the study. 
 
1.1.1 South Africa 
1.1.1.1. Indigenous South African populations 
One of the greatest known acts of human dispersal can be found in the migrations of 
Bantu-speaking people from the grasslands of Cameroon-Nigeria around 4,000 years 
ago to southern Africa about 1,500 years ago (Nurse et al., 1985). There were 
massive movements of farmers who followed agriculture and the pastoral lifestyles; 
some had the ability to fish. The movement was first across the equatorial rain 
forest into East Africa, and thereafter movement to the south across areas of 
Zambia, Zimbabwe, Tanzania, Mozambique and Botswana. People that settled in 
areas of South Africa, Mozambique, Zimbabwe, Zambia and Tanzania were part of 
the eastern stream of the “Bantu Expansion” (Guthrie, 1948; Vansina, 1984; Nurse 
et al., 1985; Soodyall and Jenkins, 1993; Salas et al., 2002). These migrations led to 
the demic diffusion and formation of several Bantu dialects. Due to the similarities in 
culture and language these people have been collectively called Southeastern 
Bantu-speakers. It must be noted that the use of ‘Bantu’ here is not intended to be 
derogatory, but to refer to groups of people who speak Bantu or Bantoid languages, 
a branch of the Niger-Congo language family. 
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In the south, Bantu-speakers came into contact with the click-speaking Khoe-San 
people and assimilated some of the click synonyms into their language (Nurse et al., 
1985; Barnard, 1992). While the click synonyms were from Khoe-San to Bantu, 
population genetic studies using mitochondrial DNA and the non-recombining 
section of the Y-chromosome have revealed gene flow had occurred predominantly 
between Khoisan-speaking females and Bantu-speaking males (Soodyall et al., 2008; 
Schlebusch, 2010a; Naidoo et al., 2010).  
 
Khoisan-speakers represent aboriginal populations of southern Africa, having lived in 
southern Africa prior to the Bantu Expansion. In the past these populations were 
collectively called ‘Khoisan’, where San groups were called ‘Bushmen’. Recent 
discussions with these groups have highlighted their distaste at the use of Khoisan 
and Bushmen, where San groups prefer to be called by their self-proclaimed 
community names Ju|’hoansi, ‡Khomani, !Xun, etc. (Crawhall, 2006; Schlebusch, 
2010b). The more appropriate terminology to use when referring to these 
populations is to use ‘Khoisan’ when referring collectively to the languages they 
speak; and ethnically to refer to them collectively as ‘Khoe-San’ (Crawhall, 2006; 
Güldemann and Stoneking, 2008; Schlebusch, 2010b). The latter refers to the 
grouping of the hunter-gatherer San populations with the pastoralist Khoe 
populations (Crawhall, 2006; Schlebusch, 2010b). This nomenclature is used here to 
refer to these populations collectively, and individually will be referred to as Khoe 
and San. Some language groups in the Khoisan phyla are thought to be extinct. From 
historic records and current data linguists have identified three major language 
families, namely Ju (Northern Khoe-San), Khoe (Central Khoe-San) and !Ui-Taa 
(Southern Khoe-San) (Güldemann et al., 2002).   
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1.1.1.1.1. Southeastern Bantu-speakers of South Africa 
Southeastern Bantu-speakers of South Africa comprise of Xhoza, Zulu, Sotho, 
Tswana, Pedi and Venda speakers, predominantly collected in and around the 
Gauteng Province. 
 
1.1.1.1.2. !Xun 
The !Xun, previously known as Sekele (Vasekele), are another group of San who 
speak a dialect related to the Ju linguistic family (Crawhall, 2006; Güldemann and 
Stoneking, 2008). They lived in southern Angola and northern Namibia, following 
hunter-gatherer liefstyles. With the migration of Bantu-speakers into these regions, 
they learned subsistence techniques in agriculture, livestock farming and fishing 
from their neighbouring Bantu-speaking agricultural and pastoralist (Barnard, 1992). 
During the war between Angola and South-West Africa (today Namibia, then under 
the ruling of South Africa) from 1966-1989 many of the !Xun people were relocated 
to a camp called Omega Base close to the border between Namibia and Angola. 
After the war, many moved to South Africa in the Schmidtsdrift region. During these 
periods samples were collected at both locations at these different time periods, 
where careful attention was taken not to duplicate samples collected from 
individuals that had contributed to the Omega Base sample. 
 
1.1.1.1.3. Khwe 
The Khwe, previously known as the “Black Bushmen” or Kwengo (Nurse et al., 1985) 
were another group sampled from the Omega Camp and Schmidtsdrift, similar to 
that described for the !Xun.  Originally they resided in southern Angola and northern 
Botswana. They are San who speak Kxoe, a Central Khoisan language (Güldemann et 
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al., 2002; Güldemann and Stoneking, 2008). They resemble their Bantu-speaking 
neighbours in physical appearance, though culturally and linguistically are more 
closely related to their San counterparts (Nurse et al., 1985). Genetically, using the 
paternally inherited Y-chromosome and the maternally inherited mitochondrial DNA 
there appears to more genetic similarity between the Khwe and southern Bantu-
speakers than their San neighbours (Soodyall et al., 2008; Schlebusch, 2010a), a 
result similar to that found using serogenetic markers (Nurse et al., 1985). In the 
past these genetic similarities were thought to be due to genetic admixture between 
the Khwe and neighbouring Bantu-speakers. More recently though, the presence of 
a specific E-M35 Y-chromosome haplotype has led to conclusions that the Khwe 
might be descendants of an east African pastoralist group (Henn et al., 2008; 
Schlebusch, 2010a; Schlebuch et al., 2012). They were responsible for introducing 
pastoral lifestyle into present day northern Botswana. This region is infested by 
tsetse flies making livestock rearing impossible, and thereby it is possible they 
adopted the fishing and hunter-gatherer lifestyles of neighbouring San populations. 
 
1.1.1.2. Sea-borne immigrants of South Africa 
1.1.1.2.1. South African Indian 
The history of Indians’ arrival in South Africa occurred from the number of 
migrations from north-eastern, southern and western parts of India.  The indentured 
immigrants and the Passenger Indians were two main groups of Indian immigrants 
that arrived in South Africa between the late 19th Century and first half of the 20th 
Century (Bhanaand Brain, 1990). Indentured Indians predominantly were from the 
north eastern and southern parts of India and spoke Hindi and Tamil or Telugu 
languages, respectively (Bhana and Brain, 1990). ‘Passenger Indians’ arrived towards 
the end of the indentured system.  Many settled further inland in parts of South 
Africa, and were primarily from the western Indian origin and spoke the Gujarati 
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language.  The South African Indian group in this study is a collection from 
Johannesburg and Durban, South Africa. 
 
1.1.1.2.2. South African White 
The South African White sample consists of immigrants who arrived in South Africa 
since the colonial periods from 1652 (Nurse et al., 1985). Many of these individuals 
have ancestral links to the Dutch, French, German and English populations of 
Europe. South African Whites today contain African derivatives of the mtDNA 
lineages indicative of an African maternal ancestor in their recent family history due 
to some admixture with Khoisan-speaking and Bantu-speaking women (Nurse et al., 
1985; Schlebusch, 2010a). 
 
1.1.1.3. South African Coloureds 
The term ‘Coloured’ is in this study is used to identify a group of admixed South 
Africans. Since the arrival of Europeans to South Africa unions between 
predominantly European men and Khoisan-speaking or Bantu-speaking women 
resulted in this admixed population. Later the arrival of Malaysian slaves via 
Malagasay to the Cape resulted in another admixed group called the Cape Malays 
(Nurse et al., 1985; Schlebusch, 2010a). These groups are collectively referred to as 
South African Coloured. The term “Coloured” maybe considered derogatory and it 
should be noted that the term is used here not with that intended purpose. The 
Coloured group in the study were collected in the Gauteng province of South Africa 
and could have had a greater level of genetic input from Bantu-speaking populations 
than those found in the Western Cape of South Africa. 
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1.1.2 Botswana 
1.1.2.1. Juǀ’hoansi 
The Juǀ’hoansi live in the regions northeast of Namibia and North in Botswana. They 
predominantly follow hunter-gather lifestyles and speak a language derived from 
the Ju linguistic family, also known as Northern Khoisan languages (Nurse et al., 
1985; Barnard, 1992; Güldemann et al., 2002; Crawhall, 2006; Güldemann and 
Stoneking, 2008). Linguists have long studied the Juǀ’hoansi establishing them as one 
of the most ancient populations known globally (Nurse et al., 1985; Barnard, 1992; 
Güldemann et al., 2002; Crawhall, 2006; Güldemann and Stoneking, 2008). Further 
affirmation of this fact can be found in genetic studies. By studying the mtDNA, Y-
chromosome and autosomal DNA of this population, geneticists have established 
that the Juǀ’hoansi have the oldest rooted DNA variants that can be found in human 
DNA tree (Knight et al., 2003; Soodyall et al., 2008; Schlebusch, 2010a, Naidoo et al., 
2010; Schuster et al., 2010; Henn et al., 2011). 
 
1.1.3 Mozambique 
1.1.3.1. Southeastern Bantu-speakers of Mozambique 
Bantu-speakers of Mozambique share a similar history as that to South African 
Bantu-speakers mentioned earlier. Their settlement in Mozambique was the result 
of the eastern movement of the Bantu Expansion, where they too would have come 
into contact with the Khoe-San populations living in this region. DNA studies have 
shown that Mozambican Bantu-speakers share genetic relics consistent with that 
found in other Niger-Congo populations; and had acquired mtDNA lineages 
commonly found in Khoe-San women indicative of the unidirectional assimilation of 
Khoe-San women into their populations (Pereira et al., 2002; Salas et al., 2002). The 
southeastern Bantu-speaker sample of Mozambique consists mainly of people 
speaking Chopi, Ronga, Shangaan and Tonga dialects. 
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1.1.4 Namibia 
1.1.4.1.   Nama 
The Nama were sampled from southern Namibia bordering South Africa, within the 
great Namakwaland area. These Khoe-speakers, also known as Northern Khoekhoe, 
are grouped into the larger group of Central Khoisan-speakers (Barnard, 1992; 
Güldemann et al., 2002; Crawhall, 2006; Güldemann and Stoneking, 2008). 
Historically, the Nama were nomads who followed a pastoral lifestyle. Influences 
introduced recently after the settlement of Bantu-speakers and Europeans into their 
territory have led to the disintegration of their traditional subsistence lifestyles 
(Barnard, 1992). Genetic data of mtDNA lineages found in the Nama indicate that 
they share mtDNA variants similar to that found in Bantu-speaking populations. In 
contrast, the paternal Y-Chromosome data indicate a closer relationship to 
neighbouring San populations (Knight et al., 2003; Wood et al., 2005; Schlebusch, 
2010a). This is consistent with the history of this population where Bantu-speaking 
women had become part of Nama populations, converse to San populations where 
San women had been assimilated into neighbouring Bantu-speaking populations 
(Güldemann and Stoneking, 2008) 
 
1.1.4.2. Dama 
The Dama are a neighbouring group to the Nama and were collected in the same 
region as the Nama. They are an enigmatic group who physically resemble Bantu-
speakers, but speak the Nama language. Genetic and serology data have showed 
greater similarities to Bantu-speakers than their Nama neighbours (Nurse et al., 
1985; Soodyall and Jenkins, 1993; Soodyall et al., 2008; Schlebusch, 2010a). 
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1.1.4.3. Southwestern Bantu-speakers  
During the great Bantu Expansion there was a second group who migrated west into 
southern Africa. There remains some debate on the route used to arrive at present 
day Angola and Namibia. It is postulated a few groups would have migrated along 
with other Bantu-speakers from East Africa to Zambia and thereafter would have 
split to move into the southwestern parts of Africa. Another theory is of a more 
direct route taken by southwestern Bantu-speakers along the west coast from the 
Cameroon-Nigeria regions (Guthrie, 1948; Vansina, 1984; Nurse et al., 1985; 
Soodyall and Jenkins, 1993; Salas et al., 2002). Southwestern Bantu-speakers in this 
study were collected in the north of Namibia and south of Angola and comprise of 
Himba, Herero and Ovambo groups.  
 
1.1.5 Zambia 
1.1.5.1. Zambian Bantu-speakers 
All samples in Zambia were collected in the capital city, Lusaka. The group consists of 
Nyanja, Lozi, Bemba and Tonga speakers, where all language groups can be found in 
the Niger-Congo, Narrow Bantu-speaking, central family. Zambians Bantu-speakers 
like those speaking languages found in the Botatwe sub-group in the upper Zambezi 
Valley in southwestern parts of Zambia have been shown to contain mtDNA genetic 
lineages found in Khoe-San populations (Barbieri et al., 2013). The Tonga though 
have been shown to be genetically distant from the Botatwe speakers (Barbieri et 
al., 2013). Barkhan (2004) examined the mtDNAs and Y-chromosomes contained in 
the Lusaka sample and showed almost no DNA evidence of maternal and paternal 
ancestries from Khoe-San populations in this sample. This study further confirmed 
similarities of the maternal and paternal ancestries of the Lusaka sample to Bantu-
speaking populations of west and central Africa. 
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1.1.6 Uganda 
1.1.6.1. Ugandan Bantu-speakers 
The samples from Uganda were collected from the districts of Kissoro, Kabale and 
Rukungiri. The group consists mainly of Bakiga, Bafumbira, Banyakole and Bahororo 
ethnic groups, who speak dialects classified within the Niger-Congo, Narrow Bantu-
speaking, central family. Barkhan (2004) examined the mtDNAs and Y-chromosomes 
contained in the Ugandan sample and confirmed the maternal and paternal 
ancestries common to those of Bantu-speaking populations of west and central 
Africa. 
 
1.1.7 Democratic Republic of Congo 
1.1.7.1. Democratic Republic of Congo Bantu-speakers 
The samples from the Democratic Republic of Congo (DRC) were collected from 
individuals residing in Luozi and Kinshasha. The group consists mainly of the 
Manyanga ethnic group, who speak a dialect classified within the Niger-Congo, 
Narrow Bantu-speaking, central family. Barkhan (2004) examined the mtDNAs and 
Y-chromosomes contained in the Luozi and Kinshasha sample and confirmed the 
maternal and paternal ancestries common to Bantu-speaking populations of west 
and central Africa.  
 
1.1.8 Central African Republic 
1.1.8.1. Central African Republic Pygmies 
This sample of Pygmies were collected from Bangui, Central African Republic (CAR), 
which consists of BiAka and Babenzele (also known as Mbenzele) Pygmies who 
belong to the Aka subgroup (Cavalli-Sfroza, 1986).  These two groups were shown to 
be genetically similar (Coia et al., 2004) and therefore were pooled into one group, 
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collectively called Pygmies. The Pygmies are historically a hunter-gatherer 
population who live in the equatorial rain forest of central and central-west Africa, 
but have since assimilated the lifestyle and language of their neighbouring farming 
communities. They have lost their original language and now speak Bantu languages 
(Grimes, 2001), yet have retained morphological features common in these 
individuals. The BiAka populations have been shown to contain some of the oldest 
DNA lineages, similar to that found in San populations, indicative of these groups 
being the oldest surving populations today (Coia et al., 2004; Sun et al., 2009; Patin 
et al., 2009). Pygmy means ‘fist’ in Greek and have been called such due to their 
short stature (Cavalli-Sfroza, 1986). The term has been considered derogatory by 
some and we stress our use of this name is not with this purpose, but to collectively 
note the biological features of a group of people who have remained (until recently) 
relatively isolated.  
 
1.1.8.2. Central African Republic Ubangian-speakers 
These are a group of people who were collected from the same area in the CAR like 
their Pygmy neighbours. They speak a Niger-Congo language called Adamawa-
Ubangian, which is unrelated to the African predominant Bantu languages. 
Adamawa-Ubangian languages have been known to have been dispersed mainly the 
Northern parts of the equator extending from north-west Nigeria through 
Cameroon, parts of southern Chad, CAR, northern Gabon, Congo and the 
Democratic Republic of Congo (Vansina, 1984; Williamson and Bench, 2000). Most 
individuals in this sample had self-proclaimed to follow the Sangha Sangha, Gbaya 
and Nzakara ethnicities. These Ubangian-speakers followed mainly agricultural and 
pastoral lifestyles. 
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1.2 Genetic studies in human diseases 
 
In the last three decades there have been considerable improvements in 
understanding the molecular genetics of diseases that could be attributed to single 
gene mutations that follows Mendelian modes of inheritance.  Recent research has 
focused on unravelling the nature of complex human diseases (Pharoah et al., 2004; 
Su et al., 2013). Complex or multi-factorial diseases, such as cancer, results from the 
combined effects of many genetic and environmental interactions (Pharoah et al., 
2004; Forsberg et al., 2013; Fransen et al., 2013).  While familial, twin and linkage 
studies have aided in mapping candidate gene mutations that are linked to cancers, 
these studies have been limited in identifying risk factors that are associated with 
cancers. Most cancers do not follow major trends of familial inheritance patterns; 
consequently linkage studies have produced inconsistent findings (Parkin, 2004; 
Fransen et al., 2013). 
 
To overcome these problems in predicting risk for cancer, association studies using 
the candidate gene approach to complex diseases have proved valuable in 
identifying the genetic link with large to moderate effects (Furberg and Ambrosone, 
2001; Futreal et al., 2004; Forsberg et al., 2013; Su et al., 2013). Association studies 
make use of genotype frequency in affected individuals (cases), compared with data 
from unaffected individuals (controls); and where differences are significant, the 
locus in question could relate to varying degrees of genetic susceptibility (Futreal et 
al., 2004; Forsberg et al., 2013; Su et al., 2013). Identifying these biomarkers has 
become the focus of many association studies, in elucidating the molecular 
pathology of cancers (Fransen et al., 2013; Su et al., 2013). By identifying the 
mechanisms of cancer development and risk factors for developing cancer, it is 
hoped that the managment of cancer would be enhanced (Furberg and Ambrosone, 
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2001; Parkin, 2004; Ferlay et al., 2010; Soerjomataram et al., 2012; Jemal et al., 
2012; Chokunonga et al., 2013).  
 
The section below highlights the burden cancer presents in Africa and describes the 
type of cancers prevalent in Africa. Given the variability among Africans and that the 
underlying cause of cancer in Africans is not well known, and there is a need to 
investigate contributing factors more intensley.  
 
1.3 Cancer epidemic in Africa 
 
Historically much focus has been given to communicable diseases affecting African 
populations. While there is growing concern about the burden of cancer in African 
populations, cancer remains a low public health priority in many African countries. 
This is mainly due to limited resources and larger emphasis on the prevention and 
cure of communicable diseases such as acquired immunodeficiency syndrome 
(AIDS)/human immunodeficiency virus (HIV) infection, malaria, and tuberculosis  
(Dalal et al., 2011; Chokunonga et al., 2013). It is possible that the magnitude of the 
disease is not known to policy makers, the general public and other public health 
agencies. There are very few cancer registries throughout Africa and limited 
regionally, rather than nationally (Jemal et al., 2012; Chokunonga et al., 2013). To 
date there are three comprehensive registries which have been active in access of 
twenty years, namely the South African National Cancer Registry, National Health 
Laboratory Service; the Zimbabwean National Cancer Register and Ugandan cancer 
registry (Chokunonga et al., 2013). Figure 1 is an account of the cancer registry 
information available used in GLOBOCAN 2008, where the many red and orange 
highlighted countries illustrates the lack  of cancer registers, with few countries 
having comprehensive active registries established. 
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Figure 1 Methods of incidence data estimation for GLOBOCAN 2008 
 
While GLOBOCAN 2008 had limited information from African countries (Figure 1), 
the study reported ~715,000 cancer cases with ~542,000 deaths (excludes non-
melonoma skin cancer) in 2008 (Ferlay et al., 2010). It is important to note these 
statistics include between ~71,000 to ~83,000 cases presenting with Kaposi’s 
sarcoma (Ferlay et al., 2010), where the incidence is driven by the African HIV 
epidemic (Dalal et al., 2011). Kaposi’s sarcoma along with other common African 
cancers such as lung, oesophageal, oral, breast, cervical, prostate and liver cancers, 
is projected to increase from the ~715,000 cases observed in 2008 to ~1.3 million 
cases in the year 2030 (Ferlay et al., 2010; Dalal et al., 2011). The implementation of 
HIV prevention programs and the increased availability of anti-retroviral treatment 
Jemal et al., Cancer. 2012;118(18):4372-84
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have reduced HIV infection rates, and it is likely that continued progress in reducing 
HIV incidence would result in lower incidence rates of Kaporsi’s sarcoma 
(Chokunonga et al., 2013).  
 
The GLOBOCAN 2008 survey further reported cancer as being the major contributor 
to 7.6 million deaths (Ferlay et al., 2010; Soerjomataram et al., 2012). With 
population growth and longer lifespans the projected incidence of cancer cases will 
increase from 12.7 million in 2008 to 21.4 million worldwide (Soerjomataram et al., 
2012). The increase will be greatest in low to middle-income countries comprising 
76% of the postulated future cases (Soerjomataram et al., 2012). Soerjomataram et 
al. (2012) used data collated in 2008 by GLOBOCAN (Ferlay et al., 2010) to calculate 
the cancer burden worldwide. The study used disability-adjusted life-years (DALYs), 
which is a measure of overall disease burden, expressed as the number of years lost 
due to ill-health, disability or early death. Figure 2 is an illustration of the DALYs 
calculated for cancer in 2008 worldwide, where the five major cancers that 
contribute largely to the sub-Saharan Africa DALY’s are liver, breast, cervical, Non-
Hodgkin lymphoma and the human immunodeficiency virus (HIV) related Karposi’s 
sarcoma (Soerjomataram et al., 2012).  
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Figure 2 Age-adjusted DALY’s of cancer in 2008 worldwide 
 
Similar to global trends, the growth of the African population from 2010 to 2030 is 
projected to increase by 50% from 1.03 billion to 1.52 billion, so to is cancer burden 
projected to increase (Jemal et al., 2012; Chokunonga et al., 2013). There are several 
reasons for the projected increase in cancer. These include change in economic 
structure, relocations and change in lifestyles. Many African countries have low to 
middle-income economies and have growing urban lifestyles paralleled with 
ecomomic growth. Populations in these developing countries are relocating to urban 
settlements, where they are exposed to lifestyle changes such as diet, physical 
activity, smoking, adiposity, and alcohol use; and reproductive factors like earlier 
menarche, delayed childbearing and low fertility (Ferlay et al., 2010; Somdyala et al., 
2010; Wentink et al., 2010; Parkin et al., 2010; Dalal et al., 2011; Jemal et al., 2012; 
Chokunonga et al., 2013). This shift to more Western lifestyles has been implicated 
in the increased burden cancer presents in African. Due to the growing concern 
Soerjomataram et al., Lancet. 2012;380(9856):1840-50
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some African countrys’ health programs have focused on determining the burden of 
cancer that exist in their constituencies with the aim of identifying associated risk 
factors (Ferlay et al., 2010; Somdyala et al., 2010; Wentink et al., 2010; Parkin et al., 
2010; Dalal et al., 2011; Chokunonga et al., 2013). 
 
Figure 3 shows the most common cancers by gender and country in Africa (Jemal et 
al., 2012). According to GLOBOCAN 2008 statistics breast cancer is most common 
(92,600 cases) among women in Africa and the second highest cause of cancer 
related deaths in women (50,000 deaths in 2008). Breast cancer in Africa is most 
common in sub-Saharan African countries, a shift from previous reports where 
cervical cancer was implicated. This was proposed to be due to the different 
reproductive factors indicated before (Ferlay et al., 2010; Jemal et al., 2012). 
Cervical cancer is reported to be the second most diagnosed cancer in women with 
80,400 cases and 50,300 deaths. Cervical cancer rates appear to be highly prevalent 
in East Africa with 50 cased per 100,000 (Ferlay et al., 2010). Similarly, these trends 
have been reported in South Africa, where in 2006 breast cancer incidence was 
reported to be 29.29 per 100,000 women per year (National Cancer Registry, 
National Health Laboratory Service, 2006). This followed by cervical cancer at an 
incidence rate of 24.72 per 100,000 women per year and Basal-cell carcinoma at an 
incidence rate of 19.20 per 100,000 women per year (National Cancer Registry, 
National Health Laboratory Service, 2006). 
 
Lung cancer is the leading cause of deaths in southern African men where it affects 
twice as many men as women. This has been attributed to the greater influences of 
tobacco consumption in southern Africa, with 65% of lung cancer cases in South 
Africa related to smoking (Jemal et al., 2012).  
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Figure 3 Most common cancer sites in Africa by sex and country are shown, GLOBOCAN 2008 
Jemal et al., Cancer. 2012;118(18):4372-84
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Liver cancer is the second highest reported in men (34,600 cases) and third in 
women (16,900 cases). In 2008 33,800 men and 16,600 women died due to liver 
cancers. The incidence of liver cancer is compounded by the comorbidity of hepatitis 
B virus infections in sub-Saharan Africa and hepatitis C virus infections in North 
Africa, accounting for 90% of the cases (Ferlay et al., 2010).  
 
In 2008, an estimated 37,200 cases and 30,900 deaths related to non-Hodgkin 
lymphoma cancers were reported (Ferlay et al., 2010). Nasopharyngeal cancer cases 
were estimated to be 8700 with 5500 deaths. The highest incidence rates of 
nasopharyngeal cancer were reported in South Africa and few North African 
countries (Ferlay et al., 2010). Esophageal cancer accounted for 27,900 new cases 
and 26,600 deaths (Ferlay et al., 2010). Squamous cell carcinomas were the 
predominant cases reported in the esophageal cancer bracket, largely affecting men 
and women of East Africa and men of South Africa. The incidence of bladder cancer 
was twice as high in North African men compared to southern African men, where 
Egyptian men having the highest incidence rates worldwide (Ferlay et al., 2010). 
Prostate cancer is the most common among men with 39,500 cases reported in 
2008, and 28,000 deaths. Prostate cancer is most commonly diagnosed among men 
of southern Africa and western Africa (Ferlay et al., 2010). 
 
1.4   Interaction of metabolic genes in cancer progression 
 
Association studies for cancers have utilised genetic variants within metabolism 
genes that are involved in the detoxification of exogenous substances. Such studies 
within sub-Saharan African populations have been limited, where studies have 
either focused on one or a few mutations and/or a few populations (Dandara et al., 
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2001; Dandara et al., 2002; Loktionov et al., 2002; Hamdy et al., 2003a; Dandara et 
al., 2003; Casson et al., 2003; Dietzsch et al., 2003; Dandara et al., 2004; Zaahl et al., 
2005; Li et al., 2005; Dandara et al., 2006; Li et al., 2008; Fujihara et al., 2009; 
Piacentini et al., 2011). This study takes a more comprehensive look using a 
population genetics approach to understand the genetic variation that exists for 15 
loci present in nine different genes within eighteen sub-Saharan African populations. 
These loci or mutations were selected as they have previously been reported to 
confer some genetic susceptibility to cancers globally and are primarily involved in 
metabolising carcinogens in two phases, namely phase I and phase II.  
 
Phase I enzymes primarily metabolise carcinogens or other exogenous agents into 
different reactive states by processes of oxidation, hydrolysis or reduction. Phase II 
enzymes then detoxify these reactive intermediates by catalytic conjugation into 
water soluble products and enables excretion from the body (Furberg and 
Ambrosone, 2001). The interaction of these genes are crucial to the maintenance of 
cell integrity and the normal process of cell proliferation, where if defaulted, could 
result in the formation of DNA adducts and cancer progression (Futreal et al., 2004).  
Figure 4 describes the possible route course from carcinogen exposure to the 
development of cancer and the interaction of phase I and II enzymes. Further 
downstream DNA repair genes (not studied here) serve as another defence 
mechanism, where failure in function can contribute to cancer development.  
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Figure 4 Pathway from carcinogen exposure to cancer development 
 
1.5 Drug metabolising enzymes (DME) 
 
The function of phase I and II genes and others in their superfamilies have been used 
in pharmacogenetic studies to understand the genetic variability that exists in global 
populations and partly account for the variable responses to drug treatments 
(Nebert, 1997; Roses, 2000; Sheweita, 2000; Peamkrasatam et al., 2006; Al-Dayel et 
al., 2008; Wu et al., 1998; Chaterjee et al., 2010; Brown et al., 2012; Roco et al., 
2012). For many years it has been observed that patients react differently to drug 
treatment, where the effects of drug treatment either have no effect or are variable 
in response (Coutts, 1994; Nebert, 1997; Roses, 2000; Sheweita, 2000; Al-Dayel et 
al., 2008; Wu et al., 1998; Chaterjee et al., 2010; Roco et al., 2012). Not only are 
there inter-population differences, there are differences in drug metabolism 
between individuals. Further there is variation in drug reactivity when drugs are 
used in combination. The underlying reasons for this variability is relatively unknown 
and has become the driver to many pharmacological studies (Wu et al., 1998; 
Chaterjee et al., 2010; Brown et al., 2012; Roco et al., 2012). While there are several 
dosage, physiological and environmental factors (Roses, 2000; Sheweita, 2000), it is 
Furberg et al., Trends in Molecular Medicine. 2001, 7(11):518
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postulated that drug treatment variability could be gravitated in the genetic 
variability in DMEs (Roses, 2000).  Understanding the genetic role could lend to a 
greater understanding of drug metabolism and dosage curves for different 
populations, and enable more effective drug regiments to curb various ailments. The 
genes investigated in this study have various DME properties where the findings of 
their genetic variability could add to the knowledge of drug treatment in sub-
Saharan Africa. The section that follows describes genes with DME properties that 
are investigated in this study, and are those previously reported to confer 
susceptibility to certain cancers. 
  
1.6 Genes under investigation 
 
For the investigation of phase I metabolisers Cytochrome P450 (CYP) superfamily 
genes have been selected. Genes from the Glutathione-S-transferases (GST’s) 
superfamily and the N-acetylation 2 class gene (NAT2) that were selected, are 
grouped along in the phase II metabolising gene group. 
 
1.6.1 Phase I genes 
Cytochrome P450 (CYP) genes are a group of phase I metabolisers that play an 
important role in the activation of various pro-carcinogens by oxidation, which often 
results in the formation of highly active intermediates.  Genes chosen from this 
superfamily are CYP1A1, CYP1A2, CYP2D6, CYP2A6 and CYP2E1.  
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1.6.1.1 CYP1A1 gene 
CYP1A1 gene is expressed mainly in extra-hepatic tissue including the lung, where 
the gene codes for a well conserved enzyme that is highly activated in the 
metabolism of polycyclic aromatic hydrocarbons (e.g. Benzo[a]prene, main 
carcinogen in cigarette smoke and air pollution). For this reason, polymorphisms 
CYP1A1*2A (rs4646903) and CYP1A1*2C (rs1048943) have been commonly 
associated with increased risk to lung cancer; and oesophageal, oral and liver 
cancers (Wu et al., 1998; Olshan et al., 2000; Dandara et al., 2002; Ingelman-
Sundberg et al., 2008; Santovito et al., 2010; Xia et al., 2013; Roco et al., 2012; Islam 
et al., 2013; Lopez-Cima et al., 2012; Souiden et al., 2012).  There is increasing 
evidence for the association of these mutations with the deficient genotypes of the 
GST genes (discussed later in this chapter) and p53 tumour suppressor mutations to 
lung, oesophagus, and head and neck cancers (Thier et al., 2003; Xia et al., 2013). 
The two mutations have been widely studied, in particular many European and Asian 
populations (Islam et al., 2013; Lopez-Cima et al., 2012; Souiden et al., 2012).  
 
CYP1A1*2A has been predominantly found in Japanese, Korean and Chinese 
populations, to lower prevalence in Caucasoid populations. In Africa, the mutation 
has been discovered in northern and western African populations to varying degrees 
where frequencies increase from North to West Africa (Okobia et al., 2005; 
Martinez-Labarga et al., 2007; Souiden et al., 2012). CYP1A1*2A is found at similar 
high frequencies in African-Americans as that found in West Africa (Olshan et al., 
2000). Many studies have reported the mutation as a risk factor for lung cancer in 
Japanese and Caucasian populations, for colon cancer in Japanese populations, and 
to some degree for breast cancer in African-American populations (Wang et al., 
2003; Kiruthiga et al., 2011; Xia et al., 2013; Yoshida et al., 2007; Islam et al., 2013; 
Souiden et al., 2012). The CYP1A1*2C mutation similarly has been found in high 
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frequencies in far-East Asian populations with lower frequencies in European and 
Indian populations. The mutation is near absent in southern African populations 
(Masimirembwa et al., 1998; Dandara et al., 2002) and relatively understudied 
throughout Africa. 
 
1.6.1.2 CYP1A2 gene 
CYP1A2 encodes for an enzyme that activates several compounds including 
carcinogenic arylamines, acetaminophen, caffeine and a number of widely 
prescribed antipsychotic drugs such as clozapine, imipramine, caffeine, paracetamol, 
phenacetin, theophylline, and tacrine (Wooding et al., 2002; Fujihara et al., 2007). It 
has been found to be highly expressed in the liver and lesser degree in the lung 
(Nakajima et al., 1999; B'chir et al., 2009).  More than 200 polymorphisms exists in 
CYP1A2 gene, however only thirteen have been found to regulate enzyme function 
(Ingelman-Sundberg et al., 2008; Wang et al., 2012).  
 
For this study two polymorphisms CYP1A2*1C (rs2069514) and CYP1A2*1F 
(rs762551) were chosen. These mutations have been for many years associated with 
lung cancer, breast cancer, colorectal cancer and stomach cancer mainly in 
Europeans (Nakajima et al., 1999; Sachse et al., 1999; Hamdy et al., 2003b; Yoshida 
et al., 2007; B'chir et al., 2009; Wang et al., 2012). However, recently a meta-analysis 
of such studies has not been able to corroborate these associations to cancers (Deng 
et al., 2013). Transcripts of CYP1A2*1C usually have low enzyme activity and for 
CYP1A2*1F displays increased enzyme activity (Nakajima et al., 1999). These 
mutations have been primarily studied in European and Asian populations.  More 
studies have been conducted on CYP1A2*1F compared to CYP1A2*1C due to its 
discovery much earlier (Deng et al., 2013). CYP1A2*1C is most prevalent in Asian and 
36 | P a g e  
 
North African populations to near absence in Caucasoid populations of Europe and 
India (Hamdy et al., 2003b; Landi et al., 2005; Yoshida et al., 2007; Gemignani et al., 
2007; B'chir et al., 2009; Singh et al., 2010). The mutation is present in Caucasian 
Americans and African-Americans, albeit at low frequencies (Rebbeck et al., 2007). 
CYP1A2*1F has been found in all populations studied globally at frequencies ranging 
from 40-70% in some populations to low proportions of 20-30% in some European 
populations (Han et al., 2001; Hamdy et al. 2003b; Cornelis et al., 2004; Soyama et 
al., 2005; Torres et al., 2005; Landi et al., 2005; Ketelslegers et al., 2006; Yoshida et 
al., 2007; Gemignani et al., 2007; Rebbeck et al., 2007; Fujihara et al., 2007; Saebø et 
al., 2008; B'chir et al., 2009; Sangrajrang et al., 2009; Anderson et al., 2012). The 
mutation is found at frequencies of 40-60% in South Africa and Zimbabwe (Dandara 
et al. 2004; Dandara et al., 2011). 
 
1.6.1.3 CYP2A6 gene 
CYP2A6 is a major metabolic enzyme of nicotine.  Nicotine is metabolized to cotinine 
by CYP2A6, and cotinine is further metabolized to trans-3’-hydroxycotinine, where 
there is a variable relationship between CYP2A6 gene polymorphisms and inter-
individual differences in nicotine metabolism (Oscarson et al., 1998; Pianezza et al., 
1998; Nurfadhlina et al., 2006). For this study, polymorphisms CYP2A6*7 
(rs5031016) and CYP2A6*8 (rs28399468) were chosen, where CYP2A6*7 decreases 
enzyme activity reducing nicotine metabolism. CYP2A6*8 effect has been noted to 
have no functional effect and is found to be in linkage disequilibrium with CYP2A6*7 
where the combined effect decreases enzyme activity reducing nicotine metabolism 
(Yoshida et al., 2002; Nakajima et al., 2006; Ingelman-Sundberg et al., 2008; 
Djordjevic et al., 2012). The reduced nicotine metabolism diminishes nicotine 
dependency and in advertently could reduce risk to lung and oesophageal cancers 
(Pianezza et al., 1998; Yoshida et al., 2002; Nakajima et al., 2006; Han et al., 2012). 
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However, this had been refuted by other studies where no association between 
CYP2A6 gene variants and reduced smoking was found (London et al., 1999; Chen et 
al., 1999; Tan et al., 2001). CYP2A6 has further been associated with the metabolism 
N-nitrosodiethylamine and aflatoxin B1 (Fernandez-Salguero et al., 1995), and of 
pharmaceutical agents such as coumarin (+)-cis-3,5-dimethyl-2-(3-pyridl)thiazolidin-
4-one hydrochloride, methoxyflurane, halothane, losigamone, letrozole, valoproic 
acid, disulfiram,  and fadrozole (Oscarson et al., 1998; Peamkrasatam et al., 2006; 
Uno et al., 2013; Han et al., 2012).  
 
Both mutations have been primarily studied in far-East Asian populations and rarely 
studied in other global populations (Nurfadhlina et al., 2006). Both mutations can be 
found in proportions less than 10% in China, Korea, and Japan, with much lower 
frequencies in India, Thailand and Malaysia (Nurfadhlina et al., 2006; Peamkrasatam 
et al., 2006; Xu et al., 2002; Djordjevic et al., 2012). From the few studies conducted 
in Europe, West Africa and North America, these mutations appear to be absent 
(Gyamfi et al., 2005; Xu et al., 2002; Djordjevic et al., 2012). 
 
1.6.1.4 CYP2D6 gene 
The CYP2D6 gene is involved in the detoxification of the tobacco-specific 
nitrosamine 4-(methylnitrosamino)-1-butanone (Krajinovic et al., 1999), and the 
metabolism of many drugs such as antiarhythmics, antihypertensives, 4-blockers, 
monoamine oxidase inhibitors, morphine derivatives, antipsychotics and tricyclic 
antidepressants (Linder et al., 1997; Coutts and Urichuk, 1999; Ingelman-Sundberg 
et al., 1999; Bradford, 2002; Lammers et al., 2010).  There are about 150 
polymorphisms present on the CYP2D6 gene. However, only a few have been 
commonly investigated due to them rendering altered enzyme function (Bradford., 
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2002). For this study CYP2D6*3 (1-bp deletion in position 2637, rs35742686) and 
CYP2D6*4 (G to A transition at position 1934, rs3892097) were chosen as they both 
have poor-metabolising properties (Sachse et al., 1997; Ingelman-Sundberg et al., 
2008; Silveira et al., 2010). These genes also alter the risk to lung, bladder, 
gastrointestinal tract, skin cervical, breast and head and neck cancers (Krajinovic et 
al., 1999; Bradford, 2002; Ouerhani et al., 2008; Lammers et al., 2010; Skretkowicz 
et al., 2011; van der Merwe et al., 2012).  
 
CYP2D6*3 has primarily been studied in Caucasoid populations of Europe and North 
America where it is found in proportions under 10% (Smith et al., 1992; Sachse et al., 
1997; Leathart et al., 1998; Krajinovic et al., 1999; Gawronska-Szklarz et al., 1999; 
Hersberger et al., 2000; Menoyo et al., 2006; Arvanitidis et al., 2007; Buzkova et al., 
2008; Correia et al., 2009; Vangsted et al., 2010; Skrętkowicz et al., 2011). The 
mutation is absent in Asia (Chida et al., 1999; Ji et al., 2002; Naveen et al., 2006; 
Nurfadhlina et al., 2006; Kiyohara et al., 2012), while evident in minute proportions 
in Africa and South America (Griese et al., 1999; Jorge et al., 1999; Dandara et al., 
2001; Lavendera et al., 2006; Roco et al., 2012). 
 
CYP2D6*4 has been more extensively studied globally where the mutation is found 
to be highly prevalent in European populations and other populations of European 
descent (Smith et al., 1992; Sachse et al., 1997; Leathart et al., 1998; Gonzalez et al., 
1998; Krajinovic et al., 1999; Gawronska-Szklarz et al., 1999; Hersberger et al., 2000; 
Menoyo et al., 2006; Arvanitidis et al., 2007; Buzkova et al., 2008; Correia et al., 
2009; Vangsted et al., 2010; Skrętkowicz et al., 2011; van der Merwe et al., 2012). In 
Asia, the mutation is absent in the far-East but present in populations of Indian 
descent (Chida et al., 1999; Ji et al., 2002; Naveen et al., 2006; Nurfadhlina et al., 
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2006; Parveen et al., 2010; Kiyohara et al., 2012). The mutation is present at similar 
high frequencies in South America and the Middle East as European populations 
(McLellan et al., 1997; Jorge et al., 1999; Aydin-Sayitoglu et al., 2006; Kouhi et al., 
2009; Gutman et al., 2009; Altayli et al., 2009; Silveira et al., 2010; Hashemi-Soteh et 
al., 2011; Roco et al., 2012). CYP2D6*4 is found in sub-Saharan Africa at lower 
frequencies than that found in other continents (Griese et al., 1999; Dandara et al., 
2001; Lavendera et al., 2006; van der Merwe et al., 2012; Brown et al., 2012; Staehli 
et al., 2013), while higher in Tunisia as that in Europe (Ouerhani et al., 2008). 
 
1.6.1.5 CYP2E1 gene 
The CYP2E1 gene is a key member of the P450 suprefamily involved in the 
metabolism of many low molecular weight compounds and potential 
procarcinogens, i.e. nitrosamines, ethanol, benzene, chlorine ethylene and 
butadiene (Thier et al., 2003; Gordillo-Bastidas et al., 2010; Zgheib et al., 2010; 
Darazy et al., 2011; Huo et al., 2012). The gene is also associated with the 
metabolism of several pharmaceutical drugs containing acetaminophen, isoniazid, 
chlorzoxazone, trimethadione and d-benzphetamine, for example anaesthetics, 
analgesics, antipyretics, theophyllines, and chlorzoxazones (Flockhart et al., 2007; 
Zgheib et al., 2010; Huo et al., 2012). Due to its metabolic effects of certain 
procarcinogens mentioned above the gene has often been associated with a 
predisposition to various cancers. These cancers include nasopharyngeal, 
oesophageal, oral, lung, prostate and gastrointestinal tract, and various hepatic and 
pancreatic diseases (Lu et al., 1986; Watanabe et al., 1990; Persson et al., 1993; 
Mirvish et al., 1995; Hildesheim et al., 1997; Murata et al., 2001; Ferreira et al., 
2003; Yang et al., 2006; Darazy et al., 2011; Huo et al., 2012). There are more than 
ten CYP2E1 genetic polymorphisms that have been reported (Watanabe et al., 1990; 
Ingelman-Sundberg et al., 2008; Zgheib et al., 2010). For this study two polymorphic 
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sites of CYP2E1 in the 5’-flanking region of the gene were chosen, PstI (rs3813867) 
and RsaI (rs2031920) in combination are classified as CYP2E1*5B. These mutations 
are harboured in the 5’-flanking regions of the gene have been shown to be in 
linkage disequilibrium. In combination these mutations increase the transcriptional 
activity of the gene resulting in a 10-fold increase in gene expression and increased 
activation of various carcinogens (Watanabe et al., 1990; Hildesheim et al., 1995; 
Gaspar et al., 2002; Balaji et al., 2011; Huo et al., 2012).  
 
Both mutations have been extensively studied in East Asian populations and 
Europeans and farely understudied elsewhere. The mutant alleles are found to be 
most prominent in East Asia, and to a lesser degree in Europe and other populations 
of European descent (Hildesheim et al., 1995; Gonzalez et al., 1998; Rodrigo et al., 
1999; Kim et al., 2000; Sarmanova et al., 2001; Kim et al., 2004; Landi et al., 2005; 
Chen et al., 2007; Gemignani et al., 2007; Hsieh et al., 2007; Nishino et al., 2008; 
Wickliffe et al., 2011; Anderson et al., 2012; Huo et al., 2012). The mutations can be 
found at similar high frequencies as in Europeans in India, Thailand, Russia, Turkey, 
Lebanon and parts of South America (Hildesheim et al., 1997; Jorge et al., 1999; 
Cornelis et al., 2004; Mittal et al., 2005; Aydin-Sayitoglu et al., 2006; Ulusoy et al., 
2007; Gemignani et al., 2007; Da Silva et al., 2008; Zgheib et al., 2010; Coutinho et 
al., 2010; Sangrajrang et al., 2010; Balaji et al., 2011; Roco et al., 2012). These 
mutations have been relatively understudied in Africa, where data from Egypt and 
South Africa indicate a near absence of the mutations (Hamdy et al., 2002; Chelule 
et al., 2006).  
 
 
 
41 | P a g e  
 
1.6.2 Phase II genes 
Genes of the Glutathione-S-transferases (GST’s) superfamily  and N-Acetylation class 
2 gene (NAT2) are involved in the detoxification of many reactive oxidant species, 
often formed from the activation by phase I genes. The detoxification action forms 
soluble compounds that can be easily excreted from the body. Genes chosen from 
these phase II metabolisers are GSTM1, GSTT1, GSTP1, and NAT2.   
 
1.6.2.1 Glutathione-S-transferase genes 
Glutathione-S-transferases (GST’s) are a superfamily of dimeric enzymes that 
detoxify a broad range of xenobiotics and carcinogens.  These enzymes catalyze the 
reaction of glutathione with a wide variety of organic compounds to form 
thioethers, which are further metabolized to a more soluble form, such as 
mercapturic acid.  The GST family is divided into four classes, namely alpha, Mu (μ), 
Pi (π) and Theta (θ), with each class consisting of several isoforms.  Polymorphisms 
of three classes (μ, θ, and π) have been implicated in genetic susceptibility for head 
and neck squamous cell carcinomas (HNSCC), lung, bladder and many other types of 
cancers (Olshan et al., 2000; Casson et al., 2003; Gajecka et al., 2005; Leichsenring et 
al., 2006; Losi-Guembarovski et al., 2008; Torresan et al., 2008; Varela-Lema et al., 
2008; Darazy et al., 2011; Lakhdar et al., 2011; Piancentini et al., 2011; Rudolph et 
al., 2012; Hashemi et al., 2012; Lopez-Cima et al., 2012; Liang et al., 2013).   
 
Null alleles, GSTM1*0 and GSTT1*0, are the result of large DNA deletions in these 
genes that render an inability to detoxify carcinogens. Due to their detoxification 
properties of GSTM1 (μ) and GSTT1 (θ) genes, both GSTM1*0 and GSTT1*0 null 
alleles along with carcinogen activating cytochrome p450 genes have been 
implicated in cancer progression of most cancers (Olshan et al., 2000; Casson et al., 
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2003; Gajecka et al., 2005; Leichsenring et al., 2006; Losi-Guembarovski et al., 2008; 
Torresan et al., 2008; Varela-Lema et al., 2008; Darazy et al., 2011; Lakhdar et al., 
2011; Rudolph et al., 2012; Hashemi et al., 2012; Gong et al., 2012). GSTM1*0 and 
GSTT1*0 have been studied for their poor metabolising ability to some 
pharmaceutical drugs.  These poor metabolising properties have been association 
with hepatotoxicity caused by anti-tuberculosis (TB) drugs, but there remains 
unconfirmed reports of this (Huang et al., 2007; Leiro et al., 2008; Lucena et al., 
2008; Kim et al., 2010; Chaterjee et al., 2010; Monteiro et al., 2012).  
 
Both null alleles have been extensively studied globally and found in all populations 
studied. In Africa though, many of the regions remain under investigated. GSTM1*0 
appears to be more frequent (40-60%) in Europe, far East Asia, Middel East, North 
Africa and Caucosoid populations of North America (Olshan et al., 2000; Millikan et 
al., 2000; Sarmanova et al., 2001; Wang et al., 2003; Van Der Hel et al., 2005; Tsai et 
al., 2006; Iarmarcovai et al., 2006; Aydin-Sayitoglu et al., 2006; Yalin et al., 2007; 
Gundacker et al., 2007; Buchard et al., 2007; Agorastos et al., 2007; Van Emburgh et 
al., 2008; Liu et al., 2009; Fujihara et al., 2009; Rafiee et al., 2010; Cantor et al., 2010; 
Salem et al., 2011; Piacentini et al., 2011; Amer et al., 2011; Abdel-Rahman et al., 
2012; Kurose et al., 2012; Rudolph et al., 2012; Lopez-Cima et al., 2012; Fischer et 
al., 2012). In contrast, GSTT1*0 is found at high frequencies (35-55%) in far East Asia 
and the few parts of sub-Saharan Africa that have been studied (Wild et al., 2000; 
Dandara et al., 2002; Adams et al., 2003; Wang et al., 2003; Tsai et al., 2006; 
Buchard et al., 2007; Liu et al., 2009; Fujihara et al., 2009; Santovito et al., 2010; 
Piacentini et al., 2011; Kurose et al., 2012).  
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GSTP1 (π) gene is a major GST expressed in the oesophagus. Two mutations, 
GSTP1*Ile105Val (rs1695) and GSTP1*Ala114Val (rs1138272) have been largely 
studied with relation to cancer predisposition. Both polymorphisms result in an 
amino acid change to Valine (Val), which results in reduced enzyme activity (Ali-
Osman et al.1997; Mittal et al., 2005; van Emburgh et al., 2008; Matejcic et al., 2011; 
Gong et al., 2012). These mutations have been implicated in rendering susceptibility 
to head and neck cancers (including oesophageal cancer), lung, prostate and to 
some degree in breast cancer (Thier et al., 2003; Cho et al., 2005; Mittal et al., 2005; 
Li et al., 2010; Gong et al., 2012; Matejcic et al., 2011; Lopez-Cima et al., 2012). 
Using gene transfection and pharmacokinetics studies, GSTP1 has been shown to be 
associated with the metabolism of many chemotherapeutic agents, including 
melphalan, cyclophosphamide, vincristine, adriamycin, cisplatin, etoposide, 
thiotepa, chlorambucil, and busulphan (Czerwinski et al., 1996; Awasthi et al., 1996; 
Hashemi et al., 2012).  
 
GSTP1*Ile105Val is found globally at varying proportions, where it is most frequent 
(10 to 50%) in Africa (Masimirembwa et al., 1998; Dandara et al., 2002; Adams et al., 
2003; Yen-Revollo et al., 2009; Lakhdar et al., 2010; Li et al., 2010; Matejcic et al., 
2011), to having having lower frequencies (<30%) in Europe, Asia, the Americas and 
Middle East (Watson et al., 1998; Olshan et al., 2000; Sarmanova et al., 2001; 
Ballerini et al., 2003; Wang et al., 2003; Landi et al., 2005; Ketelslegers et al., 2006; 
Gemignani et al., 2007; Schwartzbaum et al., 2007; Altayli et al., 2009; Coutinho et 
al., 2010; Galvan et al., 2011; Su et al., 2012; Wang et al., 2011; Kiyohara et al., 2012; 
Hashemi et al., 2012; Vural et al., 2012). African Americans contain this 
polymorphism in almost similar proportions to their African relatives (Olshan et al. 
2000).  
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The GSTP1*Ala114Val has been studied to a lesser degree; where the mutation is 
present in Africa to frequencies between 10-20% (Lakhdar et al., 2010; Li et al., 
2010), and <10% in other populations globally (Watson et al., 1998; Ballerini et al., 
2003; Landi et al., 2005; Ketelslegers et al., 2006; Gemignani et al., 2007; 
Schwartzbaum et al., 2007; Wang et al., 2011; Vural et al., 2012). 
 
1.6.2.2 N-acetylation genes 
N-acetylation (NAT) genes, NAT1 and NAT2 are another group of phase II 
metabolizers. For the purpose of this study the NAT2 gene was selected, where it is 
responsible for the N-acetylation of certain aryl amines, xenbiotics and tobacco-
related carcinogens (Hein, 2002; Touré et al., 2012). There appears to be bimomodal 
distribution of the NAT2 phenotypes globally, where individuals either have rapid 
acetylator phenotypes, or slow acetylator phenotypes with reduced or deficient 
enzyme activity (Cavaco et al., 2003; Touré et al., 2012). While NAT2 gene has over 
13 single nucleotide polymorphisms, the NAT2*14A polymorphism was selected for 
this study as it is found almost exclusively in African populations (Delomenie et al., 
1996; Bayoumi et al., 1997; Butcher et al., 2002; Adams et al., 2003; Cavaco et al., 
2003; Yoshida et al., 2007; Sabbagh et al., 2008; Dandara et al., 2010; Staehli et al., 
2013; Touré et al., 2012), and absent in other global populations not of African 
descent (Lin et al., 1994; Cascorbi et al., 1999; Gross et al., 1999; Hein, 2002; Jorge-
Nebert et al., 2002; Landi et al., 2005; Al-Moundhri et al., 2007; Staehli et al., 2013). 
Its localization to Africa is further evident by its presence in African Americans and 
Brazilians who both share an African heritage (Lin et al., 1994; Teixeira et al., 2007).  
 
NAT2*14A renders poor metabolising function where it has been associated with 
the development of urinary bladder, colorectal, breast, head and neck, lung and 
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prostate cancers (Hein, 2000; Butcher et al., 2002). The pharmacogenetic properties 
of NAT2 are in the N-acetylation of Isoniazids (INH), one of the most important drugs 
used in anti-TB treatment and in TB chemoprophylaxis (Teixeira et al., 2007). NAT2 
variation exists between global populations, where mutations of NAT2 could render 
rapid acetylation, resulting in low concentrations of INH and possible treatment 
failures. 
 
1.7 Study objectives 
 
Given the large genetic variability present within Africa and the lack of studies in 
Africa, understanding the evolutionary histories of these populations and the 
genetic variability of genes coding xenobiotic metabolising enzymes would address 
fundamental questions within the scientific literature. Such research would aid in 
our understanding of genetic factors associated with multifactorial diseases, and 
could give a better understanding of the associated pharmacological properties. 
Acknowledging the evolution and demographic history that has shaped African 
populations, this study was designed to use a population genetics approach to: 
(i) Examine the allelic variation within the CYP1A1, CYP1A2, CYP2A6, 
CYP2D6, CYP2E1, GSTM1, GSTT1, GSTP1 and NAT2 genes in some sub-
Saharan African populations;  
(ii) Use the frequencies and distribution of variants of these candidate genes 
to examine the genetic affinities within 18 sub-Saharan African 
populations;  
(iii) Evaluate the patterns of variation within Africa to non-African 
populations; 
(iv) Assess relevance of candidate loci for future studies on cancer and 
pharmacogenomics in Africa.  
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CHAPTER 2   SUBJECTS, MATERIALS AND METHODS 
 
2.1 Subjects 
 
The DNA samples from a total of 1880 subjects (males and females) residing in eight 
African countries: South African, Botswana, Mozambique, Namibia, Zambia, Uganda, 
Democratic Republic of Congo (D.R.C.), and Central African Republic (C.A.R.). Figure 
5 illustrates the locations where samples were collected. Eighteen population 
groups were classified by their geographic location, ethnicity and linguistic affiliation 
(Table 1). A description of these population histories can be found in section 1.1. 
 
The samples were collected for population genetic studies in sub-Saharan Africa by 
Professor Soodyall and colleagues in the Division of Human Genetics (National 
Health Laboratory Services and University of the Witwatersrand) (Protocol number 
M050906, renewed 29 May 2009, Appendix A). The use of these samples for this 
study was approved by the Human Research Ethics Committee (Medical) of the 
University of the Witwatersrand (Protocol number M060325; Appendix A). 
 
All samples were collected after seeking informed consent from volunteers. At the 
time of sampling volunteers were asked to provide information relating to their 
place of birth, home language and that of parents (and in some cases grand-
parents), and their self-proclaimed ethnic identity. Having reviewed the various 
factors when defining African populations (see Section 1.1), it was decided to rather 
group the sample according to individuals self-proclaimed ethnic identity, mapped 
to the countries in which they had been collected (Figure 5 and Table 1).   
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Figure 5 Map indicating position where samples were collected  
Population code key: XUN-!Xun; KHWE-Khwe; SEB-South African Bantu-speakers; 
SAI-South African Indians; SAW-South African Whites; SAC-South African Coloureds; 
MOZ-Mozambican Bantu-speakers; NAMA-Nama; DAMA-Dama; JU- Juǀ’hoansi; HIM-
Himba; HER-Herero; OVA-Ovambo; ZAM-Zambian Bantu-speakers; DRC-Democratic 
Republic of Congo Bantu-speakers; UGA-Ugandan Bantu-speakers; CAR_U-Central 
African Republic Ubangian-speakers; CAR_P-Central African Republic Pygmies.  
XUN and KHWE populations were sampled at different time periods and at two 
different locations. Colour highlights of countries represent the different regions of 
Africa: red – Southern Africa; blue – Eastern Africa; green – Central Africa; purple – 
Western Africa; and brown – Northern Africa  
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Table 1 Study population-sample origin, ethnicity, language, population code and 
sample size 
Sample Origin by Country Population Name Ethnicity(ies) € Language Classification
Population 
Group Code§
N
South Africa South African Bantu-speakers ¥
Southeastern Bantu-speakers 
(Xhoza, Zulu, Sotho, Tswana, Pedi 
and Venda)
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
SEB 115
South Africa & Namibia# !Xun ¥ San Northern Khoisan: !Xun 2 XUN 76
South Africa & Namibia# Khwe ¥ San Central Khoisan: Khwe 2 KHWE 49
South Africa South African Indians ¤ Tamil, Telugu, Hindi and Gujarati Indo-Arian & Dravidic SAI 114
South Africa South African Whites ¤ Anglo, Dutch, French and Germanic English & Afrikaans SAW 51
South Africa South African Coloureds Mixed English & Afrikaans SAC 91
Botswana Ju|'hoansi ¥ San Northern Khoisan: Ju|'hoansi 2 JU 30
Mozambique Mozambican Bantu-speakers ¥
Eastern Bantu-speakers (Chopi, 
Ronga, Shangaan and Tonga)
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
MOZ 70
Namibia Nama ¥ Khoe Central Khoisan: Nama 2 NAMA 22
Namibia Dama** ¥ Central Khoisan: Nama 2 DAMA 37
Namibia Himba ¥ Southwestern Bantu-speakers
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
HIM 40
Namibia Herero ¥ Southwestern Bantu-speakers
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
HER 79
Namibia Ovambo ¥ Southwestern Bantu-speakers
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
OVA 62
Zambia Zambian Bantu-speakers ¥
Eastern Bantu-speakers (Nyanja, 
Lozi, Bemba and Tonga)
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
ZAM 179
Uganda Ugandan Bantu-speakers ¥
Eastern Bantu-speakers (Bakiga, 
Bafumbira, Banyakole and 
Bahororo)
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
UGA 245
Democratic Republic of 
Congo D.R.C Bantu-speakers 
¥ Central Bantu-speakers 
(Manyanga/Nyanga)
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Central1
DRC 302
Central African Republic C.A.R. Pygmy ¥
Central Bantu-speakers (BiAka and 
Babenzele)
Niger-Congo, Atlantic-Congo, Volta-
Congo, Benue-Congo, Bantoid, 
Southern, Narrow Bantu, Northwest1
CAR_P 120
Central African Republic C.A.R. Ubangian-speakers ¥
Central Bantu-speakers (Sangha 
Sangha, Gbaya and Nzakara)
Niger-Congo, Atlantic-Congo, Volta-
Congo, North, Adamawa-Ubangi, 
Ubangi1
CAR_U 198
2 Güldemann et al., 2000; Güldemann et al., 2008
€ Most African ethnicities correlate with language dialects spoken
**Enigmatic group who differ from the Nama in physical appearance but have adopted the Nama language
§ These codes will  be used throughout in refence to the populations sampled
¥ Indigenous African population
¤ Sea-borne immigrants population
1 http://www.ethnologue.com/country/ZA/languages
# These samples were collected at two locations: In Namibia (then South-West Africa) at the Omega Camp and in South Africa in Schmidtsdrift region
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2.2 Comparative data 
 
Where available, data from other populations were used to compare frequencies of 
alleles at the genetic loci used in the current study. African populations have been 
divided into different regions as indicated in Figure 5. Comparative data collated for 
this study along with references to the studies used can be found in tables in 
Appendix B. 
 
2.3 Materials and methods 
 
2.3.1 DNA extractions and quantification 
Where blood samples were collected, the DNA was extracted using the salting out 
procedure described by Miller et al. (1988). Where buccal swabs were collected, 
DNA was extracted according to manufacturer’s specifications using commercial 
available kit manufactured by Gentra Systems called the PureGene® Genomic DNA 
Purification. 
 
DNA samples were quantified spectrophotometrically using the NanoDrop ND-1000 
Spectrophotometer (ColemanTechnologies Inc., LabVIEW®). Quantified DNA were 
then diluted to the required concentration and volume by diluting the DNA sample 
in sterile double distilled water (ddH2O). 
 
2.3.2 Null allele typing methods 
To determine the presence of null mutations GSTM1*0 and GSTT1*0 in the sample, 
the method reported by Casson et al. (2003) was used and optimised. This is a 
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multiplex polymerase chain reaction (PCR) where primers (Table 2) amplify across 
these deleted regions for the GSTM1 and GSTT1 genes. In addition, primers for a 
control band in the β-Globin gene was included as a positive control in the event an 
individual contained both GSTM1 and GSTT1 null alleles - to discriminate between a 
failed PCR and both mutations being absent. The primer sequences used in this 
multiplex reaction to detect null mutations are given in table 2. 
 
Table 2 Primer name and sequences for GSTM1 and GSTT1 null allele detection 
Target region Primer name Primer sequence (5’ to 3’) 
GSTM1 null allele  
ForM1 CTTGGGCTCAAATATACGGTGG 
RevM1 GAACTCCCTGAAAAGCTAAAGC 
   
GSTT1 null allele  
ForT1 TCACCGGATCATGGCCAGCA 
RevT1 TTCCTTACTGGTCCTCACATCTC 
   
β-Globin control 
β-GlbFor GAAGAGCCAAGGACAGGTAC 
β-GlbRev AACTTCATCCACGTTCACC 
      
 
 
About 100ng of DNA of each sample was used in the multiplex PCR. In addition to 
DNA, each PCR mix contained 0.2μM of each primer (Table 2), 2.5µl FastStart Taq 
Buffer solution containing 1.5mM MgCl2, 2U of FastStart Taq (Roche Applied 
Science), and 10µM dNTP mix (containing dATP, dGTP, dCTP, dTTP), all made up to a 
final volume of 25µl with ddH2O.  The thermal cycler program was as follows: one 
cycle at 95˚C for 5 minutes; followed by 30 cycles at 95˚C for 30 seconds, 61˚C for 30 
seconds, and extension at 72˚C for 1 minute; with a final extension step at 72˚C for 7 
minutes. Thereafter, 10µl of the PCR product was resolved on a 2% Agarose gel 
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stained with ethidium bromide (electrophoresis conditions: 1 x TBE running buffer, a 
loading dye, 1Kb DNA ladder [Gibco BRL] size standard). 
 
 
2.3.3 Detection of SNP markers using the Single Base Extension method 
The Single Base Extension (SBE) method is a minisequencing procedure which 
involves: 
I. Target regions containing the SNPs are first amplified using PCR either in 
single reactions or multiplex reactions. PCR products are then cleaned to 
remove all unincorporated PCR primer and other PCR components, retaining 
amlpicons only.  
II. These purified PCR products are then used in a minisequencing reaction 
along with probes (sense or anti-sense primer) designed to anneal adjacent 
to the target SNP and fluorescently tagged ddNTPs (whereby each ddNTP is 
labelled with one of four fluorescent coloured dyes). The different probes are 
in addition designed to vary in length by adding (GATC)n primer tails, where 
by size fractionation during electrophoresis it is possible to distinguish the 
different SNP loci being typed. The reaction follows where PCR products are 
denatured to become single strands to allow for probes to anneal to regions 
adjacent to SNP. In an elongation step the corresponding ddNTP to the target 
SNP binds to the probe. After several cycles probes would now contain 
ddNTPs that correspond to the SNP targeted. The products of this reaction 
are then cleaned to remove any unincorporated components to retain 
probes that contain ddNTP. 
III. These minisequencing reaction products can now be resolved using 
electrophoresis. A capillary array DNA analyser is often used to resolve probe 
fragments, where fluorescent excitation enables the detection of the ddNTP 
insert. Depending on the colour emmited by one of four fluorescent dyes and 
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the size fractionation of the peaks, the allele present for a particular SNP can 
be determined.  
 
In this study the SBE method was used to detect 13 SNP markers implicated in 
genetic susceptibility to cancer, where simultaneously an internal control band from 
the β-Globin gene was included. Table 3 lists the SNP markers used, the 
corresponding multiplex PCR primers with sequences, the SBE primer (probe) 
sequences and primer sizes with poly(GATC)n extensions, PCR product sizes, and the 
allele discrimination identifiers.  
 
2.3.3.1 Primer design 
The target regions containing the relevant SNPs were derived from DNA sequences 
of the GenBank database (refer to Appendix C). The Primer3 software (Rozen and 
Skaletsky, 2000) tool was used to design PCR and SBE primers. Primers were then 
aligned to the NCBI BLAST alignment tool to confirm template specificity. To rule-out 
primer-dimers and hairpin loop formation AutoDimer was used (Vallone and Butler, 
2004). Primers were ordered from Metabion. To ensure high quality and specificity 
in DNA amplification HPLC-purification was requested for each primer.  
 
PCR primer sets were designed to anneal at temperatures ranging from 56°C to 61°C 
to allow for some flexibility to aid in the optimization of amplifying all fragments 
optimally in a single multiplex PCR. PCR primer lengths were between 18 and 23 
mers (Table 3); where the GC content of primers varied from 39.1% to 61.9%. 
Primers were designed to amplify regions varying from 124bp to 340bp (Table 3), 
where the varying lengths would aid in differentiating products after being resolved 
by agarose gel electrophoresis.  
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 SBE primers were designed to anneal at low temperatures (~50°C) with high 
specificity to the binding region alongside the SNP; with varying lengths by adding 
poly-GATC tails of differing lengths to the 5’ end of all SBE primers, except one 
(Table 3). The SBE primers were carefully designed to allow adequate differentiation 
during capillary electrophoresis, where lengths varied between 26 to 117 mers. The 
design of SBE primer lengths is important where two or more fragments if they 
migrate together through the capillary could result in an output where dye peaks 
could lie on top of one-another and make the result undecipherable, especially if the 
fluorescent dye emission is of the same colour. 
 
2.3.3.2 Multiplex PCR optimization 
To amplify the 13 PCR fragments and the internal control band, fragments were first 
amplified in separate reactions at varying annealing temperatures ranging between 
54°C to 60°C using a gradient thermocycler.  Products for each annealing 
temperature variant were then resolved on a 3% agarose gel stained with ethidium 
bromide.  These initial reactions were done to identify the most optimal conditions 
for the each primer pair, and thereby identifying an optimal condition at which all 
primers pairs could be amplified in a multiplex reaction.   
 
For each primer pair tested (Table 3), each PCR contained about 10ng of DNA, 
0.2μM of each primer (Table 3), 2.5µl FastStartTaq Buffer, 1.5mM MgCl2,  1U of 
FastStartTaq (Roche Applied Science), and 15µM dNTP mix (containing dATP, dGTP, 
dCTP, dTTP), all made up to a final volume of 25µl with ddH2O.  The thermal cycler 
program was as follows: one cycle at 95˚C for 5 minutes; followed by 30 cycles at 
95˚C for 30 seconds, primer annealing temperature range between 54°C and 60°C 
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(as set by temperature gradient of the gradient thermocycler) for 30 seconds, and 
extension at 72˚C for 1 minute; with a final extension step at 72˚C for 7 minutes. 
 
Once optimal conditions were determined individually, all primer sets were 
combined in a multiplex reaction. The multiplex reaction was further optimized by 
varying primer set concentrations, the FastStart Taq Buffer concentration, MgCl2 
concentrations, using annealing temperatures between 54°C and 57°C, and DNA 
template amounts of 8ng, 10ng and 25ng. The final optimized reaction contained 
about 10ng of DNA, 1μl of primer mix (see table 4 for primer concentrations), 2.5µl 
FastStart Taq Buffer, 2.0mM MgCl2,  1U of FastStart Taq (Roche Applied Science), 
and 30µM dNTP mix (containing dATP, dGTP, dCTP, dTTP), all made up to a final 
volume of 25µl with ddH2O.  The thermal cycler program was as follows: one cycle at 
95˚C for 5 minutes; followed by 35 cycles at 95˚C for 30 seconds, 57°C for 30 
seconds, and extension at 72˚C for 1 minute; with a final extension step at 72˚C for 7 
minutes. 
 
PCR products were hereafter purified by adding 1.4U of Shrimp Alkaline 
Phosphatase (USB Corporation) and 4U of Exonuclease I (New England Biolabs) to 
5μl PCR product made up to a total reaction volume of 7μl with ddH2O. The reaction 
was incubated at 37˚C for 60 minutes followed by an enzyme inactivation step of 
75˚C for 15 minutes. 
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Table 3 List of SNP markers typed using SBE reaction along with primer sequences, fragment lengths, and alleles colour coded 
to the respective ddNTP fluorescent dye contained in the SBE reaction mix 
 
Locus Gene
Primer 
Direction Primer Sequence ('5 - 3')
Final 
concentration  in 
PCR (µM)#
PCR product 
size (bp) SBE primer name (gatc)n + SBE primer sequence (5' - 3')
Final 
concentration  in 
SBE reaction 
(µM)β
Total SBE primer 
length (bp)
§Alleles: colour coded by 
floresent dye colour
Control band B-Globin Forward GAAGAGCCAAGGACAGGTAC 0.10 267       β-Glb_SBE (gatc)7tggtgcatctgactcctgag 0.07 48 G
Reverse AACTTCATCCACGTTCACC 0.10
GSTP1*Ile105Val GSTP1 Forward ACCCCAGGGCTCTATGGGAA 0.10 176 GSTP105_SBE (gatc)10aggacctccgctgcaaatac 0.20 60 A allele (wild type)
Reverse TGAGGGCACAAGAAGCCCCT 0.10 G allele (mutant)
GSTP1*Ala114Val GSTP1 Forward GTTGTGGGGAGCAAGCAGAGG 0.05 216 GSTP114_SBE (gatc)20cttcacatagtcatccttgccc 0.06 102 G (C) allele (wild type)
Reverse CACAATGAAGGTCTTGCCTCCC 0.05 anti-sense primer§ A (T) allele (mutant)
CYP1A1*2A CYP1A1 Forward CAGTGAAGAGGTGTAGCCGC 0.07 340 CYP1A1*2A_SBE (gatc)10tgtttcactgtaacctccacctcc 0.20 64 T allele (wild type)
Reverse TAGGAGTCTTGTCTCATGCC 0.07  C allele (mutant)
CYP1A1*2A CYP1A1 Forward CAGCTGTCTCCCTCTGGTTA 0.04 185 CYP1A1*2C_SBE (gatc)15ggaagtgtatcggtgagacc 0.06 80 A allele (wild type)
Reverse GCCAGGAAGAGAAAGACCTC 0.04 G allele (mutant)
CYP1A2*1C CYP1A2 Forward GCTACACATGATCGAGCTATAC 0.05 155 CYP1A2*1C_SBE (gatc)5ccgcaacctccgcctctc 0.07 38 G allele (wild type)
Reverse GCATGACAATTGCTTGAATC 0.05 A allele (mutant)
CYP1A2*1F CYP1A2 Forward GATGATGTGTGGAGGAGAGA 0.05 225 CYP1A2*1F_SBE (gatc)18aaagggtgagctctgtgggc 0.12 92 C allele (wild type)
Reverse AGGGTTGAGATGGAGACATT 0.05 A allele (mutant)
CYP2A6*7_SBE (gatc)24acgtgtttgggggacacgtca 0.12 117 A (T) allele (wild type)
Forward CTCAAGTCCTCCCAGTCACC 0.10 anti-sense primer§ G (C) allele (mutant)
Reverse TCTCTTCCCTCTAGCCACCA 0.10 CYP2A6*8_SBE (gatc)8ggcaggaagctcatggtgtagttt 0.16 56 C (G) allele (wild type)
anti-sense primer§ A (T) allele (mutant)
241
CYP2A6*7Ψ
CYP2A6*8 Ψ
CYP2A6
CYP2A6
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Table 3 continued 
Locus Gene
Primer 
Direction Primer Sequence ('5 - 3')
Final 
concentration  in 
PCR (µM)#
PCR product 
size (bp) SBE primer name (gatc)n + SBE primer sequence (5' - 3')
Final 
concentration  in 
SBE reaction 
(µM)β
Total SBE primer 
length (bp)
§Alleles: colour coded by 
floresent dye colour
CYP2D6 Forward TAGGTGCTGAATGCTGTCC 0.05 185 CYD2D6*3A_SBE (gatc)22gatgagctgctaactgagcac 0.16 109 A allele (wild type)
Reverse CTCACCTTCTCCATCTCTGC 0.05 G allele (mutant)
CYP2D6 Forward GTGGGTGATGGGCAGAAG 0.08 124 CYD2D6*4_SBE (gatc)2ccgcatctcccaccccca 0.20 26 G allele (wild type)
Reverse CTTTGTCCAAGAGACCGTTG 0.08 A allele (mutant)
NAT2*14A NAT2 Forward TTAGGGGATCATGGACATTG 0.08 227 NAT2*14A_SBE (gatc)12tgatcacattgtaagaagaaacc 0.07 71 G allele (wild type)
Reverse GATTGACCTGGAGACACCAC 0.08 A allele (mutant)
CYP2E1*5B(PstI ) CYP2E1 Forward CACTGGAAAGGAAAGAGAGG 0.12 206 CYP2E1*PstI_SBE (gatc)6cccttcttggttcaggagag 0.20 44 G allele (wild type)
Reverse GCCACATAAGCAAGTCATTG 0.12 C allele (mutant)
CYP2E1*5B(RsaI ) CYP2E1 Forward AAGTGATTTGGCTGGATTGT 0.05 237 CYP2E1*RsaI_SBE (gatc)15gttcttaattcataggttgcaatttt 0.15 86 G (C) allele (wild type)
Reverse CCCTCTTCCACCTTCTATGA 0.05 anti-sense primer§ A (T) allele (mutant)
§ Anti-sense sequence used to design SBE primer, with the corresponding allele is highlighted in purple print in the last column
¥ Is the only SBE primer without a poly(gatc) tail 
Ψ One PCR amplicon containing SNPs for two SBE primers 
# Primer concentration in a 25µl PCR volume 
β SBE primer concentration in a 5µl SBE reaction volume
CYP2D6*3A 
(2549delA)
CYP2D6*4 (1846G>A)
57 | P a g e  
 
2.3.3.3 Genotyping of SNP markers using the SBE method 
Following multiplex PCR amplification and purification, 1.5μl of the purified PCR 
product was used in a SBE reaction. The SBE reaction mix consisted of 1μl of ABI 
PRISM® SNaPshotTM Multiplex Ready Reaction Mix, 1μl of the SBE primer cocktail 
(see Table 4), and made up to a volume of 5μl with ddH2O. With each SBE 
amplification round, a positive control reaction (amplified separately) supplied with 
the SNaPshotTM Multiplex Ready Reaction Mix was included. Amplification 
conditions were 35 cycles of a denaturation step at 96˚C for 10 seconds, SBE primer 
annealing at 50°C for 5 seconds and the single base ddNTP elongation step at 60˚C 
for 30 seconds. 
 
Following the SBE reaction, products were purified to retain SBE probes with 
fluorescently tagged ddNTP incorporated by adding 0.5U of Shrimp Alkaline 
Phosphatase (USB Corporation) to 5μl of the SBE reaction products, all made up to a 
total reaction volume of 7μl with ddH2O. The reaction was incubated at 37˚C for 
60min, followed by 75˚C for 15 minutes. 
 
To genotype SBE reaction samples, 2μl of cleaned SBE products were mixed with 
7.5μl Hi-Di formamide (Applied Biosystems) and 0.5μl of GeneScan-LIZ 120 internal 
size standard (Applied Biosystems). Each prepared mixture was then denatured 
briefly at 95˚C for 2 minutes and quickly cooled to 4˚C. Similar mix and treatment 
was done for the positive control supplied with the ABI PRISM® SNaPshotTM 
Multiplex Ready Reaction. SBE products were then resolved using ABI PRISM® 
3130xl Genetic Analyzer (Applied Biosystems) according to ABI PRISM® SNaPshotTM 
Multiplex Kit instructions (Applied Biosystems) and analyzed using GeneMapperID 
v3.2 software (Applied Biosystems).   
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Table 4 Multiplex PCR primer and SBE primer concentrations used in SBE method 
  
Primer name Direction
Final 
concentration 
(µM)¥
SBE Primer name
Final 
concentration 
(µM)Ψ
β-Glb-F Forward 0.10 β-Glb_SBE 0.07
β-Glb-R Reverse 0.10
P105F Forward 0.10 GSTP105_SBE 0.20
P105R Reverse 0.10
P3 Forward 0.05 GSTP114_SBE 0.06
P4 Reverse 0.05
CYP1A1*2F Forward 0.07 CYP1A1*2_SBE 0.20
CYP1A1*2R Reverse 0.07
CYP1A1*3F Forward 0.04 CYP1A1*3_SBE 0.06
CYP1A1*3R Reverse 0.04
CYP1A2-R2 Forward 0.05 CYP1A2-1C_SBE 0.07
CYP1A2-Cr Reverse 0.05
CYP1A2-Ff Forward 0.05 CYP1A2-1F_SBE 0.12
CYP1A2-Fr Reverse 0.05
CYP2A6*7F Forward 0.10 CYP2A6*7_SBE§ 0.12
CYP2A6*7R Reverse 0.10 CYP2A6*8_SBE§ 0.16
CYP2D6*3F Forward 0.05 CYP2D6*3_SBE 0.16
CYP2D6*3R Reverse 0.05
CYP2D6*4F Forward 0.08 CYP2D6*4_SBE 0.20
CYP2D6*4F Reverse 0.08
NAT2*14F Forward 0.08 NAT2*14_SBE 0.07
NAT2*14R Reverse 0.08
NAT1*10F Forward 0.20 NAT1*10_SBE 0.16
NAT1*10R Reverse 0.20
CYP2E1-PsF Forward 0.05 CYP2E1-PstI_SBE 0.15
CYP2E1-PsR Reverse 0.05
CYP2E1-RsF Forward 0.12 CYP2E1-RsaI_SBE 0.20
CYP2E1-RsR Reverse 0.12
§ One PCR amplicon containing SNPs for two SBE primers 
¥ Primer concentration in a 25µl PCR volume 
Ψ SBE primer concentration in a 5µl SBE reaction volume
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A macro was designed in the GeneMapperID v3.2 software (Applied Biosystems) 
according to manufacturer’s recommendations where the genotypes of each SBE 
fragment would be automatically scored and an allele output per marker would be 
generated. In table 3, the last column lists the alleles for each SNP and is colour 
coded to represent the respective fluorescent dye colour that would be presented 
on electropherogram outputs. Table 3 in addition displays the expected fragment 
size of the SBE product. The macro designed uses the GeneScan-LIZ 120 internal size 
standard (Applied Biosystems) to determine the SBE product size relative to the 
migration in the electrophoresis run, where the size of the fragment serves as an 
identifier of a SNP being detected. 
 
2.4 Statistical analysis 
 
Genotypes for the null allele PCR were read off the gel images taken after PCR 
products were resolved on agarose gels. The presence or absence of the null alleles 
in the GSTM1 and GSTT1 genes were entered into EXCEL spreadsheets. From these 
collated data tables genotype frequency calculations were computed for each 
population. 
  
SNP markers were typed using the SBE technique described here. The 
GeneMapperID v3.2 software was used to analyse the outputs of these genotyping 
runs, where the samples were automatically scored to the respective genotype for 
the respective region, and hereafter tabulated in EXCEL spreadsheet. The tabulated 
results were checked against the electropherograms to ensure genotyping call 
accuracy of the macro designed in the GeneMapperID v3.2 software (Applied 
Biosystems) and allele call. Using these collated data tables, CONVERT Ver.1.31 
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(Glaubitz, 2004) was used to calculate allele frequencies for each locus in each 
populations and to compile input files for use in other software tools.  
 
2.4.1 Population statistics and neutrality testing 
 
2.4.1.1 Hardy-Weinberg equilibrium 
The Hardy-Weinberg model describes a non-evolving population, in which allele 
frequencies do not change from generation to generation (Hardy, 1908). When 
allele frequencies do not change from generation to generation the population is 
considered to be in Hardy-Weinberg Equilibrium (HWE). Genetic drift, gene flow, 
mutation, non-random mating and natural selection are five factors which can 
influence evolution of a population or cause it to deviate from HWE. 
 
In this study, each population was examined to establish whether the allelic variants 
were in HWE in ARLEQUIN version 3.0 (Excoffier et al., 2005). Analogous to HWE 
test, the exact test was further applied to data using in ARLEQUIN version 3.0 
(Excoffier et al., 2005). 
 
2.4.1.2 Neutrality testing 
Tajima's D statistic (Tajima 1989a, 1989b, 1993) calculation was applied to each SNP 
locus using the ARLEQUIN version 3.0 software to determine which locus is under 
selection. Tajima's D is a statistical test that is able to distinguish between a DNA 
sequence evolving randomly ("neutrally") and one evolving under a non-random 
process, including directional selection or balancing selection, demographic 
expansion or contraction, genetic hitchhiking, or introgression. A randomly evolving 
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DNA sequence contains mutations with no effect on the fitness and survival of an 
organism. In other words the statistic tests the null hypothesis of mutation-drift 
equilibrium and constant population size. 
 
2.4.1.3 Population diversity  
Genetic diversity for each of the 18 populations in the study was calculated using 
allele frequencies for each locus analysed. To calculate the genetic diversity the 
standard diversity indices was selected in ARLEQUIN version 3.0 (Excoffier et al., 
2005). The standard diversity index is proportional to the diversity within the 
population across the loci tested, i.e. the higher the index value (between 0 and 1), 
the greater the genetic diversity of that population.   
 
2.4.2 Population affinity  
To determine the genetic relationship of populations a pairwise comparison was 
conducted by calculating Fst distances in ARLEQUIN version 3.0 (Excoffier et al., 
2005). The Fst distance matrix output of ARLEQUIN was use to view the spatial 
genetic relationship of populations through Principle Component Analysis (PCA) and 
cluster analysis in PAST v.1.54 (Hammer et al., 2001). Fst matrix was further used to 
construct population trees using the Neighbour Joining (NJ) method in PAST v.1.54 
(Hammer et al., 2001). 
 
To determine the distribution of variance among populations Analyses of Molecular 
Variance (AMOVA) was calculated in ARLEQUIN version 3.0 (Excoffier et al., 2005). 
The distribution of variance was determined in three levels: 
o between individuals in a population 
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o between population within groups defined by geographic distribution and 
language  
o between groups 
 
2.4.3 Population structure 
A widely used program called STRUCTURE is used to determine population structure 
using genotypic data from microsatellite DNA regions, restriction fragment length 
polymorphisms (RFLPs) or SNPs. The program assumes genotypes are in linkage 
equilibrium with one another in a population and that genotypes are in HWE 
proportion. In this study we used the program STRUCTURE Ver2.0 (Pritchard et al., 
2000; Falush et al., 2003). The software uses allele frequencies in a Bayesian 
Clustering analysis to divide individuals into K number of clusters. The K is a prior set 
by the user, where STRUCTURE apportions genotypes of individuals into the K 
number of clusters with a certain probability. For example, if K=2 then STRUCTURE 
would divide the total genotypic variation for the entire sample then by statistical 
measure allocate individuals in the sample into either of the two clusters. For this 
analysis the admixed model was used along with default settings recommended for 
allelic data, those being for the correlated allelic frequency model. These settings 
assume that the populations share genetic traits where allelic frequencies are similar 
either due to shared ancestry or due to migration events. Since the number of 
clusters (K) is not known a number of runs were conducted from K=2 to K=10, to 
determine which K value apportions variation in populations with the greatest 
likelihood. A total of 10000 iterations with a burn-in phase of 1000 iterations were 
computed for each K cluster. Outputs of the inferred clustering was depicted in a bar 
chart output of the program, which was used to show the individual variation 
apportion for each individual for each K run. The program further outputs the 
average inferred clustering for each population. These population averages were 
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used as priors for the program Distruct Ver1.1 (Rosenberg, 2004), where the 
variation apportioned per population for each K run was depicted in a bar chart.  
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CHAPTER 3   RESULTS 
 
This chapter describes the results that emerged from this study. The sections include 
the sample populations of the study and comparisons to other populations 
described in the comparative data collated (Appendix B). Study population labels 
used in this chapter correspond to the population codes that are listed Table 1. 
Firstly a brief discussion of the results of the techniques used to detect mutations is 
given.  Secondly a description of the results obtained for mutations are provided. 
Thirdly trends within the study populations and published data are highlighted. 
Fourth the genetic affinities with respect to these markers are examined to describe 
the genetic histories of populations.  
 
3.1. Mutation detection 
 
The result of each run was analyzed using GeneMapperID v3.2 software (Applied 
Biosystems), where a macro was designed to score each SBE fragment automatically 
based on the fluorescent tag detected on the end of SBE fragments and the size of 
the SBE fragments. Figure 6 shows examples of electropherogram outputs by the 
GeneMapperID v3.2 software (Applied Biosystems). In Figure 6: sample (A) is 
heterozygous for CYP1A1*2A, CYP1A2*1C, CYP1A2*1F and GSTP1*Ile105Val; sample 
(B) is heterozygous for CYP1A1*2A, CYP1A1*2C and GSTP1*Ala114Val; sample (C) is 
heterozygous for CYP2A6*7 and CYP2D6*4; and sample (D) is heterozygous 
NAT2*14A. Populations in this study were all monozygotic for the wild-type allele for 
loci CYP2A6*8, CYP2D6*3A, CYP2E1*5B(PstI) and CYP2E1*5B(RsaI), therefore 
examples presented in Figure 6 have one peak each. 
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The Figure 6 also shows an additional marker than those mentioned above, the 
second peak from the left end of the electropherogram, which was designed to 
detect the NAT1*10 mutation (rs1057126). Unfortunately, following genotyping and 
checking of data it was discovered that the SBE primer designed for this marker was 
three nucleotide positions off in detecting the mutation. In reviewing reference 
sequences (extract April 2008) used to design the probe it was evident that the 
sequence used contained three bases less than that found in the most recent update 
(NCBI, ss279716933 last update 16 December 2010). The region of this SNP contains 
six AAT repeat sequences, whereas the reference sequence in 2008 contained only 
five. It is possible after the most recent realignment of the human DNA sequences 
submitted to NCBI database the reference sequence had changed to include the one 
AAT repeat, hence the error in the design of the SBE probe used. Due to this error all 
results for this marker were not included in the analysis for this study. 
 
The large deletion mutations of the GSTM1 and GSTT1 genes, called GSTM1*0 and 
GSTT1*0 null mutations respectively, were genotyped using a multiplex reaction 
described earlier in section 2.3.2. The products of these reactions were resolved by 
electrophoresis on 2% Agarose gel. Images of these Agarose gels were captured and 
samples individually scored based on the bands visible from the gel images (Figure 
7). The existence of a GSTM1 band or a GSTT1 band is an indication of the absence 
of GSTM1*0 and GSTT1*0, respectively. A control band from the β-Globin gene was 
included as a positive control in the event an individual contained deletions in both 
GSTM1 and GSTT1 genes, thereby distinguishing a true failed PCR from samples that 
contained both null mutations.  
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Figure 6 Examples of electropherogram results obtained during genotyping of SNP 
markers using SBE technique. 
- SNP Marker names are labelled above the first electropherogram, where the 
peak position corresponds to the marker label above.  
- Numbers on the X-axis of each electropherogram represent the fragment 
size as calculated using the internal size standard. 
- Numbers on the Y-axis of each electropherogram represents peak heights 
- Below each peak in the electropherograms is/are the allele/s calls generated 
by the genotyping software used and the macro developed for this purpose. 
- The highlights in the background of peaks are the bin regions allocated for 
each marker in the macro, within which alleles could be scored. Colour 
highlights correspond to the nucleotide base call for the respective allele. 
- Electropherogram (A) shows heterozygous loci CYP1A1*2A, CYP1A2*1C, 
CYP1A2*1F and GSTP1*Ile105Val; electropherogram (B) shows heterozygous 
loci CYP1A1*2A, CYP1A1*2C and GSTP1*Ala114Val; electropherogram (C) 
shows heterozygous loci CYP2A6*7 and CYP2D6*4; and electropherogram 
(D) heterozygous for NAT2*14A.  
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Due to the nature of the multiplex reaction it is not possible to distinguish between 
individuals who were heterogygous at these loci, therefore in the case of a band 
being present the sample was genotyped as not having the deletion mutation. Only 
where a band is absent can it be determined that an individual is homozygous for 
the respective null allele. An example of the results for this multiplex reaction can be 
found in Figure 7, where lane 1, 4, 5 and 7 are examples of individuals who were 
scored as having the wild-type genotype for both loci; lane 2 and 6 contains only the 
control band and thereby would have been scored as having both GSTM1*0 and 
GSTT1*0 genotypes; lane 8 does not have the GSTT1 band and thereby scored as 
having the GSTT1*0 genotype; lane 9 does not have the GSTM1 band and thereby 
scored as having the GSTM1*0 genotype; and lane 3 a 1 Kb Plus DNA Ladder 
(Invitrogen™) size standard. 
 
Figure 7 Gel picture showing results of GSTM1 and GSTT1 multiplex reaction  
PCR products in the gel image above were resolved on a 2% Agarose gel 
Represented in the figure above: 
• Lanes 1, 4, 5 and 7 - are examples of individuals who were scored as having 
the wild-type genotype for both loci;  
• Lanes 2 and 6 contains only the control band and thereby would have been 
scored as having both GSTM1*0 and GSTT1*0 genotypes;  
• Lane 8 does not have the GSTT1 band and thereby scored as having the 
GSTT1*0 genotype;  
• Lane 9 does not have the GSTM1 band and thereby scored as having the 
GSTM1*0 genotype;  
• lane 3 a 1 Kb Plus DNA Ladder (Invitrogen™) size standard. 
 
Lane
GSTT1 band 
(458bp)
1 2 3 4 5 6 7 8 9
GSTM1 band 
(219bp)
Β-Globin 
control band 
(267bp)
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3.2. Phase I metabolizing genes 
 
The following section describes the allele frequencies found for CYP1A1*2A and *2C; 
CYP1A2*1C and *1F; CYP2A6*7 and *8; CYP2D6*3A (2549delA) and 
CYP2D6*4(1846G>A); and CYP2E1*5B(PstI) and CYP2E1*5B(RsaI) polymorphisms. 
These polymorphisms are found in phase I metabolism genes described earlier. Data 
for these polymorphisms is presented in Table 5 and Figure 8 to Figure 17. Table 5 
contains the frequencies of the mutant alleles identified in the study along with the 
total sample size tested. Comparative data for these polymorphisms can be found in 
Appendix B, Tables A to E. Current study and comparative data for these 
polymorphisms were collated in bar charts to illustrate the trends of these 
polymorphisms within Africa and globally, as shown in  Figure 8 to Figure 17. Where 
more than one study reported findings for a mutation in that population the average 
frequency was used in the collation of bar charts. 
 
3.2.1. CYP1A1*2A allele frequencies 
In sub-Saharan Africa CYP1A1*2A is present in all populations, where Bantu-
speakers display similar proportions of the allele varying from 26.6% in ZAM to 
13.6% in UGA (Table 5 and Figure 8). The frequency is highest among the San-
speakers (XUN, 39.6%; JU, 30.8%; KHWE, 28.6%) with lower frequencies in the Khoe-
speakers (NAMA, 10.5%), a possible indication of the mutation’s existence in Africa 
before human migration out of Africa. Pygmies were found to have similar high 
frequencies of the mutation as that found in Bantu-speakers (CAR_P, 25.9%). 
CYP1A1*2A allele is found in SAC at a frequency of 20.6%. Compared with parental 
populations, Khoe-San and SAW this appears to be intermediate in frequency. The 
SAI have the mutation present at 33%, much higher than that found in India. The 
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higher frequency in SAI is possibly due to founder events following the migration of 
Indians to South Africa.  
 
The mutation tends to decrease further north outside sub-Saharan Africa towards 
the Middle East and Europe, becoming most prevalent in Asia especially the far-East 
(Figure 8 and comparative data in Appendix B, Table A). African-Americans, similar 
to their African relatives contain the mutation at a relatively high frequency (22.0%). 
In contrast, Caucasian Americans (9.0%) have similar low frequency for the mutation 
as their European relatives. Costa Ricans (31.4%) and Chileans (37.0%) too contain 
large frequencies for CYP1A1*2A allele. Overall, the data available tends to indicate 
that the mutation can be found in all populations globally at varying frequencies. 
 
3.2.2. CYP1A1*2C allele frequencies 
CYP1A1*2C is near absent in sub-Saharan Africa (Table 5 and Figure 9). The mutation 
is found in Ivory Coast (38.3%), Ghana (8.0%), HIM (1.3%), and MOZ (0.9%), where it 
is likely that individuals in these populations acquired the mutation from non-African 
descendants in the recent past (Figure 9 and  comparative data in Appendix B, Table 
A). A likely corroboration of this aspect can be found in the SAC where the mutation 
is found at 5.3%. Given the ancestral history of the SAC, the near absence of the 
allele in neighbouring indigenous populations, the CYP1A1*2C would more likely 
have been introduced by parental populations SAI (13.8%) and SAW (9.1%).  
 
CYP1A1*2C increases in frequency from North Africa (Egypt, 27%), towards the 
Middle East, to being most frequent in Asia. The mutation is found at appreciably 
lower frequencies in Europe (ranging between 2% and 5%). Consistent with their 
70 | P a g e  
 
heritage Caucasoid populations of North America contain low frequencies of the 
mutation. African-Americans have the mutation as well, possibly due to the 
introduction from their European descendants similar to that observed for the SAC. 
In South America, the mutations is present at high frequencies in Mexico (50%) and 
Chile (32%), to lower a frequency in Brazil (16%), possibly due to the sample in 
Mexico and Chile mostly consisting of Amerindian populations (Figure 9 and  
comparative data in Appendix B, Table A). 
 
3.2.3. CYP1A2*1C allele frequencies 
During raw data checks of SBE runs for this marker it was apparent that the reaction 
did not work equally well for some populations where the missing data ranged from 
8.1% (DAMA) to 96.3% (JU), where average missing data was 49%. Due to low peak 
heights of this marker not all typings could be considered as true allele scoring for 
this locus and therefore were not included in the final dataset. Figure 6 (sample B) 
shows an example of such a sample where the amplification of this locus was very 
low and the result could not be considered as true. Due to the amplification success 
in some populations and not others it is likely that the lack of success in typing this 
locus was sample dependent.  For this reason this study cannot confirm the true 
frequency profiles of this locus in the study populations. Evident though, the 
mutation is present in most in sub-Saharan African populations (Table 5 and Figure 
10). From comparative data available the allele tends to be most frequent in far-East 
Asia (Japan, 26%), to 7% in India and Egypt (Figure 10 and comparative data in 
Appendix B, Table B). The mutation is found at appreciably lower frequencies in 
Europeans ranging from 1% to 4%, and it is therefore likely that SAW could have this 
mutation.   
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Table 5 SNP loci mutant allele frequencies only – current study population  
 
African region 
Country of sample
Population Code ¥
Locus N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
CYP1A1*2A                 
rs4646903T>C
70 22.1 67 39.6 49 28.6 85 20.6 103 33.0 42 14.3
CYP1A1*2C                              
rs1048943A>G
70 0.0 69 0.7 49 0.0 85 5.3 105 13.8 44 9.1
CYP1A2*1C                              
rs2069514G>A
33 27.3 29 31.0 30 31.7 42 3.6 58 3.5 10 0.0
CYP1A2*1F                              
rs762551C>A
70 59.3 69 66.7 49 61.2 85 68.8 105 62.9 44 71.6
CYP2A6*7                                
rs5031016A>G
70 0.7 69 8.0 49 3.1 85 5.9 105 5.7 44 3.4
CYP2A6*8                            
rs28399468C>A
70 0.0 69 0.0 49 0.0 85 0.0 105 0.0 44 0.0
CYP2D6*3                                               
rs35742686delA
67 0.0 61 0.0 47 0.0 78 0.0 103 0.0 34 0.0
CYP2D6*4                                
rs3892097G>A
70 1.4 69 0.0 49 3.1 85 5.3 104 5.3 43 10.5
CYP2E1*5B (PstI)                                  
rs3813867G>C
69 0.0 66 0.0 49 0.0 83 0.0 103 0.0 37 0.0
CYP2E1*5B (RsaI)                                    
rs2031920G>A
68 0.0 61 0.0 44 0.0 75 0.0 75 0.0 34 0.0
GSTP1*Ile105Val                       
rs1695A>G 70 55.0 69 72.5 49 57.1 85 48.2 105 27.6 44 38.6
GSTP1*Ala114Val                       
rs1138272G>A 70 1.4 69 0.0 49 0.0 85 4.7 105 6.7 44 14.8
NAT2*14A                   
rs1801279G>A
70 8.6 68 4.4 49 5.1 85 5.3 105 0.0 44 0.0
¥ For population name and ethnicity refer to table 1
N represents the total sample size
South Africa
South Africa & 
Nambia
South Africa & 
Nambia South Africa South Africa South Africa
SAW
Southern Africa
SEB XUN KHWE SAC SAI
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Table 5 continued… SNP loci mutant allele frequencies only – current study population  
 
African region 
Country of sample
Population Code ¥
Locus N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
CYP1A1*2A                 
rs4646903T>C
26 30.8 19 10.5 37 23.0 78 25.6 40 22.5 60 21.7
CYP1A1*2C                              
rs1048943A>G
27 0.0 19 0.0 37 0.0 78 0.0 40 1.3 60 0.0
CYP1A2*1C                              
rs2069514G>A
1 100.0 9 5.6 34 17.7 39 37.2 36 33.3 23 17.4
CYP1A2*1F                              
rs762551C>A
27 70.4 19 71.1 37 39.2 78 61.5 40 50.0 60 52.5
CYP2A6*7                                
rs5031016A>G
27 11.1 19 0.0 37 0.0 78 0.6 40 1.3 60 0.0
CYP2A6*8                            
rs28399468C>A
27 0.0 19 0.0 37 0.0 78 0.0 40 0.0 60 0.0
CYP2D6*3                                               
rs35742686delA
22 0.0 18 0.0 37 0.0 77 0.0 39 0.0 60 0.0
CYP2D6*4                                
rs3892097G>A
27 0.0 19 0.0 37 2.7 78 3.2 40 0.0 60 2.5
CYP2E1*5B (PstI)                                  
rs3813867G>C
26 0.0 19 0.0 37 0.0 76 0.0 40 0.0 60 0.0
CYP2E1*5B (RsaI)                                    
rs2031920G>A
15 0.0 17 0.0 34 0.0 77 0.0 39 0.0 60 0.0
GSTP1*Ile105Val                       
rs1695A>G 27 74.1 19 65.8 37 56.8 78 55.1 40 46.3 60 45.8
GSTP1*Ala114Val                       
rs1138272G>A 27 0.0 19 0.0 37 0.0 78 1.3 40 0.0 60 0.0
NAT2*14A                   
rs1801279G>A
27 0.0 19 5.3 37 1.4 78 10.3 40 13.8 60 10.0
¥ For population name and ethnicity refer to table 1
N represents the total sample size
Botswana Namibia Namibia Namibia Namibia Namibia
Southern Africa
JU NAMA DAMA HER HIM OVA
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Table 5 continued… SNP loci mutant allele frequencies only – current study population 
 
African region 
Country of sample
Population Code ¥
Locus N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
N
Mutant 
allele 
(%)
CYP1A1*2A                 
rs4646903T>C
52 20.2 175 26.6 224 13.6 177 22.3 81 25.9 160 21.9
CYP1A1*2C                              
rs1048943A>G
54 0.9 175 0.0 227 0.0 179 0.0 91 0.0 171 0.0
CYP1A2*1C                              
rs2069514G>A
40 10.0 137 21.2 160 18.1 87 16.7 25 34.0 33 27.3
CYP1A2*1F                              
rs762551C>A
54 50.0 175 54.6 227 46.9 179 56.4 91 76.4 170 53.8
CYP2A6*7                                
rs5031016A>G
54 2.8 175 1.7 227 3.3 179 11.7 91 3.9 171 23.7
CYP2A6*8                            
rs28399468C>A
54 0.0 175 0.0 227 0.0 179 0.0 91 0.0 171 0.0
CYP2D6*3                                               
rs35742686delA
53 0.0 172 0.0 226 0.0 164 0.0 90 0.0 129 0.0
CYP2D6*4                                
rs3892097G>A
54 2.8 175 3.7 227 3.1 179 3.1 91 3.3 171 7.0
CYP2E1*5B (PstI)                                  
rs3813867G>C
52 0.0 175 0.0 225 0.0 171 0.0 82 0.0 121 0.0
CYP2E1*5B (RsaI)                                    
rs2031920G>A
54 0.0 170 0.0 223 0.0 165 0.0 72 0.0 123 0.0
GSTP1*Ile105Val                       
rs1695A>G 54 45.4 175 42.6 227 44.9 179 43.9 91 36.8 169 43.8
GSTP1*Ala114Val                       
rs1138272G>A 54 0.9 175 0.0 227 0.7 179 0.0 91 0.0 171 0.3
NAT2*14A                   
rs1801279G>A
54 9.3 175 11.1 227 7.3 179 6.2 91 4.4 171 9.1
¥ For population name and ethnicity refer to table 1
N represents the total sample size
Democratic 
Republic of 
Congo
Mozambique Zambia Uganda
Central African 
Republic
Central African 
Republic
MOZ ZAM UGA CAR_U
Eastern Africa Middle Africa
CAR_P DRC
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Figure 8 Bar chart showing CYP1A1*2A allele proportions worldwide 
NB: ME = Middle East; NA = North America; SA = South America  
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Figure 9 Bar chart showing CYP1A1*2C allele proportions worldwide 
NB: ME = Middle East; NA = North America; SA = South America
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3.2.4. CYP1A2*1F allele frequencies 
The CYP1A2*1F allele is found throughout the globe (Table 5 and Figure 11 with 
comparative data in Appendix B, Table B). In sub-Saharan Africans the mutation is 
present at frequencies greater than 40% (Table 5 and Figure 11). There is no 
apparent trend in the distribution of this mutation throughout Africa. Its high 
prevalence in Khoe-San and CAR_P populations indicates that the allele had evolved 
in Africa before humans migrated out of Africa. Similar as in Africa, the mutation is 
present at high frequencies in Europe, Asia, North America and South America to 
varying degrees. The CYP1A2*1F allele in the SAI (62.9%) is greater than that found 
in India (44%), where the difference can be attributed to the Indian sample mainly 
consisting of North Indians and the SAI being migrants from North, South and 
eastern India. 
 
3.2.5. CYP2A6*7 allele frequencies 
CYP2A6*7 allele is present among all sub-Saharan African populations investigated 
here, with the exception of the NAMA, DAMA and OVA (Table 5 and Figure 12).. The 
allele is most frequent in Central Africa to being low in southern Africans. The allele 
is present in San populations (JU, 11.1%; XUN, 8%; and KHWE, 3.1%) and absent in 
Khoe (NAMA).  Data from literature is scarce where no data was found for North 
Africa, Middle Eastern and South American populations. From the data available for 
this locus, the mutation is present in far-East Asians and absent in Caucasians and 
African Americans of Canada (Figure 12 and comparative data in Appendix B, Table 
C). While Indian and Swedish populations do not have the mutation, it is present in 
the SAI and SAW respectively. This indicates that the allele could be present in 
Indians and Europeans, likely at low frequencies. 
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3.2.6. CYP2A6*8 allele frequencies 
The CYP2A6*8 allele is absent in sub-Saharan Africans (Table 5 and Figure 13). From 
current comparative data the mutation is present in far-East populations but absent 
elsewhere (Figure 13 and comparative data in Appendix B, Table C). The marker’s 
exclusivity in Asia cannot be confirmed though as the data is underrepresented for 
several global populations. Further investigation is required within Africa and 
globally to understand the allele’s distribution. 
 
3.2.7. CYP2D6*3A (2549delA) allele frequencies  
Data for this allele is shows that a single allele is present only in Tanzanians (0.3%) 
and absent in all other investigated African populations (Table 5 and Figure 14). 
Outisde Africa, CYP2D6*3A is absent in Asians; while present in Europeans, Iranians, 
and Caucasoid populations of North America (Figure 14 and comparative data in 
Appendix B, Table D). The allele is found in African-Americas (0.6%). Given the 
history of this population and the absence of this marker in Africans it is likely that 
the presence of this allele was contributed by European descendants. The mutation 
is found in North and South Americans, albeit at low frequency in Mexican (0.4%), 
American Indians (0.3%), Argentinians (2.5%), and Chileans (1.0%). Its absence in 
other American populations (Panamanian and Columbian) and the low prevalence in 
those listed above seems to indicate that the mutation is not indigenous to Native 
Americans, and rather was introduced by European settlers. The high proportion in 
Brazilians (13.8%) can be explained by the distribution of the sample where the 
authors reported the sample comprising mostly (86.4%) of those who phenotypically 
resembled Europeans (Silviera et al., 2010). 
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Figure 10 Bar chart showing CYP1A2*1C allele proportions worldwide 
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Figure 11 Bar chart showing CYP1A2*1F allele proportions worldwide 
NB: WAf = Western Africa; NAf = Northern Africa; NA = North America; SA = South America 
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Figure 12 Bar chart showing CYP2A6*7 allele proportions worldwide   
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Figure 13 Bar chart showing CYP2A6*8 allele proportions worldwide 
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Figure 14 Bar chart showing CYP2D6*3A allele proportions worldwide  
NB: ME = Middle East; NA = North America; SA = South America 
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3.2.8. CYP2D6*4 (1846G>A) allele frequencies 
CYP2D6*4 is absent in all Khoe-San populations, except the KHWE (3.1%) (Table 5 
and Figure 15). CYP2D6*4 is present in all Bantu-speakers including the CAR_P 
(ranging from 1% to 7%), where the frequency increases in the west (Ghana, 13%) 
and north (Tunisia, 9%)  Africa. DAMA exhibit a similar proportion of the allele (2.7%) 
as in Bantu-speakers. This corroborates other findings that DAMA are biologically 
more closely related to Bantu-speakers, even though they speak Nama (Nurse et al., 
1985; Soodyall and Jenkins, 1993; Soodyall et al., 2008; Schlebusch, 2010a). South 
African Bantu-speakers and South African Coloured populations of the current study 
and in literature all show that the allele is present at similar proportions as that 
found in other southern Bantu-speakers. 
 
The allele is most frequent in Europeans and other European derived populations 
(Figure 15 and comparative data in Appendix B, Table D). CYP2D6*4 is found in 
Middle East, North American and South American populations. Given the high 
prevalence in Native Americans it is possible that the mutation was present in these 
populations prior to European settlement, when Europeans were introduced or a 
combination of both these reasons. The mutation is present in Indians (14%) and SAI 
(5.3%). In contrast to the trend seen in Asia for other locus investigated here, the 
mutation is near absent in far-East Asians. SAW and SAI contain the mutant allele at 
lower frequencies compared to parental populations, likely due to the founder 
events following their migration to South Africa.  
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Figure 15 Bar chart showing CYP2D6*4 allele proportions worldwide 
NB: WAf = Western Africa; NAf = Northern Africa; ME = Middle East; SA = South America 
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3.2.9. CYP2E1*5B(PstI) allele frequencies  
The CYP2E1*5B(PstI) allele is absent in sub-Saharan Africans, with highest 
frequencies observed in far-East Asians, Chileans and Caucasoid populations of 
North America (Table 5 and Figure 16 with comparative data in Appendix B, Table E). 
The allele is present in Europe and India at low frequencies, and absent in Lebanon.  
Comparative data for the mutation was not available for most western Europeans. 
Given the migrant history of Europeans to North America, its presence in Caucasians 
from the United States of America and Canada indicates that it possibly exists in 
Western Europe. The allele’s absence in SAW is surprising and is possibly due to the 
founder events of these populations. 
 
3.2.10. CYP2E1*5B(RsaI) allele frequencies 
CYP2E1*5B(RsaI) is absent in all sub-Saharan African populations (Table 5 and Figure 
17 and comparative data in Appendix B, Table E), with the exception of a minute 
proportion found in South African Bantu-speakers from a literature source (2.7%, 
Chelule et al., 2006). The presence of nine CYP2E1*5B(RsaI) alleles in this study is 
interesting as the mutation is absent in other southern African Bantu-speakers. This 
study’s sample was collected in Kwa-Zulu Natal, different to the SEB sample of the 
current study. This difference in samples could indicate the introgression of the 
allele from European and/or Indian descendants. The mutation is further found in 
North Africa (Egypt, 1.7%). 
 
Although there is limited comparative data for this allele compared to 
CYP2E1*5B(PstI), CYP2E1*5B(RsaI) appears to be similarly distributed globally as 
that observed for the CYP2E1*5B(PstI) allele. This is not surprising as many studies 
have reported that the two loci are highly linked to one another (Hildesheim et al., 
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1995; Gonzalez et al., 1998; Rodrigo et al., 1999; Kim et al., 2000; Sarmanova et al., 
2001; Kim et al., 2004; Landi et al., 2005; Chen et al., 2007; Gemignani et al., 2007; 
Hsieh et al., 2007; Nishino et al., 2008; Wickliffe et al., 2011; Anderson et al., 2012; 
Huo et al., 2012). CYP2E1*5B(RsaI) is found at low frequencies in Europeans and 
South Americans. In contrast to the trend seen for CYP2E1*5B(PstI),  
CYP2E1*5B(RsaI) is present in Lebanon at low frequencies (1.4%).  
 
3.3. Phase II metabolizing genes 
 
The following section describes the genotype frequencies of the GSTM1*0 and 
GSTT1*0 null mutations, and allele frequencies for GSTP1*Ile105Val and *Ala114Val; 
and NAT2*14A polymorphisms. These polymorphisms are found in phase II 
metabolism genes described earlier. Data for these polymorphisms are presented in 
Table 5 and Table 6, and in Figure 18 to Figure 23. Table 6 contains genotype 
frequencies obtained for the GSTM1*0 and GSTT1*0 null mutations for populations 
investigated in this study. Comparative data for GSTM1*0 and GSTT1*0 null 
mutations can be found in Appendix B, Table F. Table 5 contains the frequencies of 
both wild-type and mutant alleles of GSTP1*Ile105Val, GSTP1*Ala114Val and 
NAT2*14A polymorphisms. Comparative data for GSTP1*Ile105Val, 
GSTP1*Ala114Val and NAT2*14A polymorphisms can be found in Appendix B, Tables 
G and H. Current study and comparative data for these polymorphisms were 
collated in bar charts to illustrate the trends of these polymorphisms within Africa 
and globally, as shown in  Figure 18 to Figure 23. Where more than one study 
reported findings for a mutation in that population the average frequency was used 
in the collation of bar charts. 
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Figure 16 Bar chart showing CYP2E1*5B(PstI) allele proportions worldwide 
NB: ME = Middle East; SA = South America
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Figure 17 Bar chart showing CYP2E1*5B(RsaI) allele proportions worldwide 
NB: NAf = Northern Africa; ME = Middle East; NA = North America; SA = South America 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
So
ut
h 
Af
ric
an
 B
an
tu
-sp
ea
ke
rs
SE
B
XU
N
KH
W
E
SA
C JU
NA
M
A
DA
M
A
HE
R
HI
M
OV
A
M
OZ
ZA
M
UG
A
CA
R_
U
CA
R_
P
DR
C
Eg
yp
tia
n
Tu
rk
ish
Ro
m
an
ia
n
Po
lis
h
Ru
ss
ia
n
Hu
ng
ar
ia
n
Slo
va
ki
an
s
Sp
an
ish
Sla
vic
SA
W
Ch
in
es
e
Ta
iw
an
es
e
Th
ai
In
di
an SA
I
Le
ba
no
ne
se
M
ex
ica
n
Ch
ile
an
Central 
Africa
Eastern
Africa
Southern Africa
Africa
Europe Asia
NAf
NA
ME
SA
89 | P a g e  
 
3.3.1. GSTM1*0 genotype frequencies 
In sub-Saharan Africa, the GSTM1*0 mutation is present in almost all populations 
at varying frequencies (Table 6 and Figure 18). Khoe-San populations, with the 
exception of KHWE (13%), contain low frequencies of the GSTM1*0 genotype, to 
being absent in JU.  Southern Bantu-speakers contain GSTM1*0 at frequencies 
ranging from 22.6% (OVA) to 5.4% (DAMA). Its distribution in Bantu-speakers 
appears to be similar in eastern, western and Central Africa, ranging from 36.1% 
(Ivory Coast) to 2.8% (Cameroon). In South African Coloured group, GSTM1*0 
was found at a frequency of 22.2%, somewhat intermediate between Africans 
and Europeans. 
 
The mutation’s frequency increases from the south to North Africa and continues 
out of Africa being most frequent in Europe, Asia and the Middle East (Figure 18 
with comparative data in Appendix B, Table F). In the Middle East the GSTM1*0 
genotype ranges between 37.4% (Iran) to 53.4% (Saudi Arabia). Middle East’s 
high prevalence is not surprising considering that this region borders Europe 
where the frequency ranges from 66.1% (France) to 49.1% (Italy). In Asia, 
GSTM1*0 is low in Indians (30%), becoming more frequent towards the far-East. 
The mutation is further present in North and South Americans, where the 
frequency is largest in Caucasoid populations of North America (Canadian 
Caucasians, 56.5%; Caucasian Americans, 53.5%). 
 
3.3.2. GSTT1*0 genotype frequencies 
The mutation is found in all Khoe-San populations investigated at varying 
frequencies from 41.3% (KHWE) to 33.8% (XUN) (Table 6 and Figure 19). Among 
southern Bantu-speakers the GSTT1*0 genotype ranged between 41.0% (HIM) to 
16.4% (ZAM). Further north there appears to be no distinct trend in the 
distribution of GSTT1*0 among Central, eastern, western and Northern Africans 
(Figure 19, with comparative data in Appendix B, Table F). In contrast to most 
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Bantu-speaking populations investigated in the study, the GSTT1*0 genotype is 
present at a very low frequency in the CAR_P (5.9%). GSTT1*0 was found at a 
frequency of 21.7% in SAC, this is somewhat intermediate to that found in 
parental populations. The frequency in SAC is much lower than the South African 
Coloured group (SAC[1], 57%) described in Adams et al. (2003). This Coloured 
group was sampled in the Western Cape of South Africa, different to those in this 
study who were sampled primarily in Johannesburg. These two groups do have 
different histories where it is known that the Coloured groups of Western Cape 
predominantly have been born from the Khoe-San natives and European 
migrants (Schlebusch, 2010a). 
 
Globally, the GSTT1*0 genotype is found in Europe, Middle East, Asia and the 
Americas. In Europe, with the exception of Greece (43.3%), the mutation is found 
at lower frequencies than that found in Africa (Figure 19, with comparative data 
in Appendix B, Table F). The GSTT1*0 genotype is found in far-East Asians at 
similar high frequencies as that in Africans, ranging from 50.9% (Koreans) to 
25.6% (Mongolians). The mutation is further found in the Middle East ranging 
between 39% (Saudi Arabia) and 19.2% (Iran). With the exception of Greenland 
(46%), GSTT1*0 is found at relatively lower frequencies. This is possibly due to 
the population being primarily small and isolated as compared to other 
populations globally. 
 
Individuals that contain both GSTM1*0 and GSTT1*0 genotypes, potentially have 
higher disfunctionality of these GSTM1 and GSTT1 genes than those having 
either one of the mutant genes. The data present in Table 6, column header 
‘Presence of both GSTM1*0 and GSTT1*0’, shows individuals in the study that 
were homozygous for both mutations. This data along with that available in 
literature were used to compile the barchart illustration (Figure 20). With 
exception of JU and OVA, all study populations have individuals who are 
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homozygous for both mutations. The proportions of these individuals range from 
being low in Khoisan-speakers to slightly higher in Bantu-speakers of East and 
Central Africa. CAR_P (1.7%), too contain very low proportion of individuals who 
have this trait. Compared with African populations investigated in the study the 
number of individuals homozygous for both mutations is higher in SAW (11.1%). 
Such individuals appear to increase further north in Africa (Tunisia, 21%), being 
more frequent in the Middle East (Saudi Arabia, 22.7%; Lebanon, 16.3%; and 
Bahrain, 14.4%).  
 
Table 6 GSTM1 and GSTT1 null genotype frequency  
 
 
Population Code ¥
African region &                 
country of sample
Presence of 
both GSTM1*0 
& GSTT1*0
Presence of 
GSTM1*0
Presence of  
GSTT1*0
Total 
Sample
Southern Africa
SEB South Africa 6 (5%) 25 (20.7%) 25 (20.7%) 121
XUN South Africa & Nambia 2 (2.7%) 2 (2.7%) 25 (33.8%) 74
KHWE South Africa & Nambia 2 (4.3%) 6 (13%) 19 (41.3%) 46
SAC South Africa 5 (5.6%) 20 (22.2%) 17 (18.9%) 90
SAI South Africa 6 (5.3%) 26 (23%) 12 (10.6%) 113
SAW South Africa 5 (11.1%) 17 (37.8%) 4 (8.9%) 45
JU Botswana 0 (0%) 0 (0%) 13 (39.4%) 33
NAMA Namibia 1 (4.5%) 1 (4.5%) 9 (40.9%) 22
DAMA Namibia 1 (2.7%) 2 (5.4%) 10 (27%) 37
HER Namibia 4 (5.5%) 5 (6.8%) 29 (39.7%) 73
HIM Namibia 2 (5.1%) 6 (15.4%) 16 (41%) 39
OVA Namibia 0 (0%) 14 (22.6%) 17 (27.4%) 62
Eastern Africa
MOZ Mozambique 4 (5.7%) 9 (12.9%) 16 (22.9%) 70
ZAM Zambia 11 (6.2%) 29 (16.4%) 29 (16.4%) 177
UGA Uganda 19 (8.1%) 40 (16.9%) 66 (28%) 236
Central Africa
CAR_U Central African Republic 17 (8.8%) 32 (16.6%) 54 (28%) 193
CAR_P Central African Republic 2 (1.7%) 22 (18.6%) 7 (5.9%) 118
DRC Democratic Republic of 
Congo
16 (5.7%) 45 (15.9%) 68 (24%) 283
¥ For population name and ethnicity refer to table 1
NB: Frequecies indicate proportion of genotypes in populations
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Figure 18 Bar chart showing GSTM1*0 genotype proportions worldwide 
NB: WAf = Western Africa; NAf = Northern Africa; ME = Middle East; NA = North America; SA = South America
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Figure 19 Bar chart showing GSTT1*0 genotype proportions worldwide 
NB: WAf = Western Africa; NAf = Northern Africa; ME = Middle East; NA = North America; SA = South America 
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 Figure 20 Bar chart showing the proportion of individuals who are homozygous for both GSTM1*0 and GSTT1*0 mutations worldwide 
NB: WAf = Western Africa; NAf = Northern Africa; ME = Middle East; NA = North America; SA = South America 
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3.3.3. GSTP1*Ile105Val allele frequencies 
This mutant allele is found at largest proportions in Khoe-San varying from 74.1% 
(JU) to 57.1% (KHWE) (Table 5 and Figure 21. Southern Bantu-speakers contain 
the allele at frequencies between 55.1% (HER) to 45.8% (OVA). Across Central, 
eastern and western Africa, GSTP1*Ile105Val is found in Bantu-speakers at 
frequencies ranging from 50% in Ghana to 16% in Tanzania (Table 5 and Figure 
21 with comparative data in Appendix B, Table G). The allele is found in SAC at a 
frequency of 48.2%, slightly higher when compared to the South African 
Coloured (43%) group reported in Adams et al. (2003). This is probably due to the 
different histories for each group where the Coloured population was sampled 
primarily in Johannesburg and the other from Adams et al. (2003) in the Western 
Cape, South Africa. GSTP1*Ile105Val is found in SAI (27.6%) and SAW (38.6%) at 
similar similar proportions to those of Indians and Europeans, respectively. 
  
Further north of Africa, the mutation decreases, where in Europe its proportion 
ranges from 36.3% (Netherlands) to 25.7% (Turkey) (Table 5 and Figure 21 with 
comparative data in Appendix B, Table G). In Asia the GSTP1*Ile105Val allele is 
found in Indians at a frequency of 27.3%, where its proportion decreases 
towards the far-East (China, 17.9; Taiwan, 17.8%; and Japan, 15.1%). In the 
Americas the allele appears to decrease from north to south, where it is present 
at frequencies from 48.1% in Mexico to 34.1% in Brazil. Caucasian Americans 
(34.1%) contain the allele at similar proportions as most European populations. 
Further, GSTP1*Ile105Val is found in African-Americans at a frequency of 42.2%, 
similar to that observed in African populations.  
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Figure 21 Bar chart showing GSTP1*Ile105Val allele proportions worldwide  
NB: WAf = Western Africa; NAf = Northern Africa; ME = Middle East; NA = North America; SA = South America 
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3.3.4. GSTP1*Ala114Val allele frequencies 
GSTP1*Ala114Val is primarily absent in Africans, with the exception of South 
African Bantu-speakers (13.4%; Li et al., 2010), SEB (1.4%), HER(1.3%), MOZ (1%), 
and UGA (1%) (Table 5 and Figure 22) . From the literature available the mutation 
is most frequent in Europeans ranging from 9.7% (Danish) to 5.1% (Spanish) 
(Table 5 and Figure 22  with comparative data in Appendix B, Table G). Similar to 
parental populations, the mutation is found at a frequency of 14.7% in SAW. The 
mutation is present in SAI (6.7%) and Indians (6.5%).  
 
Its presence in Europeans and Indians, and near absence in Africa indicates the 
mutations was recently introduced by Europeans and/or Indians in SEB, HER, 
MOZ, and UGA populations. Similarly, this explains the mutation’s presence in 
SAC at a frequency of 4.7% and the Coloured group (10.9%) from Li et al. (2010). 
African-Americans contain the mutation at a frequency of 2.7%. Given their 
ancestral history, and the absence in the African parental population it can be 
assumed that African-Americans inherited the mutation from their European 
descendants.  
 
3.3.5. NAT2*14A allele frequencies 
NAT2*14A is exclusively found in Africa with highest proportions in sub-Saharan 
Africans (Table 5 and Figure 23). The mutation is present in all Khoe-San (range 
5.3% to 4.4%) populations except the JU. Among Bantu-speakers, the mutation is 
present at higher frequencies from 23% in Mbuti Pygmies of the DRC to 1.4% in 
DAMA. Towards the north of Africa the mutation tends to be low to absent 
(Somalia, 1%; Ethiopia, 0%; and Morocco, 0%). 
 
Outside Africa, the trend seen in North Africa continues where the mutation is 
absent in Europe, Asia, the Middle East and the Americas (Table 5 and Figure 23 
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with comparative data in Appendix B, Table H). Exceptions to this trend are 
found in the Italians (1%), Slavics (0.1%), Spanish (0.1%), Cambodians (2%), 
African-Americans (8%), Nicaraguans (0.4%), Brazilians (4%) and Colombians 
(2%). Africans were the likely contributors of this allele to these populations. 
Further, argument of African contribution can be made for South African 
Coloured populations, given their history being born from European, Asian and 
African descendants. This distribution pattern observed in this study for the 
NAT2*14A allele has been reported before (Delomenie et al., 1996; Bayoumi et 
al., 1997; Butcher et al., 2002; Adams et al., 2003; Cavaco et al., 2007; Yoshida et 
al., 2007; Sabbagh et al., 2008; Dandara et al., 2010; Staehli et al., 2013; Touré et 
al., 2012).   
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Figure 22 Bar chart showing GSTP1*Ala114Val allele proportions worldwide  
NB: NAf = Northern Africa; NA = North America 
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Figure 23 Bar chart showing NAT2*14A allele proportions worldwide  
NB: NAf = Northern Africa; ME = Middle East; NA = North America; SA = South America 
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3.4. Hardy-Weinberg Equilibrium and Tajima’s D statistic tests performed 
 
The allele frequencies for the 13 loci were evaluated for Hardy-Weinberg 
Equilibrium (HWE) and Tajima’s D statistic with a 95% confidence interval, for 
each of the 18 populations used in this study. The results of these tests are given 
in the Table 7 to Table 24, where significant tests p-values have been highlighted 
in blue. Loci CYP2A6*8, CYP2D6*3A, CYP2E1*5B(PstI) and CYP2E1*5B(RsaI) were 
all monomorphic containing only wild-type allele for all 18 populations, and 
therefore could not be examined for HWE. In the SEB, the GSTP1*Ala114Val was 
the only locus found to deviate from HWE (Table 11). HER population was found 
to deviate from HWE for the GSTP1*Ile105Val locus (Table 13). The ZAM 
populations deviated from HWE proportions for the NAT2*14A locus (Table 18). 
The CYP1A1*2A marker was found to deviate from HWE proportions in both 
CAR_U and DRC populations (Table 19 and Table 20). In addition, the DRC 
population deviated from HWE for loci CYP1A2*1C and CYP2A6*7 (Table 19). The 
SAI were the only sea-borne population that showed to have deviated from 
HWE, this for the CYP1A2*1F marker (Table 24).  Due to the low amplification 
success for CYP1A2*1C, the JU population contained only two alleles for this 
locus, both were mutant alleles and therefore HWE test was not conducted 
(Table 7). 
 
As listed above, there where some loci that were found to deviate from HWE in 
the various populations. However, when allelic data for the 18 populations were 
applied to Tajima’s D statistic test all loci except one was not significant for 
selective neutrality. CYP1A1*2C was found to be under selection within the XUN 
population (Table 8), D=-0.9921 (p=0.0000). The negative D-value is an indication 
for this locus there is an excess of lower frequency alleles and the population size 
is at expansion probably following some bottleneck event. This is surprising as 
the XUN contains only one mutant allele (1%) among the 69 individuals typed for 
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this marker. Given that the marker was not found to deviate from HWE (Table 8), 
it is possible that the mutation is not under selection. 
 
Table 7 HWE and Tajima’s D statistic tests performed for JU population 
 
 
Table 8 HWE and Tajima’s D statistic tests performed for XUN population  
 
 
 
 
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 52 0.6154 0.4344 0.0581 1.2807 0.8677
CYP1A1*2C 54 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 2 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1F 54 0.5926 0.4249 0.0586 1.2332 0.8609
CYP2A6*7 54 0.2222 0.2013 1.0000 -0.1092 0.2789
CYP2A6*8 54 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 44 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 54 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Pst I) 52 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 30 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 54 0.4444 0.3913 0.6395 1.0318 0.8371
GSTP1*Ala114Val 54 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 54 Monomorphic - test not done 0.0000 1.0000
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 134 0.5522 0.4818 0.3102 1.7731 0.9423
CYP1A1*2C 138 0.0145 0.0145 1.0000 -0.9921 0.0000
CYP1A2*1C 58 0.4138 0.4356 1.0000 1.3151 0.8724
CYP1A2*1F 138 0.5217 0.4477 0.1908 1.5769 0.8960
CYP2A6*7 138 0.1594 0.1478 1.0000 -0.2017 0.2690
CYP2A6*8 138 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 122 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 138 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Pst I) 132 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 122 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 138 0.4348 0.4020 0.5579 1.3059 0.8583
GSTP1*Ala114Val 138 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 136 0.0588 0.0850 0.1109 -0.5771 0.2131
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 9 HWE and Tajima’s D statistic tests performed for KHWE population 
 
 
 
Table 10 HWE and Tajima’s D statistic tests performed for NAMA population 
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 98 0.4490 0.4124 0.7267 1.2971 0.8668
CYP1A1*2C 98 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 60 0.3667 0.4401 0.4112 1.3506 0.8751
CYP1A2*1F 98 0.6122 0.4797 0.0709 1.6968 0.9335
CYP2A6*7 98 0.0612 0.0600 1.0000 -0.7953 0.1557
CYP2A6*8 98 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 94 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 98 0.0612 0.0600 1.0000 -0.7953 0.1626
CYP2E1*5B(Pst I) 98 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 88 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 98 0.4082 0.4949 0.2487 1.7867 0.9597
GSTP1*Ala114Val 98 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 98 0.1020 0.0978 1.0000 -0.5704 0.2147
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 38 0.1053 0.1935 0.1627 -0.2712 0.2442
CYP1A1*2C 38 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 18 0.1111 0.1111 1.0000 -1.1647 0.1299
CYP1A2*1F 38 0.4737 0.4225 1.0000 1.1231 0.8484
CYP2A6*7 38 Monomorphic - test not done 0.0000 1.0000
CYP2A6*8 38 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 36 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 38 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Pst I) 38 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 34 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 38 0.3684 0.4623 0.6059 1.3656 0.8766
GSTP1*Ala114Val 38 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 38 0.1053 0.1024 1.0000 -0.8255 0.1631
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 11 HWE and Tajima’s D statistic tests performed for SEB population  
 
 
 
Table 12 HWE and Tajima’s D statistic tests performed for MOZ population  
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 140 0.3571 0.3473 1.0000 0.9842 0.8208
CYP1A1*2C 140 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 66 0.4242 0.4028 1.0000 1.1506 0.8475
CYP1A2*1F 140 0.4429 0.4862 0.4668 1.8083 0.9449
CYP2A6*7 140 0.0143 0.0143 1.0000 -0.9906 0.0725
CYP2A6*8 140 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 134 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 140 0.0286 0.0284 1.0000 -0.9071 0.1195
CYP2E1*5B(Pst I) 138 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 136 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 140 0.4714 0.4986 0.8083 1.8814 0.9690
GSTP1*Ala114Val 140 0.0000 0.0284 0.0063 -0.9071 0.1113
NAT2*14A 140 0.1143 0.1579 0.0680 -0.1391 0.2952
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 104 0.3269 0.3254 1.0000 0.7937 0.7965
CYP1A1*2C 108 0.0185 0.0185 1.0000 -1.0193 0.0746
CYP1A2*1C 80 0.1500 0.1823 0.3201 -0.1168 0.2862
CYP1A2*1F 108 0.4444 0.5047 0.4261 1.8653 1.0000
CYP2A6*7 108 0.0556 0.0545 1.0000 -0.8057 0.1550
CYP2A6*8 108 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 106 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 108 0.0556 0.0545 1.0000 -0.8057 0.1527
CYP2E1*5B(Pst I) 104 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 108 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 108 0.5370 0.5004 0.7814 1.8396 0.9757
GSTP1*Ala114Val 108 0.0185 0.0185 1.0000 -1.0193 0.0734
NAT2*14A 108 0.1482 0.1696 0.3670 -0.1228 0.2841
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 13 HWE and Tajima’s D statistic tests performed for HER population 
 
 
 
Table 14 HWE and Tajima’s D statistic tests performed for HIM population  
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 156 0.3846 0.3838 1.0000 1.2218 0.8521
CYP1A1*2C 156 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 78 0.3846 0.4732 0.3048 1.6088 0.9160
CYP1A2*1F 156 0.5897 0.4764 0.0539 1.7714 0.9322
CYP2A6*7 156 0.0128 0.0128 1.0000 -0.9787 0.0761
CYP2A6*8 156 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 154 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 156 0.0641 0.0625 1.0000 -0.6844 0.1936
CYP2E1*5B(Pst I) 152 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 154 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 156 0.6154 0.4979 0.0395 1.8989 0.9733
GSTP1*Ala114Val 156 0.0256 0.0255 1.0000 -0.9037 0.1094
NAT2*14A 156 0.1539 0.1853 0.1703 0.0443 0.7032
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 80 0.4000 0.3532 0.6523 0.9001 0.8147
CYP1A1*2C 80 0.0250 0.0250 1.0000 -1.0527 0.0823
CYP1A2*1C 72 0.5000 0.4507 0.7080 1.4568 0.8959
CYP1A2*1F 80 0.5500 0.5063 0.7495 1.8116 1.0000
CYP2A6*7 80 0.0250 0.0250 1.0000 -1.0527 0.0813
CYP2A6*8 80 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 78 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 80 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Pst I) 80 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 78 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 80 0.6250 0.5035 0.2026 1.7946 0.9814
GSTP1*Ala114Val 80 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 80 0.2750 0.2402 1.0000 0.2279 0.7326
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 15 HWE and Tajima’s D statistic tests performed for OVA population  
 
 
 
Table 16 HWE and Tajima’s D statistic tests performed for DAMA population 
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 120 0.3667 0.3423 0.7157 0.9238 0.8127
CYP1A1*2C 120 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 46 0.1739 0.2937 0.0977 0.3995 0.7588
CYP1A2*1F 120 0.5167 0.5029 1.0000 1.8765 0.9894
CYP2A6*7 120 Monomorphic - test not done 0.0000 1.0000
CYP2A6*8 120 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 120 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 120 0.0500 0.0492 1.0000 -0.8149 0.1200
CYP2E1*5B(Pst I) 120 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 120 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 120 0.3833 0.5007 0.0749 1.8632 0.9765
GSTP1*Ala114Val 120 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 120 0.2000 0.1815 1.0000 -0.0299 0.2999
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 74 0.3514 0.3588 1.0000 0.9152 0.8213
CYP1A1*2C 74 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 68 0.2941 0.2950 1.0000 0.5144 0.7685
CYP1A2*1F 74 0.5135 0.4832 0.7426 1.6564 0.9315
CYP2A6*7 74 Monomorphic - test not done 0.0000 1.0000
CYP2A6*8 74 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 74 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 74 0.0541 0.0533 1.0000 -0.9046 0.1319
CYP2E1*5B(Pst I) 74 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 68 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 74 0.5405 0.4976 0.7386 1.7424 0.9580
GSTP1*Ala114Val 74 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 74 0.0270 0.0270 1.0000 -1.0613 0.0831
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Page | 107  
 
Table 17 HWE and Tajima’s D statistic tests performed for UGA population 
 
 
 
Table 18 HWE and Tajima’s D statistic tests performed for ZAM population 
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 448 0.2277 0.2358 0.5712 0.5171 0.7793
CYP1A1*2C 454 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 320 0.2500 0.2977 0.0609 0.8369 0.8084
CYP1A2*1F 454 0.5066 0.4992 0.8924 2.1019 0.9854
CYP2A6*7 454 0.0661 0.0640 1.0000 -0.5128 0.2414
CYP2A6*8 454 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 452 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 454 0.0617 0.0599 1.0000 -0.5376 0.2380
CYP2E1*5B(Pst I) 450 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 446 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 454 0.5374 0.4960 0.2246 2.0824 0.9715
GSTP1*Ala114Val 454 0.0132 0.0132 1.0000 -0.8185 0.1140
NAT2*14A 454 0.1454 0.1351 0.6151 -0.0858 0.3211
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 350 0.3714 0.3913 0.5648 1.4111 0.8715
CYP1A1*2C 350 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 274 0.2920 0.3350 0.1946 1.0334 0.8291
CYP1A2*1F 350 0.5543 0.4972 0.1774 2.0446 0.9792
CYP2A6*7 350 0.0343 0.0338 1.0000 -0.7276 0.1650
CYP2A6*8 350 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 344 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 350 0.0743 0.0717 1.0000 -0.5007 0.2413
CYP2E1*5B(Pst I) 350 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 340 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 350 0.5200 0.4904 0.4378 2.0035 0.9670
GSTP1*Ala114Val 350 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 350 0.1543 0.1986 0.0090 0.2582 0.7488
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 19 HWE and Tajima’s D statistic tests performed for DRC population  
 
 
 
Table 20 HWE and Tajima’s D statistic tests performed for CAR_U population 
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 320 0.2625 0.3429 0.0053 1.1065 0.8309
CYP1A1*2C 342 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 66 0.2424 0.4028 0.0305 1.1506 0.8491
CYP1A2*1F 340 0.5000 0.4985 1.0000 2.0472 0.9823
CYP2A6*7 342 0.4737 0.3626 0.0000 1.2351 0.8459
CYP2A6*8 342 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 258 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 342 0.1404 0.1309 1.0000 -0.1501 0.3074
CYP2E1*5B(Pst I) 242 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 246 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 338 0.5089 0.4937 0.7544 2.0175 0.9660
GSTP1*Ala114Val 342 0.0059 0.0059 1.0000 -0.8978 0.0616
NAT2*14A 342 0.1462 0.1653 0.1441 0.0559 0.7173
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 354 0.2881 0.3477 0.0277 1.1520 0.8419
CYP1A1*2C 358 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 174 0.2414 0.2794 0.2432 0.6230 0.7832
CYP1A2*1F 358 0.5028 0.4931 0.8780 2.0239 0.9674
CYP2A6*7 358 0.2346 0.2077 0.1400 0.3160 0.7536
CYP2A6*8 358 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 328 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 358 0.0615 0.0597 1.0000 -0.5694 0.2180
CYP2E1*5B(Pst I) 342 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 330 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 358 0.5084 0.4938 0.7694 2.0282 0.9676
GSTP1*Ala114Val 358 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 358 0.1229 0.1157 1.0000 -0.2346 0.2882
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 21 HWE and Tajima’s D statistic tests performed for CAR_P population 
 
 
 
Table 22 HWE and Tajima’s D statistic tests performed for SAC population 
 
 
  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 162 0.3210 0.3865 0.1423 1.2450 0.8560
CYP1A1*2C 182 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1C 50 0.6000 0.4580 0.1783 1.4124 0.8926
CYP1A2*1F 182 0.4286 0.3629 0.1387 1.1269 0.8395
CYP2A6*7 182 0.0769 0.0744 1.0000 -0.5858 0.2080
CYP2A6*8 182 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 180 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 182 0.0659 0.0641 1.0000 -0.6468 0.1965
CYP2E1*5B(Pst I) 164 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 144 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 182 0.5165 0.4678 0.3742 1.7497 0.9248
GSTP1*Ala114Val 182 Monomorphic - test not done 0.0000 1.0000
NAT2*14A 182 0.0659 0.0845 0.1489 -0.5257 0.2161
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 170 0.3177 0.3289 0.7454 0.9127 0.8174
CYP1A1*2C 170 0.1059 0.1009 1.0000 -0.4407 0.2380
CYP1A2*1C 84 0.0714 0.0697 1.0000 -0.7743 0.1621
CYP1A2*1F 170 0.3882 0.4317 0.4469 1.5224 0.8865
CYP2A6*7 170 0.1177 0.1114 1.0000 -0.3783 0.2569
CYP2A6*8 170 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 156 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 170 0.1059 0.1009 1.0000 -0.4407 0.2449
CYP2E1*5B(Pst I) 166 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 150 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 170 0.5177 0.5023 0.8283 1.9417 0.9902
GSTP1*Ala114Val 170 0.0941 0.0902 1.0000 -0.5039 0.2325
NAT2*14A 170 0.0824 0.1009 0.1986 -0.4407 0.2411
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Page | 110  
 
Table 23 HWE and Tajima’s D statistic tests performed for SAW population  
 
Table 24 HWE and Tajima’s D statistic tests performed for SAI population  
  
Given that majority of the sample had not deviated from HWE proportions, we 
used the exact test (Raymond and Rousset, 1995), reported to be more accurate 
when expected outcomes are small. Table 25 shows that most (58.8%) pair-wise 
comparisons are significant (p<0.05, yellow highlighted combinations). These 
significant combinations indicate these populations are significantly different to 
each other, possibly due to differing population sizes and/or allelic frequency 
differences.  
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 84 0.2381 0.2479 1.0000 0.2850 0.7355
CYP1A1*2C 88 0.1364 0.1672 0.2956 -0.1835 0.2681
CYP1A2*1C 20 Monomorphic - test not done 0.0000 1.0000
CYP1A2*1F 88 0.4318 0.4114 1.0000 1.2682 0.8509
CYP2A6*7 88 0.0682 0.0666 1.0000 -0.7813 0.1704
CYP2A6*8 88 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 68 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 86 0.2093 0.1896 1.0000 -0.0557 0.2737
CYP2E1*5B(Pst I) 74 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 68 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 88 0.5000 0.4796 1.0000 1.6734 0.9331
GSTP1*Ala114Val 88 0.2500 0.2547 1.0000 0.3366 0.7352
NAT2*14A 88 Monomorphic - test not done 0.0000 1.0000
Note 2n indicates the total number of alleles used in tests
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
Observed 
Heterozygosity
Expected 
Heterozygosity
P-value Tajima's D 
statistic
P-value
CYP1A1*2A 206 0.4078 0.4444 0.5019 1.6341 0.8993
CYP1A1*2C 210 0.2191 0.2392 0.4105 0.4180 0.7638
CYP1A2*1C 116 0.0690 0.0672 1.0000 -0.7152 0.1778
CYP1A2*1F 210 0.3238 0.4692 0.0018 1.7848 0.9279
CYP2A6*7 210 0.0952 0.1083 0.2823 -0.3601 0.2638
CYP2A6*8 210 Monomorphic - test not done 0.0000 1.0000
CYP2D6*3 206 Monomorphic - test not done 0.0000 1.0000
CYP2D6*4 208 0.1058 0.1007 1.0000 -0.4069 0.2477
CYP2E1*5B(Pst I) 206 Monomorphic - test not done 0.0000 1.0000
CYP2E1*5B(Rsa I) 150 Monomorphic - test not done 0.0000 1.0000
GSTP1*Ile105Val 210 0.4571 0.4017 0.2234 1.3840 0.8731
GSTP1*Ala114Val 210 0.1333 0.1250 1.0000 -0.2605 0.2793
NAT2*14A 210 Monomorphic - test not done 0.0000 1.0000
Note 2n indicates the total number of alleles used in tests
Significant tests p-values have been highlighted in blue
Locus
Sample size 
(2n)
Hardy-Weinberg Equilibrium test Tajima's D test for neutral 
selection
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Table 25 Exact Test of sample differentiation based on allele frequencies 
 
NB: For each combination, the first value is the p-value and the value following the ‘±’ is the standard deviation. Yellow highlighted 
combinations represent significant combinations between two population groups (p<0.05)
CAR_U CAR_P DAMA DRC HER HIM JU KHWE MOZ NAMA OVA SAC SAI SAW SEB UGA XUN
CAR_P 0.01270+0.0060
DAMA 0.83760+0.0581 0.00000+0.0000
DRC 0.00000+0.0000 0.01800+0.0127 0.00000+0.0000
HER 0.34780+0.0513 0.00910+0.0055 0.22155+0.0241 0.06310+0.0451
HIM 0.40820+0.0783 0.00000+0.0000 0.20485+0.0217 0.00000+0.0000 0.70520+0.0384
JU 0.02270+0.0213 0.06180+0.0209 0.00000+0.0000 0.35065+0.1045 0.00890+0.0043 0.00000+0.0000
KHWE 0.24705+0.0620 0.05905+0.0245 0.00150+0.0010 0.05535+0.0360 0.59140+0.0471 0.54765+0.0349 0.03955+0.0148
MOZ 0.66565+0.0832 0.00000+0.0000 0.57320+0.0257 0.00040+0.0004 0.04710+0.0231 0.00820+0.0075 0.00000+0.0000 0.00000+0.0000
NAMA 0.34905+0.0508 0.74520+0.0312 0.00235+0.0024 0.56835+0.0921 0.42695+0.0382 0.07505+0.0152 0.22330+0.0268 0.75710+0.0326 0.01770+0.0087
OVA 0.74320+0.0461 0.13260+0.0223 0.03515+0.0088 0.10350+0.0356 0.65460+0.0346 0.01730+0.0048 0.00405+0.0025 0.53490+0.0238 0.09570+0.0233 0.27895+0.0387
SAC 0.10955+0.0287 0.18950+0.0476 0.00000+0.0000 0.00485+0.0017 0.02715+0.0108 0.00160+0.0012 0.00005+0.0001 0.18985+0.0265 0.00130+0.0011 0.91600+0.0233 0.33100+0.0268
SAI 0.00225+0.0025 0.00000+0.0000 0.19880+0.0591 0.00000+0.0000 0.00000+0.0000 0.00705+0.0062 0.00825+0.0047 0.00865+0.0029 0.12530+0.0320 0.14980+0.0316 0.02885+0.0100 0.16195+0.0423
SAW 0.00000+0.0000 0.08060+0.0323 0.00040+0.0004 0.25110+0.0776 0.00600+0.0055 0.02155+0.0082 0.02760+0.0064 0.02650+0.0188 0.00000+0.0000 0.66825+0.0498 0.02850+0.0120 0.41190+0.0411 0.03470+0.0161
SEB 0.42270+0.0610 0.21870+0.0358 0.04120+0.0086 0.05415+0.0191 0.63265+0.0685 0.09230+0.0300 0.00240+0.0022 0.24155+0.0301 0.08835+0.0319 0.81170+0.0312 0.14085+0.0253 0.53380+0.0486 0.00000+0.0000 0.00525+0.0050
UGA 0.05005+0.0287 0.00000+0.0000 0.67750+0.0475 0.00000+0.0000 0.01720+0.0106 0.05415+0.0189 0.00000+0.0000 0.00000+0.0000 0.14610+0.0419 0.07210+0.0286 0.02385+0.0116 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000
XUN 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000 0.04375+0.0323 0.01205+0.0046 0.26385+0.0243 0.11575+0.0273 0.00000+0.0000 0.11795+0.0410 0.00695+0.0073 0.00225+0.0017 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000
ZAM 0.55670+0.0512 0.00000+0.0000 0.94350+0.0210 0.00000+0.0000 0.04205+0.0206 0.29400+0.0717 0.00000+0.0000 0.00000+0.0000 0.17000+0.0548 0.12235+0.0406 0.02880+0.0207 0.00000+0.0000 0.00000+0.0000 0.00000+0.0000 0.02445+0.0182 0.00315+0.0018 0.00000+0.0000
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3.5. Average gene diversity and average heterozygosity 
 
The average gene diversity calculated across the 13 SNP loci for each of the study 
populations (Figure 24). In Figure 24, above each bar the average diversity is 
given, with the bracket line above indicating the standard deviation. Average 
diversity ranges between 0.2049±0.1340 in DRC to 0.1170±0.0864 in the CAR_P. 
San populations have intermediate average diversity indices within the sample, 
ranging between 0.1549±0.1031 in XUN to 0.1420±0.0977 in the JU. The average 
gene diversity in sea-borne migrants SAW (0.1985±0.1283) and SAI 
(0.1700±0.1081) are the second and fifth highest, respectively in the sample.  
This is possibly due to these populations having larger proportions of the less 
frequent allele for CYP1A1*2C, CYP2D6*4, GSTP1*Ile105Val and 
GSTP1*Ala114Val loci compared to indigenous African populations in the study 
(Table 5). Overall, all populations show fairly low gene diversity across the loci 
investigated with large standard deviations. This can be due to CYP2A6*8, 
CYP2D6*3A, CYP2E1*5B(PstI) and CYP2E1*5B(RsaI) loci monomorphic nature, 
accounting for 30.8% of the loci investigated in the study. 
 
The average observed heterozygosity within each population is given in Figure 
25, calculated from the observed heterozygosity indices for each of the 13 loci 
(Table 7 to Table 24). This is a measure of genetic variability, where the JU have 
the highest (0.4687±1809). Other Khoe-San populations and the CAR_P have 
similar average observed heterozygosity indices to that found in neighbouring 
Bantu-speaking populations. The lowest genetic variability is found at 
0.1950±1943 in the MOZ. All populations had large standard deviations possibly 
due to many monomorphic loci being present; this more so for the JU and NAMA 
where both populations had only 4 polymorphic loci. In the sample an average of 
6 polymorphic loci was observed. Sea-borne migrants SAW and SAI both had 7 
polymorphic loci (Table 23 and Table 24), and the admixed SAC have the most (8 
polymorphic loci, Table 22). 
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 Figure 24 Average gene diversity across 13 SNP loci in study populations 
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Figure 25 Average observed heterozygosity across 13 SNP loci in study population
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3.6. Population affinities and evolution measured by genetic distance 
 
To understand the genetic variation that exists among sub-Saharan Africans in 
the study, allele frequencies for the 13 SNP loci were used to determine genetic 
distances among indigenous African populations in this study (excluding sea-
borne migrants SAI and SAW). Pair-wise Fst genetic distances were calculated 
(Appendix D) and used to understand the genetic affinities of the 16 indigenous 
African populations.  
 
For the evolutionary relationships of indigenous African populations in the study, 
the genetic distance matrix (Appendix D) was used to compute a Neighbour-
Joining population tree. Figure 26 gives the result of this analysis, showing the 
minimum evolutionary relationship of each population to each other as 
measured from genetic distances across the 13 SNP loci. Evident from the 
population tree the branch lengths are largest for the Khoe-San (except KHWE), 
where JU and XUN appear to be the oldest populations. CAR_P have a shorter 
branch length than Khoe-San, but much greater than other populations. The 
placement of branches of JU, XUN, NAMA and CAR_P indicates that these 
populations are the oldest and share a closer evolutionary history to each other 
than to Bantu-speakers. An exception to the Khoe-San can be seen for the KHWE 
who are closer to HER population, consistent with previous reports (Schlebusch, 
2010a). Bantu-speakers are closely related and are much younger than Khoe-San 
and Pygmy populations. Similar to the associations seen in the PCA plots, the 
DAMA are more closely related to Bantu-speakers than to their linguistically 
related NAMA. In relation to the branch topology in the tree there is no 
concordance with the geographic location among the Bantu-speakers. The SAC 
branch is closely placed to SEB, indicating close evolutionary history with the SAC 
slightly older than SEB. This assessment though as in the PCA plots, needs to be 
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treated with caution as the sea-borne parental populations SAW and SAI have 
been excluded here. 
 
 
Figure 26 Neighbour-Joining population tree for indigenous populations 
 
The spatial representation of the population’s distances with each other is given 
in principle component analysis plots (PCA), Figure 27 and Figure 28. Figure 27 
shows the PCA plot representing the majority of the variation detected, where 
the component 1 (x-axis) contains 64.9% of the total variation and the 
component 2 (y-axis) 18.3% of the variation. Relative to the distance observed on 
the x-axis: San populations JU and XUN cluster together and are furthest 
removed from other population; the Khoe (NAMA) is intermediately placed in 
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the plot along with the CAR_P; and all Bantu-speakers cluster together towards 
the left hand-side of the plot. There appears to be no geographic association 
among southeastern and Southwestern Bantu-speakers. Similarly, there is no 
geographic concordance between East, West, and Central African Bantu-peakers. 
Relative to the y-axis: Bantu-speakers appear somewhat different with DRC most 
removed from the group; again though no geographic concordance exists in this 
cluster. CAR_U cluster along with Bantu-speakers relative to the x-axis, and are 
further placed on the y-axis, possibly indicating an ancestral relation to all Niger-
Kordafanian speakers where divergence had occurred over a long period. 
Relative to the x-axis the DAMA cluster closely with Bantu-speakers, but are 
further removed relative to the y-axis. DAMA though are much removed from 
neighbours NAMA, corroborating previous reports of this population more 
closely related to Bantu-speakers than their Nama dialect speaking neighbours 
(Nurse et al. ,1985; Soodyall and Jenkins, 1993; Soodyall et al., 2008; Schlebusch, 
2010a). While NAMA and CAR_P are closes to one another relative to the x-axis, 
they are placed far apart on the y-axis.  
 
Figure 28 shows the third dimension in the PCA plot, where the component 3 
contains 12.7% of the total variation observed. Relative to component 3, all 
Bantu-speakers cluster tightly. Again no geographic concordance for Bantu-
speakers appears to be evident. The CAR_U are positioned within this cluster, 
further affirming the previously mentioned ancestral relation to Bantu-speakers. 
Although the DAMA are closely positioned on the x-axis to Bantu-sepakers, 
relative to the third component are further removed. Khoe-San populations and 
CAR_P continue to be furthest removed from each other and Bantu-speakers in 
the plot.  The SAC are too closely placed to Bantu-speakers, more closer than to 
Khoe-San populations. Their placement though needs to be treated with caution 
as their sea-borne parental populations SAW and SAI have been excluded here. 
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The results of the Analyses of Molecular Variance (AMOVA) for the indigenous 
African populations are summarized in Table 26. Populations were grouped by 
(1) Language, (2) Geographic position, and (3) Geography & Language. For all 
three AMOVA tests the DAMA and SAC were treated as separate entities. From 
the three AMOVA analyses the greatest variation can be found within 
populations. Test results for all permutations were all significant to p<0.05. 
Evident from the results of the three AMOVA tests performed, using language 
alone as a criterion to group populations (AMOVA analysis 1), the greatest 
proportion of variation was observed among groups rather than populations 
within the groups. This showing that language is a better confouder for these 
indigenous African populations. 
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Figure 27 Principal component analysis of Fst values from allele distribution of 13 loci – component 1 versus component 2 
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Figure 28 Principal component analysis of Fst values from allele distribution of 13 loci – component 1 versus component 3
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Table 26 AMOVA analysis summary of indigenous African sample 
 
AMOVA 
analysis 
number
Criteria for grouping Grouping
Among 
groups
Among 
populations 
within a 
group
Within 
populations
Khoe-San speakers (JU; XUN; KHWE; NAMA)
Bantu-speakers (SEB; MOZ; HIM; HER; OVA; ZAM; UGA; DRC; CAR_U; CAR_P)
Enigmatic (DAMA)
English and Afrikaans speakers (SAC)
Southern Africa (JU; XUN; KHWE; NAMA; DAMA; SEB; HIM; HER; OVA; SAC)
Eastern Africa (MOZ; ZAM; UGA)
Central Africa (DRC; CAR_U; CAR_P)
Southern African Khoe-San speakers (JU; XUN; KHWE; NAMA)
Southeastern Bantu-speakers (SEB; MOZ)
Southwestern Bantu-speakers (HIM; HER; OVA)
Eastern Africa (ZAM; UGA)
Central Africa (DRC; CAR_U; CAR_P)
Enigmatic (DAMA)
South African mixed population - English and Afrikaans speakers (SAC)
Note all values significant to P<0.05
2 Geography 1.10 1.89 97.01
3
Geography &      
Language
1.41 1.48 97.11
Fst (% variation)
1 Language 2.39 1.76 95.85
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3.7. Population structure 
 
Allele frequencies for SNP loci investigated in this study were used in the 
software program Structure to assess the average genetic variation within the 
study population. Figure 29 depicts the results of the apportioned variation that 
exists individually and the average within a population (population assignment). 
Iterations for K=2 to K=6 were done, where K represents the number of portions 
or clusters the variation had been divided into. In the K=2 analysis, two portions 
of the genetic variation was assigned where the green portion appears larger in 
oldest African populations, the Khoe-San and the CAR_P. The green portion likely 
represents that which is ancient in humans, and the red that which is more 
recent in variation, which tends to be larger in Bantu-speakers, SAC, SAW and 
SAI. With successive runs K was increased, where the green and the red portions 
differentiate further. At K=6 the greatest likely average posterior value is 
observed (likely best number of clusters for data), where the green portion 
continues to be larger in Khoe-San and CAR_P populations compared to other 
populations. The green portion is at its lowest in SAC, and sea-borne migrants 
SAW and SAI. Further at K=6, the yellow portioned variation is smallest in most 
African populations appearing larger in SAW and SAI. With the exception of these 
differences, when the variation is apportioned into six clusters there appears to 
be little distinction between the apportion variation within each population.   
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Figure 29 Results of the Structure runs (K=2 to K=6) for SNP loci in genes CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP2E1, GSTP1 and NAT2  
Individual Assignment Population Assignment
K=5
K=2
K=3
K=4
K=6
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CHAPTER 4   DISCUSSION 
 
The interaction of phase I and phase II metabolic genes are crucial to the 
maintenance of cell integrity and the normal process of cell proliferation, where 
if defaulted, could result in the formation of DNA adducts and cancer progression 
(Futreal et al., 2004). While many association studies investigating these genes 
have focused on European and Asian populations, little attention has been paid 
to the role of these genes among African populations. Given the paucity of 
genetic data from sub-Saharan Africa populations, this study was designed to 
unravel the genetic variation that exists in this region.  The polymorphisms 
selected for the study were identified from the literature where loci had been 
reported to confer moderate susceptibility to cancers. While this study has no 
direct clinical relevance; the screen for 15 loci at nine genes provides a robust 
survey of genetic variation across the African continent for these important 
xenobiotic genes. The genetic relationships between 18 sub-Saharan African 
populations were assessed with respect to these loci. Data from literature was 
used to compare the genetic variation between Africans and non-Africans to 
identify differences in distribution of mutant alleles globally, and to assess their 
evolutionary histories.  In deciphering the global distribution patterns of loci 
investigated, the study provides important insight into the relevance of these 
candidate loci for future studies on cancer and pharmacogenetics in Africa. To 
our knowledge this is a first most comprehensive study to investigate these 
cancer related genetic markers in Africa.  
 
4.1. Phase I metabolizers 
 
CYP1A1, CYP1A2, CYP2A6, CYP2D6 and CYP2E1 genes have been for several years 
been implicated in cancer susceptibility (Lu et al., 1986; Watanabe et al., 1990; 
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Persson et al., 1993; Watanabe et al., 1994; Fernandez-Salguero et al., 1995; 
Mirvish et al., 1995; Hildesheim et al., 1997; Wu et al., 1998; Oscarson et al., 
1998; Pianezza et al., 1998; Ingelman-Sundberg et al., 1999; Coutts and Urichuk, 
1999; London et al., 1999; Nakajima et al., 1999; Olshan et al., 2000; Murata et 
al., 2001; Yoshida et al., 2002; Fujihara et al., 2009; Santovito et al.,2010; 
Piacentini et al., 2011). These genes activate carcinogens and other exogenous 
agents into more reactive chemical compounds which have been evident in 
cancer progression due to their DNA damage capability (Watanabe et al., 1994). 
Phase I mutations investigated in this study were CYP1A1*2A and *2C; 
CYP1A2*1C and *1F; CYP2A6*7 and *8; CYP2D6*3A (2549delA) and 
CYP2D6*4(1846G>A); and CYP2E1*5B(PstI) and CYP2E1*5B(RsaI).  
 
CYP1A1*2A was prevalent in all global populations, to varying degrees in sub-
Saharan Africans. Among study populations, the allele was most frequent in 
Khoe-San populations. Conversely, CYP1A1*2C allele was near absent in sub-
Saharan Africans. Either mutant allele renders high enzyme activity of the 
CYP1A1 gene (da Silva et al., 2008) which could result in the high levels of 
reactive oxidants from the metabolism of many carcinogens including polycyclic 
aromatic hydrocarbons. This could indicate that these populations are 
susceptible to lung, oesophageal, oral and liver cancers (Wu et al., 1998; Fujihara 
et al., 2009; Piacentini et al., 2011). The incidence of such cancers have been 
noted as highly prevalent in sub-Saharan Africans (Ferlay et al., 2010), hereby 
indicating possible genetic implications. The presence of both CYP1A1*2A and 
*2C mutant alleles is appreciably prevalent in SAW and SAI, consistent with 
previous reports of susceptibility to cancers (Watanabe et al., 1994).  
 
Both CYP1A1*2A and CYP1A1*2C mutant alleles are more frequent in non-
African populations, being most frequent in far-East Asians. Far-East Asians are 
likely to have many more high activity enzymes than Africans. This is consistent 
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with previous association study reports of susceptibility to many cancers in these 
populations (Wang et al., 2003; Kiruthiga et al., 2011; Xia et al., 2013; Yoshida et 
al., 2007; Islam et al., 2013; Souiden et al., 2012). High proportions for 
CYP1A1*2A and CYP1A1*2C mutant alleles are found in some Native American 
populations and could indicate possible susceptiblity to lung, oesophageal, oral 
and liver cancers. 
 
CYP1A2*1C and *1F have both been associated in the aetiology of lung cancer, 
breast cancer, colorectal cancer and stomach cancer mainly in Europeans 
(Nakajima et al., 1999; Sachse et al., 1999; Hamdy et al., 2003b; Yoshida et al. 
2007; B'chir et al., 2009; Wang et al., 2012). The study dataset contained large 
proportions of missing data for the CYP1A2*1C locus, and while the locus did not 
deviate from HWE for all populations, a more conservative consensus of its 
distribution in the study sample should be taken. CYP1A2*1C was found in all 
sub-Saharan African populations. Data from literature tends to suggest that 
CYP1A2*1C is most frequent in far-East Asians. CYP1A2*1F is found at high 
frequencies throughout the world, where in sub-Saharan African populations the 
mutation is present at frequencies greater than 40%. CYP1A2*1F‘s high 
prevalence in Khoe-San and CAR_P populations could indicate that the allele had 
evolved in Africa before humans migrated out of Africa.  
 
The presence of CYP1A2*1F mutation decreases CYP1A2 enzyme activity 
(Cornelis et al., 2004). In contrast, the mutant allele for CYP1A2*1C renders an 
increased inducibility of the CYP1A2 enzyme (Cornelis et al., 2004). While little 
data was collected for the CYP1A2*1C locus, its presence of in most populations 
suggests that all populations in the study could contain CYP1A2 genes that have 
increased inducibility properties.  
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CYP1A2 encodes for an enzyme that activates several compounds including 
carcinogenic arylamines, acetaminophen, caffeine and a number of widely 
prescribed antipsychotic drugs such as clozapine, imipramine, caffeine, 
paracetamol, phenacetin, theophylline, and tacrine (Wooding et al., 2002; 
Fujihara et al., 2007). It is highly expressed in the liver and lesser degree in the 
lung (Nakajima et al., 1999; B'chir et al., 2009).  CYP1A2*1C high inducibility 
property induces highly active CYP1A2 genes and could result in a greater 
conversion of the before mentioned compounds into reactive oxidant species, 
potentially creating greater stress on cell integrity and susceptibility to cancers. 
CYP1A2*1F decreased enzyme activity conversely potentially could result in a 
reduction in the conversion of these compounds and hereby possibly reduces the 
susceptibility to cancer formation. While CYP1A2*1F had not deviated from 
Tajima’s D statistic test for selective neutrality, its decreased enzyme activity 
property and high prevalence could attribute to its retention in populations due 
to some protective measure. These functional profiles too would result in 
differences in CYP1A2 metabolising drugs such as clozapine, imipramine, 
caffeine, paracetamol, phenacetin, theophylline, tracrine and some neurotoxins 
(Olshan et al., 2000).  
 
Data for CYP2A6*7 and *8 mutations in the current sample and from the 
literature shows that these mutations are relatively underinvestigated. 
CYP2A6*7 was observed in most sub-Saharan African populations at varying 
frequencies, where the allele was most frequent in Central Africans. CYP2A6*7 
was found in all Khoisan-speakers with the exception of NAMA and DAMA.  
Globally, CYP2A6*7 was most frequent in far-East Asians. In contrast, CYP2A6*8 
was observed exclusively among Asian populations and possibly indicates an 
ascertainment bias where the mutation was first observed in far-East Asians.  
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The presence of the CYP2A6*7 mutant allele has been associated with reduced 
enzyme activity, while CYP2A6*8 is reported to render no effect (Landi et al., 
1994; Parveen et al., 2010). The presence of the mutant allele for CYP2A6*7 in 
most populations in the study possibly indicates that most sub-Saharan 
populations contain low activity CYP2A6 genes. CYP2A6 genes have been 
implicated in reduced nicotine dependency and reduced risk to lung and 
oesophageal cancer (Nakajima et al., 1999; Santovito et al., 2010). There is 
though some debate to the association in nicotine dependency and reduced 
enzyme activity of CYP2A6 (Pianezza et al., 1998; London et al., 1999; Yoshida et 
al., 2002) and further investigation is necessary. This though could indicate the 
high presence of CYP2A6*7 in DRC could relate to a greater proportion of these 
individuals having reduced nicotine dependency. Likewise, DRC could be greatly 
limited in their ability in the uptake of pharmaceutical agents such as coumarin 
(+)-cis-3,5-dimethyl-2-(3-pyridl)thiazolidin-4-one hydrochloride, methoxy-
flurane, halothane, losigamone, letrozole, valoproic acid, disulfiram,  and 
fadrozole (Tan et al., 2001). 
 
In this study, the CYP2D6*3A allele is absent in most Africans and minutely 
present in Europeans.  CYP2D6*4 was found in almost all sub-Saharan Africans. 
With the exception of the KHWE the mutation was not found in Khoe-San 
populations. CYP2D6*4 is most frequent in Europeans, Indians and Middle 
Eastern populations; and absent in far-East Asians.  
 
The presence of CYP2D6*4 in KHWE and CAR_P presents an interesting question: 
why is CYP2D6*4 absent in other Khoe-San populations? The population tree 
(Figure 26) suggests a very old ancestral relationship between Khoe-San and 
Pygmy (CAR_P). Firstly, it is possible that over time this mutantation was lost in 
Khoe-San due to genetic drift from these populations becoming extinct and living 
in isolation for many years. Secondly, it could be that it was introduced into the 
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KHWE and CAR_P by neighbouring Bantu-speaking populations. Another 
possibility could be that the mutant gene existed in Africa before the African 
exodus and following population divergence was retained in Bantu-speakers and 
possibly lost in Khoe-San. The last argument seems more plausible given the 
higher frequencies of CYP2D6*4 in Ghanaians, Tunisians and non-African 
populations; and the less likely that the mutation came from non-African 
sources. This argument could also explain the mutation’s presence in the KHWE, 
where it is postulated that they were originally a Bantu-speaking group who 
changed their pastoral lifestyle for the hunter-gatherer lifestyle practised by 
neighbouring San. This further affirms previous reports of the evolutionary 
history of the KHWE. In assessing the genetic affinities of the populations in the 
study to each other (PCA plots and population tree), it is likely that the CYP2D6 
mutant gene was retained in the CAR_P, and lost in the Khoe-San.  
 
The presence of either mutant alleles for CYP2D6*3A and CYP2D6*4 renders 
poor metabolism properties for the CYP2D6 enzyme (Rostami-Hodjegan et al., 
1998; Arneth et al., 2009). The presence of these mutations in Europeans, and 
Middle Eastern populations is an indication that these populations possibly have 
many more poor-metabolizer CYP2D6 genes in comparison with other 
populations. The high prevalence of CYP2D6*4 in Indians and Native American 
populations possibly indicates that these populations contain poor-metabolizer 
CYP2D6 genes. With respect to the CYP2D6 loci investigated here, the data 
suggests that poor-metabolizer genes are absent in far-East Asians with the 
exception of the Japanese who contain low proportion of the CYP2D6*4 
mutation. However, it is possible other functional related mutations for the 
CYP2D6 gene do exist in these populations and therefore cannot rule out the 
possible of dysfunctional CYP2D6 genes in these populations. The presence of 
these poor-metabolizer genes possibly reduces the risk to lung cancer (Rostami-
Hodjegan et al., 1998).  
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CYP2D6 gene is implicated in the metabolism of more than 25% clinically related 
drugs (van der Merwe et al., 2012), where reduced metabolic properties reduces 
the uptake of several neuroleptics, tricyclic antidepressant drugs, serotonin 
inhibitors and β-blockers (Linder et al., 1997; Sachse et al., 1997; Krajinovic et al., 
1999). The reduction in uptake of such compounds is important in HIV drug 
treatment research (Brown et al., 2012). Breast cancer patients that have been 
prescribed tamoxifen (antidepressant) to cope with psychological effects of the 
condition have shown subsequent treatment relapses and associated increased 
risk of breast cancer recurring (van der Merwe et al., 2012), possibly due to 
dysfunctional CYP2D6 genes. The data for the CYP2D6 gene observed here 
suggests that most Khoisan-speakers could be susceptible to lung cancer and 
could likely metabolize drugs mentioned above better than other African 
populations. 
 
Both CYP2E1*5B(PstI) and CYP2E1*5B(RsaI) loci are absent in sub-Saharan 
Africans and none contain mutant genes. CYP2E1 genes containing both mutant 
alleles render a 10-fold increased enzyme activity (Watanabe et al., 1994; Kim et 
al., 1996; Bolt et al., 2003). Outside Africa, both mutations are present in far-East 
Asians and Chileans at high frequencies, and in Europeans and Indians at lower 
frequencies. By inference, it is possible that far-East Asians and Chileans have 
high frequencies of the 10-fold increased enzyme activity genes; being present at 
lower frequencies in in Europeans and Indians. It is therefore possible that far-
East Asians, Europeans and Chileans could be genetically susceptible to 
nasopharyngeal, oesophageal, oral, prostate and lung cancer progression (Lu et 
al., 1986; Watanabe et al., 1990; Persson et al., 1993; Mirvish et al., 1995; 
Hildesheim et al., 1997; Sachse et al., 1997; Linder et al., 1997; Coutts and 
Urichuk, 1999; Ingelman-Sundberg et al., 1999; Murata et al., 2001; Ferreira et 
al., 2003; Yang et al., 2006). It is further possible that individuals in these 
populations carrying these mutations could be highly induced by ethanol and 
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isoniazid; and could possibly have a high uptake or metabolism of anaesthetics, 
analgesics, antipyretics, theophyllines, and chlorzoxazones (Flockhart, 2007). 
 
4.2. Phase II metabolizers 
 
The presence of null mutations of the GSTM1 and GSTT1 genes reduces the 
function of the respective gene which causes reduced expression, diminishing 
inactivation of various carcinogen-intermediates thereby increasing oxidative 
stress and the risk of DNA adducts forming (Olshan et al., 2000). Many studies 
have found that with the inability of these mutations in detoxifying tobacco-
related carcinogens and several environmental carcinogens, individuals 
presenting with these mutations are more likely ‘at risk’ of developing Head and 
Neck Squamous cell carcinoma (HNSCC), lung, bladder and other types of cancers 
(Olshan et al., 2000; Casson et al., 2003; Gajecka et al., 2005; Leichsenring et al., 
2006; Losi-Guembarovski et al., 2008; Torresan et al., 2008; Varela-Lema et al., 
2008).  
 
Within Africa the GSTM1*0 genotype was found in all populations albeit at lower 
frequencies compared to non-Africans. The mutation was though not present in 
JU. In Africa, the mutation increases in frequency from south to north where it is 
most frequent outside Africa. It is likely that GSTM1*0 was present in Africa long 
before human migration out of Africa, and over time due to founder effects 
during the course of migration throughout the world became highly prevalent in 
Europe, Asia and Middle East. Khoisan-speakers display the lowest frequency of 
GSTM1*0 among African populations, exceptions found in the KHWE and DAMA 
populations. Similar to trends seen for other loci, the GSTM1*0 mutation 
presence in the KHWE and DAMA is an indication of their genetic similarity to 
Bantu-speaking populations. This confirming previous reports of the genetic 
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histories of these population (Nurse et al., 1985; Soodyall et al., 2008; Henn et 
al., 2008; Schlebusch, 2010a; Schlebusch et al., 2012).  
 
In contrast, GSTT1*0 genotype is highly prevalent in Africans and where there 
appears to be little or no clinal distribution in Africa as that seen for GSTM1*0. 
While, GSTT1*0 is found at appreciably high frequencies in the Khoe-San, it is 
very low in the CAR_P. Given the evolutionary history observed for these 
populations in this study, the low proportion of the GSTT1*0 genotype could be 
due to drift and bottleneck effects following decline in population size. 
Conversely, the GSTM1*0 genotype is found at higher frequencies in CAR_P than 
in Khoe-San population. Given the well documented evolutionary history of 
humans, the presence of both mutations in these populations could indicate 
their existence in Africa for thousand’s of years, possible long before the African 
exodus. The proportions of both GSTM1*0 and GSTT1*0 null genotypes in 
populations of admixed ancestry (SAC, African-Americans and Brazilians) tend to 
be similar. Even though their ancestral histories are slightly different they have 
similar contributors in European and African descendants. 
 
Almost all global populations display >20% proportions of either GSTM1*0 and 
GSTT1*0 null genotypes. Given that these mutations render an inability to 
detoxify tobacco-related carcinogens and xenobiotics, almost all global 
populations could be adversely predisposed to cancers. This predisposition is due 
to their inability in detoxifying reactive oxidant species produced by phase I 
metabolic enzymes or detoxifiers. Pharmacologically, GSTM1*0 and GSTT1*0 
mutations have found to have significant association in hepatotoxicity induced 
by TB drugs (Roy et al., 2001; Huang et al., 2007; Leiro et al., 2008). However, 
one study has found no association in Indians (Chatterjee et al., 2010). Therefore 
further investigation to understanding the drug detoxifying effects of GSTM1*0 
and GSTT1*0 mutations is required. The presence of these mutations found in 
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sub-Saharan African populations highlights the importance in understanding 
genetic compositions of population with relation to drug treatment. This would 
be vital in regard to the treatment of TB that is a major communicable disease 
concern in southern Africa. 
 
There were individuals who were homozygous for both GSTM1*0 and GSTT1*0 
mutations. Such individuals were found in all study populations, except the JU 
and OVA. The frequencies of individuals homozygous for both mutations were 
highest in Bantu-speakers and low in the Khoe-San and CAR_P. Where reported 
in the literature, non-Africans have higher frequencies of both mutations being 
present (Adams et al., 2003; Gundacker et al., 2007; Al-Dayel et al., 2008; 
Fujihara et al., 2009; Santovito et al., 2010; Salem et al., 2011). Individuals 
homozygous for both mutations effectively have both GSTM1 and GSTT1 non-
functional genes.  Given the effects of each mutation, these individuals are 
possibly more susceptible to cancer development, and likely lack the ability to 
metabolise exogenous substances. 
 
Glutathione S-transferase class π (GSTP1) is an important phase II metabolising 
enzyme involved in detoxification of many hydrophobic and electrophilic 
compounds by catalytic conjugation activity. In this study two mutations for this 
gene was studied, GSTP1*Ile105Val and GSTP1*Ala114Val. The GSTP1*Ile105Val 
mutant allele was found in all African and other global populations. This 
mutation is frequently evident in southern African populations and found in high 
frequencies in Khoisan-speakers. GSTP1*Ile105Val decreases in frequency from 
the south towards north Africa, with lower frequencies observed in European, 
Asian and American populations. The GSTP1*Ala114Val mutant allele in contrast 
is near absent in sub-Saharan Africans.  
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The presence of the mutant allele for GSTP1*Ile105Val is reported to render a 3-
fold decreased enzyme activity (Ali-Osman et al., 1997). This mutation is frequent 
in most populations of this study, and most prevalent in the Khoe-San. The 
presence of either GSTP1*Ile105Val and GSTP1*Ala114Valalleles has been 
reported to render a decrease in enzyme activity (Ali-Osman et al., 1997).  The 
high frequencies of both these alleles in SAW and SAI is consistent with 
observations made in European and Asian populations, where Europeans and 
Asians contain a large proportion of GSTP1 genes with 3 to 4-fold reduced 
activity (van Lieshout et al., 1999; Abbas et al., 2004; Buchard et al., 2007).   
 
This reduced enzyme activity properties have for many years been associated 
with susceptibility to many head and neck cancers, including oesophageal and 
lung cancer (Cho et al., 2005); and associated reduced ability to metabolize 
chemotherapeutic agents, including melphalan,  cyclophosphamide, vincristine, 
adriamycin, cisplatin, etoposide, thiotepa, chlorambucil, and busulphan 
(Czerwinski et al., 1996; Awasthi et al., 1996). The presence of GSTP1*Ile105Val 
in sub-Saharan Africans (more so Khoisan-speakers), possibly indicates that a few 
individuals containing this mutation from these populations are incapable of 
using their GSTP1 genes in detoxifying carcinogens and have predisposition to 
cancer development. Further, the reduced ability to metabolize 
chemotherapeutic compounds could result in an altered susceptibility to 
chemotherapy-induced carcinogenesis and indicates the need for careful drug 
selection in cancer therapy of these populations. Allan et al. (2001) showed that 
the GSTP1*Ile105Val mutant allele was associated with reduced activity and 
inability to detoxify chemotherapy drugs, specifically to therapy-related acute 
myeloid leukemia, which can produce devastating complications in long-term 
cancer survival. 
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NAT2*14A, consistent with previous reports (Dandara et al., 2003; Teixeira et al., 
2007) was observed exclusively in Africans and admixed populations of African 
descent. The NAT2 gene is responsible for the N-acetylation of certain aryl 
amines, xenbiotics and tobacco-related carcinogens. The polymorphism 
NAT2*14A renders poor metabolising function and is likely to render associated 
risk in African populations in the development of urinary bladder, colorectal, 
breast, head and neck, lung and prostate cancers (Hein, 2000; Butcher et al., 
2002). In anti-TB treatment, NAT2 is associated with N-acetylation of Isoniazids 
(INH), one of the most important drugs used in TB chemoprophylaxis (Teixeira et 
al., 2007). TB is highly prevalent in 3.9 million Africans and with an incidence rate 
in Africa of 340 person per 100,000 a year is responsible for 50/100,000 deaths 
per year (http://www.who.int/mediacentre/factsheets/fs104/en/). The poor 
metabolic properties of NAT2*14A in Africans thus becomes of particular 
concern in anti-TB treatment choice. This result suggests a likely reason for INH 
treatment failure in some sub-Saharan Africans. However, there are four other 
mutations on this gene which also have slow modulation properties which can be 
found in African (Dandara et al., 2003), therefore illustrates the need to 
investigate NAT2 polymorphisms further in African populations. 
 
4.3. Role of Phase I and Phase II metabolisers in Africa 
 
In humans the interaction of phase I metabolisers with phase II metabolisers play 
an important role in maintaining cell integrity and preventing cancer progression 
(Furberg and Ambrosone, 2001). Bartsch et al. (2000) highlighted the importance 
of CYP1A1 mutations in combination with GSTM1 null mutations in smoking 
related cancers. Similarly, the interaction of CYP2E1 and GSTP1 genes have been 
implicated in increased risk of cancer development to European industrial 
workers exposed to styrene (Thier et al., 2003). Another example where toxic 
nitrosamines found in tobacco smoke can be slowly degraded overtime in 
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individuals who contain slow modulators for the NAT2 gene, in combination with 
high acetylators in the CYP2D6 and CYP1A2 genes could result in increased risk to 
cancer (Nebert, 1997).  Mutations of CYP1A1, CYP2A6 and CYP2E1, along with 
the deficiencies of GST genes have long been associated with increased 
susceptibility to various cancers (Dandara et al., 2001).  
 
These studies are a few examples of the interaction of phase I and II genes 
necessary to maintain cell integrity. These associations have come from several 
studies done in European and Asian populations, and associated with different 
environmental factors. Given that cancer is a multifactorial disease we cannot 
exclude the possibility that there are other biological and environmental 
variables which contribute to these associations, which are possibly not present 
in sub-Saharan Africans. However, if these interactions are present in sub-
Saharan Africans what can be deduced from the data of the present study? 
 
In review of the genetic data in this study alone, given the association identified 
in Bartsch et al. (2000), it is possible that this association may not be relevant to 
Africans. Africans have a higher predominance for the GSTT1*0 null mutation 
than for the GSTM1*0, and the CYP1A1*2C mutation is near absent.  Thier et al. 
(2003) implicated CYP2E1 and GSTP1 mutations in cancer progression. Given the 
absence of CYP2E1 mutations in the study, this combined genetic factor cannot 
be confirmed for indigenous Africans. The association between slow modulators 
for the NAT2 gene, in combination with high acetylators in the CYP2D6 and 
CYP1A2 genes (Nerbet, 1997), could possibly be demonstrated in study 
populations.  Africans contain the NAT2*14A allele rendering poor metabolic 
properties for the NAT2 gene and have the CYP1A2*1C mutation which renders 
an increased inducibility of the CYP1A2 enzyme. These genetic combinations 
though cannot be entirely confirmed or refuted though in this study. Therefore, 
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such combinations should be investigated further in African populations along 
with associated risk to other biological and environmental factors. 
 
4.4. Population genetic diversity  
 
Tajima’s D statistic was applied to all 13 SNP loci in each population to assess if 
they were under neutral selection. While several loci were found to deviate from 
HWE within certain populations, only CYP1A1*2C was found to be under 
selection within the XUN population albeit that the locus was not found to 
deviate from HWE. In addition, an analogous computation to the HWE test, the 
exact test was applied to determine population differences. Unlike the HWE, the 
exact test indicates a larger proportion of populations that were significantly 
different when compared to each other in pair-wise comparisons.  
 
A possible reason for the differences in the outcome of the HWE and exact tests 
could be due to the varying sample sizes.  The exact test is known to be more 
accurate when the expected number is low (Excoffier et al., 2005). In the case of 
the study sample, some populations had smaller sample sizes to others. It is 
likely that populations contained lower proportions of alleles than the expected 
outcomes. The latter is observed in the low average gene diversity and low 
average observed heterozygosity seen in each population across the 13 SNP loci 
investigated. These low diversity indices observed is likely due to all populations 
being monomorphic for CYP2A6*8, CYP2D6*3A, CYP2E1*5B(PstI) and 
CYP2E1*5B(RsaI) loci, accounting for 30.8% of the loci investigated in the study. 
In addition to these loci, indigenous African populations in the sample had many 
other monomorphic loci. CYP1A1*2C loci was monomorphic in all populations 
with the exception of the XUN, MOZ and HIM populations; likely due to recent 
introduction of the mutant allele from non-African sources. Similarly 
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GSTP1*Ala114Val loci was monomorphic in almost all populations, except for 
DRC, HER, MOZ, SEB and UGA populations where the proportions of the mutant 
allele is low and likely came from non-African individuals.  CYP2A6*7 loci was 
monomorphic in the NAMA, DAMA and OVA populations. The CYP2D6*4 loci was 
monomorphic in near all Khoe-San populations (JU, XUN and NAMA) and HIM 
population. In contrast, sea-borne migrants SAW and SAI had 7 polymorphic loci, 
and the admixed SAC had 8 polymorphic loci. 
 
The presence of these monomorphic loci in the indigenous African populations is 
not only key in understanding the evolutionary histories of these populations, 
but enhances our understanding of the genetic predisposition to cancers in these 
populations. All monomorphic loci highlighted above contained the wild-type 
allele. Therefore it is possible that these monomorphic loci are not candidate loci 
to be used for future cancer clinical studies within African populations. Given the 
increasing concern of the cancer burden in Africa, other markers implicated in 
cancer susceptibility should be investigated to better understand the genetic 
susceptibility that exists among Africans.  
 
4.5. Genetic relationships of sub-Saharan Africans 
 
To elucidate the genetic relationship of sub-Saharan Africans in the study, the 
genetic distances of indigenous African populations were used in PCA, 
population tree and AMOVA analyses. The results of these analyses show that 
sub-Saharan Africans are largely similar to each other, with a few exceptions. The 
PCA plot indicates that Bantu-speakers are closely related with little or no 
difference that corresponds to their geographic positions. The placement of 
Bantu-speakers in the topology of the population tree confirms this. AMOVA 
tests further indicate the greatest population difference is between language 
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groups, and not for populations grouped to their geographical locations. The 
great Bantu expansion is more likely the reason for this observation where 
migrants practicing pastoral and agricultural lifestyles left West Africa to 
populate the rest of sub-Saharan Africa during a period spanning approximately 
4000 years (Nurse et al., 1985; Güldemann et al., 2002; Lambert and Tishkoff, 
2009). Bantu-speakers moved to southern Africa following both eastern and 
western routes ~1500 years ago (Nurse et al., 1985). It is possible that time 
depth of these dispersion events would have been too short to allow for greater 
genetic differentiation. The Khoe-San were the aboriginal populations of 
southern Africa and they too remained genetically distinct from their Bantu-
speaking neighbours. Hence, language was evident as a major confounder to the 
variation seen among sub-Saharan Africans in this study. Previous reports of 
African populations concordant to language relationships corroborates these 
findings (Nurse et al., 1985; Cavalli-Sfroza et al., 1994; Tishkoff et al,. 2007; Behar 
et al., 2008; Naidoo et al., 2010; Schlebusch et al., 2010b; Schlebusch et al., 
2012). Language is reported to have a near one-to-one relationship with “tribal” 
or ethnicity grouping and where linguistic classification is synonymously used to 
define a population groups (Cavalli-Sforza et al., 1994; MacEachern et al., 2000). 
Similarly, a putative parallelism of linguistics and genetic change exists in Africans 
(MacEachern et al., 2000; Scheinfeldt et al., 2010).  
 
When migrating to the south, Bantu-speakers would have encountered Khoisan-
speakers. During these encounters Bantu-speakers would have introduced 
culture and subsistence practises to the Khoe-San populations (Nurse et al., 
1985). The interactions between these populations resulted largely in 
asymmetric assimilation of Khoe-San women into Bantu-speaking populations 
(Tishkoff et al., 2007; Soodyall et al., 2008; Naidoo et al., 2010; Schlebusch et al., 
2011; Sikora et al., 2011). This aspect could explain the similarities between 
some Khoisan-speaking populations and Bantu-speaking populations. However, 
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in the case of the KHWE, their genetic similarities to Bantu-speakers are much 
greater than to Khoisan-speakers. This finding is consistent with previous reports 
that the KHWE are not true Khoe-San. That they may be descendants of an east 
African pastoralist group that introduced the pastoralist culture into present day 
northern Botswana (Henn et al., 2008; Schlebusch et al., 2010a; Schlebusch et al., 
2012). In contrast, the DAMA appear genetically closer to Bantu-speakers while 
speaking the Nama dialect. This relationship further confirms the proposed 
genetic heritage of DAMA being of Bantu-speaking groups (Nurse et al. 1985; 
Soodyall et al., 2008; Schlebusch et al., 2010a; Schlebusch et al., 2012).  
 
Among Khoisan-speakers, the JU and XUN cluster together and are far removed 
from other clusters in the PCA plot. The population tree confirms this 
relationship and indicates these populations being the oldest in the sample. The 
NAMA too are quite different from other populations where their placement in 
the PCA is somewhat intermediate between Khoe-San and Bantu-speakers. The 
placement of the NAMA and the branch length in the population tree indicates 
NAMA are closely related to JU and XUN populations, but not as old. The CAR_P 
too show to be one of the older populations and distantly related to Bantu-
speakers and the Khoe-San. These differences are consistent with previous 
reports of the JU, XUN and CAR_P populations representing some of the oldest 
surviving populations in Africa (Nurse et al. 1985; Sikora et al., 2011; Schlebusch 
et al., 2012). All three populations followed hunter-gatherer subsistence and for 
many years due to linguistic and anthropological barriers had little interaction 
with neighbouring Bantu-speakers (Tishkoff et al., 2007; Nurse et al., 1985; 
Sikora et al., 2011; Schlebusch et al., 2012).  
 
The South African Coloured represent an admixed group born primarily from the 
unions of individuals from Khoisan-speaking, Bantu-speaking, South African 
White populations, and to a degree from Asian populations. Data in the study 
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indicates a high degree of mutant alleles not normally present in Africans having 
come from sea-borne migrants. The SAC population appeared to have closer 
genetic affinities to Bantu-speakers than to the Khoe-San. The SAC were sampled 
in the Gauteng province, South Africa. They had somewhat different histories to 
other coloured groups of South Africa where considerable contact with Bantu-
speakers were likely. This in comparison to Coloured groups of the Western Cape 
who have had considerable contributions from the Khoe-San or are extinct 
populations of the KhoeKhoe misclassified as ‘Coloured’ (Schlebusch, 2010a). The 
different histories of these South African Coloured groups could explain the 
differences in mutation proportions observed in the study between the SAC and 
Coloured groups from literature sources. 
  
Among the Eurasians, the SAW and SAI are largely distinct from sub-Saharan 
Africans. These populations mostly contained mutations that were present in 
parental populations and absent in their southern African neighbours. This 
aspect is confirmed by the higher than average gene diversity observed for these 
populations. For certain loci SAW and SAI contained slightly lower proportions of 
mutant alleles in comparison to parental populations. This trend is likely due to 
founder effects following their migration to South Africa, where their gene pools 
were a subset of that found in parental populations and the current surviving 
individuals have maintained these allele proportions.  
 
Structure analysis further confirmed these genetic relationships observed in PCA 
and the population tree. In apportioning the variation observed in the sample 
into ‘K’ clusters, the highest likelihood of the divisions was reached at K=6. At 
K=6 the JU, XUN and CAR_P contained higher proportions of older clusters. 
Bantu-speakers contained similar proportions of the six clusters. The KHWE and 
DAMA too had similar proportions of the sixth cluster as that of Bantu-speakers. 
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Sea-borne migrants contained a larger proportion of the sixth cluster, further 
distinguishing these populations from Africans in the study. 
 
4.6. Limitations of the study 
 
Caution should be taken when reviewing the evolutionary associations observed 
here and the implication of these variants in disease susceptibility to cancer. 
Similarly, no direct conclusions can be drawn to these variant’s pharmacogenetic 
properties in the study sample. The resolution within these genes is only a subset 
of those known to exist. More extensive research is required. Since no pathology 
information was collected from volunteers at the time of sample collection 
understanding these gene’s association to disease cannot be accurately inferred. 
Further, there could be other biological and environmental factors that could not 
be considered in this study which may impact on the underlying relevance of 
these gene mutations to diseases and pharmacogenetic properties.  
 
The low diversity observed in many of these populations could likely explain the 
largely compactness of the relationships detected. Therefore these findings 
should be seen as that representative of the markers investigated here, and that 
they do not necessarily relate to actual genetic distances between these 
populations. Where corroborating evidence from literature has been highlighted 
here, it more likely affirms the trends in evolutionary history seen among these 
populations. 
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4.7. Future studies and concluding remarks 
 
While the study has improved our understanding of the distribution of these 
mutations in sub-Saharan Africans, further investigation is required. Only a 
subset of the loci implicated in cancers was investigated and the monomorphic 
loci found in indigenous Africans is an indicator of these loci being less 
informative in an African context to assess cancer susceptibility. Further, there 
are several other biological factors to consider and therefore the interpretation 
to the relative genetic predisposition from this study should be treated with 
caution. 
 
In designing future studies, the evolutionary biology of these phase I and phase II 
metabolism genes and their functional interactions needs to be taken into 
account. Such genes have evolved over millions of years, in eukaryotes and other 
multicellular organisms to render vital life functions. Overtime these genes 
would have mutated towards adaptation in diets, niches and exposure to various 
xenobiotic species. The divergence from eukaryotes to multicellular organisms 
would have required dynamic interactions of these gene products (Nebert, 
1997). It is possible various polymorphism had been retained in populations as 
their combinations allowed for balanced functionality. This “balanced trait” 
would have allowed for ‘shared benefit’ in various metabolic systems and 
thereby maintaining functionality to survive during African’s exposure to 
changing climatic and dietary conditions as they migrated throughout Africa.  
 
Another aspect to consider in the increasing incidence of cancer in Africans, is 
that Africans are fast adopting western lifestyles (Ferlay et al., 2010; Somdyala et 
al., 2010; Wentink et al., 2010; Parkin et al., 2010; Dalal et al., 2011; Jemal et al., 
2012; Chokunonga et al., 2013). Genetic adaptations to environmental pressures 
is less likely in the next few decades and necessitates that future studies 
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investigate these environmental factors along with genetic factors in identifying 
associated risk factors to cancer that presents in Africa. Therefore, future studies 
should take cognisance to incorporating larger sample sizes, increase the number 
of genetic loci to investigate, and where possible incorporate other biological 
and environmental factors. By this design, future studies may unravel the 
mysteries in cancer progression within Africa with greater rigour. 
 
With respect to these loci we confirm previous genetic relationships reported for 
study populations. The study has shown the importance in elucidating the 
ancestral backgrounds of African populations to understand the possible 
underlying molecular epidemiology of certain diseases, namely cancer. More 
specifically, using a population genetic approach the study has shown that 
linguistic and anthropological relationships should be considered in the design of 
future clinical trials within sub-Saharan Africa. 
 
The data further indicated candidate loci which could be used in future clinical 
trial studies to better understand cancer progression in Africa. Non-
communicable diseases like cancer are on the increase in Africa, exacerbated by 
the increasing adoption to western lifestyles by Africans. Future studies would 
probably identify more candidate loci, and by incorporating other association 
factors the underlying aetiology of cancers and other non-communicable 
diseases may become evident. Finally, by unravelling the global distribution of 
mutations using both current study data and that found in the literature, the 
study has added to the pharmacological picture with respect to loci investigated, 
which could have benefits to the design of future pharmacological studies.  
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Appendix B: Comparative data 
Table A) Comparative data - CYP1A1*2A and CYP1A1*2C allele frequencies  
   
Wild type Mutant Wild type Mutant
Southern Africa
South Africa South African Bantu-speakers — — 192 (100%) 0 (0%) Masimirembwa et al., 1998
  
Eastern Africa   
Zimbabwe Zimbabwean — — 296 (100%) 0 (0%) Masimirembwa et al., 1998
  
Western Africa   
Benin Benin — — 94 (100%) 0 (0%) Jiang et al., 2005
Ghana Ghanaian 290 (88.8%) 37 (11.2%) 300 (91.9%) 27 (8.1%) Gronau et al., 2003
Ivory Coast Ivorian — — 82 (61.7%) 51 (38.3%) Santovito et al., 2010
Mali Malian 88 (76%) 28 (24%) 116 (100%) 0 (0%) Garte et al., 1998
Nigeria Nigerian 335 (76.5%) 103 (23.5%) — — Okobia et al., 2005
  
Northern Africa     
Egypt Egyptian — — 381 (73.3%) 139 (26.7%) El-Shennawy et al., 2011
Lybian Tuaregs 101 (95.3%) 5 (4.7%) 104 (98.1%) 2 (1.9%) Martinez-Labarga et al., 2007
Tunisia Tunisian 248 (89.7%) 29 (10.3%) — — Souiden et al., 2012
  
Europe     
Czech Republic Slavic 47 (92.7%) 4 (7.3%) 54 (96.6%) 2 (3.4%) Gemignani et al., 2007
Czech Republic Slavic 587 (91%) 58 (9%) — — Šarmanová et al., 2001
Greece Greek 188 (75.5%) 61 (24.5%) — — Agorastos et al., 2007
Hungary Hungarian 95 (92.9%) 7 (7.1%) 110 (96.4%) 4 (3.6%) Gemignani et al., 2007
Italy Italian — — 742 (95.6%) 35 (4.4%) Canova et al., 2010
Italy Italian — — 447 (95.8%) 20 (4.2%) D'Alo et al., 2004
Poland Polish 168 (92.9%) 13 (7.1%) 196 (96.5%) 7 (3.5%) Gemignani et al., 2007
Poland Polish 610 (94.7%) 34 (5.3%) 633 (98.3%) 11 (1.7%) Seremak-Mrozikiewicz et al., 2005
Romania Romanian 76 (92.8%) 6 (7.2%) 89 (96.5%) 3 (3.5%) Gemignani et al., 2007
Russia Russian 60 (92.9%) 5 (7.1%) 69 (96.4%) 3 (3.6%) Gemignani et al., 2007
Russia Russian 937 (85.2%) 163 (14.8%) — — Khvostova et al., 2012
Slovakia Slovakians 50 (91.7%) 5 (8.3%) 58 (96.4%) 2 (3.6%) Gemignani et al., 2007
Spain Spanish 126 (89.6%) 15 (10.4%) 125 (88.9%) 16 (11.1%) Esteller et al., 1997
Spain Spanish 590 (89%) 73 (11%) 658 (96%) 28 (4%) Landi et al., 2005
Spain Spanish 1399 (88.6%) 180 (11.4%) — — Lopez-Cima et al., 2012
Turkey Turkish 252 (85.4%) 43 (14.6%) — — Aydin-Sayitoglu et al., 2006
  
Asia     
Bangladesh Bangladeshi 156 (70%) 67 (30%) 176 (79.3%) 46 (20.7%) Islam et al., 2012
China Chinese 252 (60%) 168 (40%) 344 (77.3%) 101 (22.7%) Chen et al., 2007
China Chinese 304 (60.8%) 196 (39.2%) 388 (77.6%) 112 (22.4%) Yang et al., 2006
India Indian 32 (64%) 18 (36%) 37 (74%) 13 (26%) Kiruthiga et al., 2011
India Indian 403 (80.6%) 97 (19.4%) — — Parveen et al., 2010
Japan Japanese 510 (60.6%) 332 (39.4%) 624 (74.1%) 218 (25.9%) Kiyohara et al., 2012
Japan Japanese 145 (60.2%) 96 (39.8%) — — Nishino et al., 2008
Japan Japanese 126 (69%) 57 (31%) 153 (81%) 36 (19%) Sugawara et al., 2003
Japan Japanese 114 (61%) 73 (39%) 145 (77.5%) 42 (22.5%) Yoshida et al., 2007
Korea Korean 116 (55.8%) 92 (44.2%) — — Kim et al., 2004
Korea Korean — — 1598 (75.5%) 518 (24.5%) Kim et al., 2012
Korea Korean 225 (62.2%) 137 (37.8%) — — Kim et al., 2000
Thailand Thai 551 (51.7%) 514 (48.3%) 732 (71.5%) 292 (28.5%) Sangrajrang et al., 2009
  
Middle East     
Iran Iranian — — 336 (88.5%) 44 (11.5%) Razmkhah et al., 2011
Israel Jewish 144 (87.5%) 21 (12.5%) 137 (83.2%) 28 (16.8%) Guy et al., 2009
Lebanon Lebanonese 159 (93.2%) 12 (6.8%) — — Darazy  et al., 2011
  
North America     
Canada Canadian Caucasian 1584 (87.6%) 225 (12.4%) — — Anderson et al., 2012
Canada Canadian Caucasian 434 (92.4%) 36 (7.6%) 451 (96.1%) 19 (3.9%) Krajinovic et al., 1999
United States of America African-American 86 (98.9%) 1 (1.1%) — — Olshan et al., 2000
United States of America African-American 369 (76%) 117 (24%) 477 (96.2%) 19 (3.8%) Taioli et al., 1998
United States of America African-American 410 (76%) 129 (24%) 523 (97%) 16 (3%) Garte et al., 1998
United States of America Caucasian American 262 (96%) 11 (4%) — — Olshan et al., 2000
United States of America Caucasian American 116 (82.5%) 25 (17.5%) 130 (92%) 11 (8%) Wickliffe et al., 2011
Mexico Mexican — — 180 (66%) 92 (34%) Gallegos-Arreola et al., 2004
Mexico Mexican — — 174 (46%) 208 (54%) Martínez-Ramírez et al., 2012
Mexico Mexican — — 241 (46%) 288 (54%) Perez-Morales et al., 2008
Costa Rica Costa Rican 1238 (68.6%) 567 (31.4%) — — Cornelis et al., 2004
  
South America
Brazil Brazilian 234 (91.1%) 23 (8.9%) 216 (84%) 41 (16%) Gaspar et al., 2002
Chile Chilean 160 (63%) 94 (37%) 122 (67.8%) 58 (32.2%) Roco et al., 2012
Region &                                     
country of sample Population name Reference
CYP1A1*2A  
rs4646903T>C
CYP1A1*2C    
rs1048943A>G
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Table B) Comparative data - CYP1A2*1C and CYP1A2*1F allele frequencies 
 
  
Wild type Mutant Wild type Mutant
Southern Africa
South Africa South African Bantu-speakers — — 600 (61%) 383 (39%) Dandara et al., 2011
Namibia Ovambo — — 96 (54%) 82 (46%) Fujihara et al., 2007
    
Eastern Africa     
Zimbabwe Zimbabwean — — 124 (43.4%) 162 (56.6%) Dandara et al., 2004
Tanzania Tanzanian — — 73 (51.4%) 69 (48.6%) Dandara et al., 2004
Ethiopia Ethiopian — — 87 (50.4%) 86 (49.6%) Aklillu et al., 2004
    
Western Africa     
Benin Benin — — 40 (43%) 54 (57%) Jiang et al., 2005
    
Nothern Africa     
Egypt Egyptian 198 (93.4%) 14 (6.6%) 68 (31.8%) 145 (68.2%) Hamdy et al., 2003
Tunisia Tunisian — — 101 (50.5%) 99 (49.5%) B'chir et al., 2009
    
Europe     
Czech Republic Slavic 53 (98.8%) 1 (1.2%) 39 (68.2%) 18 (31.8%) Gemignani et al., 2007
Denmark Danish — — 28 (24.8%) 85 (75.2%) Christiansen et al., 2000
Hungary Hungarian 109 (99%) 1 (1%) 78 (67.2%) 38 (32.8%) Gemignani et al., 2007
Italy Italian — — 264 (34.6%) 498 (65.4%) Canova et al., 2010
Netherlands Dutch — — 73 (72.5%) 28 (27.5%) Ketelslegers et al., 2006
Norway Norwegian — — 114 (28.5%) 286 (71.5%) Saebo et al., 2008
Poland Polish 192 (98.9%) 2 (1.1%) 139 (67.5%) 67 (32.5%) Gemignani et al., 2007
Romania Romanian 87 (98.9%) 1 (1.1%) 63 (67.8%) 30 (32.2%) Gemignani et al., 2007
Russia Russian 68 (99%) 1 (1%) 49 (67.2%) 24 (32.8%) Gemignani et al., 2007
Russia Russian — — 524 (30.9%) 1174 (69.1%) Khvostova et al., 2012
Slovakia Slovakians 57 (99%) 1 (1%) 41 (67.1%) 20 (32.9%) Gemignani et al., 2007
Spain Spanish 612 (98.2%) 12 (1.8%) 229 (33.5%) 454 (66.5%) Landi et al., 2005
Switzerland Swiss 196 (98%) 4 (2%) 64 (32%) 136 (68%) Todesco et al., 2003
Turkey Turkish — — 124 (47.1%) 139 (52.9%) Altayli et al., 2009
Turkey Turkish 193 (96.2%) 8 (3.8%) 130 (49.2%) 134 (50.8%) Uslu et al., 2010
    
Asia     
China Chinese — — 160 (37.8%) 263 (62.2%) Chen et al., 2007
China Chinese — — 79 (32.6%) 162 (67.4%) Han et al., 2001
India Indian 373 (93.3%) 27 (6.8%) 226 (56.5%) 174 (43.5%) Singh et al., 2010
Japan Japanese — — 298 (37%) 508 (63%) Shimada et al., 2009
Japan Japanese 133 (74.3%) 46 (25.7%) 65 (37.1%) 110 (62.9%) Yoshida et al., 2007
Korea Korean — — 171 (68.4%) 79 (31.6%) Fujihara et al., 2007
Mongolia Mongolian — — 121 (78.8%) 33 (21.2%) Fujihara et al., 2007
Thailand Thai — — 236 (22.8%) 799 (77.2%) Sangrajrang et al., 2009
    
North America     
Canada Canadian Caucasian — — 558 (30.7%) 1260 (69.3%) Anderson et al., 2012
Canada Canadian Caucasian — — 117 (28.3%) 295 (71.7%) Kotsopoulos et al., 2007
United States of America African-American — — 338 (58.6%) 239 (41.4%) Rebbeck et al., 2007
United States of America Caucasian American — — 633 (54.4%) 531 (45.6%) Rebbeck et al., 2007
United States of America Caucasian American — — 45 (31.6%) 96 (68.4%) Wickliffe et al., 2011
Costa Rica Costa Rican — — 574 (31.8%) 1232 (68.2%) Cornelis et al., 2004
    
South America     
Brazil Brazilian — — 265 (34%) 513 (66%) Shimada et al., 2009
Chile Chilean — — 59 (23.1%) 195 (76.9%) Roco et al., 2012
    
Region &                                     
country of sample Population name
CYP1A2*1C   
rs2069514G>A
CYP1A2*1F   
rs762551C>A Reference
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Table C) Comparative data - CYP2A6*7 and CYP2A6*8 allele frequencies  
  
Wild type Mutant Wild type Mutant
Western Africa
Ghana Ghanaian 420 (100%) 0 (0%) 420 (100%) 0 (0%) Gyamfi et al., 2005
    
Europe     
Sweden Swedish 380 (100%) 0 (0%) 380 (100%) 0 (0%) Djordjevic et al., 2012
    
Asia     
China Chinese 320 (93%) 24 (7%) 339 (98.6%) 5 (1.5%) Nurfadhlina et al., 2006
India Indian 348 (100%) 0 (0%) 345 (99.1%) 3 (0.9%) Nurfadhlina et al., 2006
Japan Japanese 118 (93.7%) 8 (6.3%) 124 (98.4%) 2 (1.6%) Xu et al., 2002
Japan Japanese 172 (93.5%) 12 (6.5%) 180 (97.8%) 4 (2.2%) Yoshida et al., 2002
Korea Korean 256 (88.9%) 32 (11.1%) 286 (99.3%) 2 (0.7%) Djordjevic et al., 2012
Korea Korean 403 (96.4%) 15 (3.6%) 412 (98.6%) 6 (1.4%) Yoshida et al., 2002
Malaysia Malaysian 517 (95.7%) 23 (4.3%) 513 (95%) 27 (5%) Nurfadhlina et al., 2006
Thailand Thai 228 (95%) 12 (5%) 240 (100%) 0 (0%) Peamkrasatam et al., 2006
    
North America     
Canada Canadian African-American 226 (100%) 0 (0%) 226 (100%) 0 (0%) Mwenifumbo et al., 2005
Canada Canadian Caucasian 220 (100%) 0 (0%) 220 (100%) 0 (0%) Mwenifumbo et al., 2005
Canada Canadian Caucasian 602 (100%) 0 (0%) 602 (100%) 0 (0%) Xu et al., 2002
    
Region &                                     
country of sample Population name Reference
CYP2A6*7                       
rs5031016A>G
CYP2A6*8                            
rs28399468C>A
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D) Comparative data - CYP2D6*3 and CYP2D6*4 allele frequencies  
  
Wild type Mutant Wild type Mutant
Southern Africa
South Africa South African Bantu-speakers 152 (100%) 0 (0%) 147 (96.7%) 5 (3.3%) Dandara et al., 2001
South Africa South African Coloured — — 120 (96.8%) 4 (3.2%) vd Merwe et al., 2012
South Africa South African White — — 38 (76%) 12 (24%) vd Merwe et al., 2012
    
Eastern Africa     
Zimbabwe Zimbabwean 228 (100%) 0 (0%) 223 (98%) 5 (2%) Dandara et al., 2001
Tanzania Tanzanian 387 (99.7%) 1 (0.3%) 381 (98.2%) 7 (1.8%) Dandara et al., 2001
Tanzania Tanzanian — — 129 (95.9%) 6 (4.1%) Hodel et al., 2012
Malawi Malawian — — 25 (98%) 1 (2%) Brown et al., 2012
    
Western Africa     
Ghana Ghanaian 519 (100%) 0 (0%) 485 (93.4%) 34 (6.6%) Griese et al., 1999
Ghana Ghanaian — — 250 (76.5%) 77 (23.5%) Gronau et al., 2003
    
Northern Africa     
Tunisia Tunisian — — 172 (90.7%) 17.5 (9.3%) Ouerhani et al., 2008
    
Europe     
Czech Republic Slavic 441 (98.9%) 5 (1.1%) 344 (77.1%) 102 (22.9%) Buzkova et al., 2008
Denmark Danish 343 (98.7%) 5 (1.3%) 272 (78.1%) 76 (21.9%) Vangsted et al., 2010
Germany German — — 1178 (100%) 0 (0%) Sachse et al., 1997
Greece Greek 553 (97.7%) 13 (2.3%) 466 (82.3%) 100 (17.7%) Arvanitidis et al., 2007
Poland Polish 142 (97.9%) 3 (2.1%) 112 (76.9%) 34 (23.1%) Gawronska-Szklarz et al., 1999
Portugal Portuguese 99 (98.6%) 1 (1.4%) 87 (86.7%) 13 (13.3%) Correia et al., 2009
Spain Spanish — — 240 (87.1%) 36 (12.9%) Gonzalez et al., 1998
Spain Spanish 208 (99.1%) 2 (1%) 181 (86.2%) 29 (13.8%) Menoyo et al., 2006
Switzerland Swiss 114 (100%) 0 (0%) 82 (71.9%) 32 (28.1%) Hersberger et al., 2000
Turkey Turkish — — 175 (66.3%) 89 (33.7%) Altayli et al., 2009
Turkey Turkish 290 (98.3%) 5 (1.7%) 250 (84.7%) 45 (15.3%) Aydin-Sayitoglu et al., 2006
United Kingdom English 931 (98.1%) 18 (1.9%) 909 (79.6%) 233 (20.4%) Smith et al., 1992
    
Asia     
Cambodia Cambodian   74 (100%) 0 (0%) Hodel et al., 2012
China Chinese 446 (100%) 0 (0%) 445 (99.8%) 1 (0.2%) Ji et al., 2002
India Indian 447 (100%) 0 (0%) 414 (92.7%) 33 (7.3%) Naveen et al., 2006
India Indian — — 402 (80.4%) 98 (19.6%) Parveen et al., 2010
Japan Japanese 296 (100%) 0 (0%) 292 (98.6%) 4 (1.4%) Furuno et al., 2001
    
Middle East     
Iran Iranian 99 (99%) 1 (1%) 91 (91%) 9 (9%) Hashemi-Soteh et al., 2011
Iran Iranian — — 175 (87.5%) 25 (12.5%) Kouhi et al., 2009
Israel Jewish — — 136 (82.6%) 29 (17.4%) Guy et al., 2009
Jordan Jordanian — — 168 (87.2%) 25 (12.8%) Zihlif et al., 2012
Saudi Arabia Saudi Arabian — — 195 (96.5%) 7 (3.5%) McLellan et al., 1997
    
North America     
Canada Canadian Caucasian 457 (97.3%) 13 (2.7%) 391 (81.7%) 88 (18.3%) Krajinovic et al., 1999
United States of America African-American 489 (99.4%) 3 (0.6%) 456 (92.7%) 36 (7.3%) Leathart et al., 1998
United States of America American Indian 373 (99.7%) 1 (0.3%) 296 (79.1%) 78 (20.9%) Fohner et al., 2013
United States of America Caucasian American 917 (98.8%) 11 (1.2%) 760 (81.9%) 168 (18.1%) Leathart et al., 1998
United States of America Caucasian American 372 (98.4%) 6 (1.6%) 277 (73.3%) 101 (26.7%) Skrętkowicz et al., 2011
Mexico Mexican 829 (99.6%) 3 (0.4%) 794 (95.5%) 38 (4.5%) Salazar-Flores et al., 2012
Panama Panamanian 105 (100%) 0 (0%) 87 (82.9%) 18 (17.1%) Jorge et al., 1999
    
South America     
Argentina Argentinian 234 (97.5%) 6 (2.5%) 199 (82.9%) 41 (17.1%) Lavandera et al., 2005
Brazil Brazilian 373 (86.2%) 60 (13.8%) 415 (96.1%) 17 (3.9%) Silviera et al., 2010
Chile Chilean 251 (99%) 3 (1%) 223 (88.1%) 30 (11.9%) Roco et al., 2012
Colombia Colombian 136 (100%) 0 (0%) 117 (86%) 19 (14%) Jorge et al., 1999
    
Region &                                     
country of sample Population name
CYP2D6*3                                
rs35742686delA
CYP2D6*4                                
rs3892097G>A Reference
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E) Comparative data - CYP2E1*5B (PstI) and CYP2E1*5B (RsaI) allele frequencies 
  
Wild type Mutant Wild type Mutant
Southern Africa
South Africa South African Bantu-speakers 331 (100%) 0 (0%) 322 (97.3%) 9 (2.7%) Chelule et al., 2006
    
Northern Africa     
Egypt Egyptian — — 231 (98.3%) 4 (1.7%) Hamdy et al., 2002
    
Europe     
Czech Republic Slavic 43 (97.8%) 1 (2.2%) 54 (97.5%) 1 (2.5%) Gemignani et al., 2007
Czech Republic Slavic — — 605 (98%) 13 (2%) Šarmanová et al., 2001
Hungary Hungarian 89 (98%) 2 (2%) 109 (97.5%) 3 (2.5%) Gemignani et al., 2007
Poland Polish 156 (98%) 3 (2%) 194 (97.5%) 5 (2.5%) Gemignani et al., 2007
Romania Romanian 71 (97.9%) 2 (2.1%) 89 (97.5%) 2 (2.5%) Gemignani et al., 2007
Russia Russian 56 (98%) 1 (2%) 68 (97.5%) 2 (2.5%) Gemignani et al., 2007
Slovakia Slovakians 47 (98%) 1 (2%) 57 (97.6%) 1 (2.4%) Gemignani et al., 2007
Spain Spanish 261 (94.7%) 15 (5.3%) — — Gonzalez et al., 1998
Spain Spanish 622 (97.2%) 18 (2.8%) 568 (97.7%) 14 (2.3%) Landi et al., 2005
Spain Spanish 413 (95.9%) 18 (4.1%) — — Rodrigo et al., 1999
Turkey Turkish — — 281 (95.3%) 14 (4.7%) Aydin-Sayitoglu et al., 2006
Turkey Turkish 412 (100%) 0 (0%) 404 (98.1%) 8 (1.9%) Ulusoy et al., 2007
    
Asia     
China Chinese — — 358 (82.2%) 78 (17.8%) Chen et al., 2007
China Chinese 489 (81.6%) 110 (18.4%) 465 (77.4%) 136 (22.6%) Huo et al., 2012
China Chinese 385 (77%) 115 (23%) 385 (77%) 115 (23%) Yang et al., 2006
India Indian 283 (97.8%) 7 (2.2%) 283 (97.8%) 7 (2.2%) Balaji et al., 2011
India Indian 100 (100%) 0 (0%) — — Mittal et al., 2005
Japan Japanese 185 (76.8%) 56 (23.2%) — — Nishino et al., 2008
Korea Korean 119 (78.3%) 33 (21.7%) — — Kim et al., 2004
Korea Korean 294 (81.1%) 69 (18.9%) — — Kim et al., 2000
Taiwan Taiwanese — — 538 (78.6%) 147 (21.4%) Hildesheim et al., 1997
Taiwan Taiwanese 241 (75.2%) 80 (24.8%) — — Hsieh et al., 2007
Thailand Thai — — 865 (84.9%) 154 (15.1%) Sangrajrang et al., 2010
    
Middle East     
Lebanon Lebanonese 216 (100%) 0 (0%) 213 (98.6%) 3 (1.4%) Zgheib et al., 2010
    
North America     
Canada Canadian Caucasian 1745 (96.4%) 65 (3.6%) — — Anderson et al., 2012
United States of America Caucasian American 115 (84.6%) 21 (15.4%) — — Wickliffe et al., 2011
Mexico Mexican — — 497 (73.5%) 179 (26.5%) Gordillo-Bastidas et al., 2010
    
South America     
Chile Chilean 155 (85.8%) 26 (14.2%) 155 (85.8%) 26 (14.2%) Roco et al., 2012
    
Region &                                     
country of sample Population name
CYP2E1*5B (PstI)                                  
rs3813867G>C
CYP2E1*5B (RsaI)                                    
rs2031920G>A Reference
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F) Comparative data - GSTM1*0 and GSTT1*0 genotype frequencies 
 
Region & country of sample Population ¥
Presence of both 
GSTM1*0 & 
GSTT1*0
Presence of 
GSTM1*0
Presence of  
GSTT1*0
Total Sample References ₭
Southern Africa
South Africa & Nambia SEB [1] € 49 (21.8%) 66 (33.4%) 1; 2
South Africa SAC [1] 9 (13%) 14 (20%) 39 (57%) 69 2
Namibia OVA [1] 4 (3%) 15 (11.2%) 48 (35.8%) 134 3
Eastern Africa
Zimbabwe Zimbabwean € 36 (24.3%) 32 (26%) 1
Ethiopia Ethiopia 67 (43.8%) 57 (37.3%) 153 4
Somalia Somalia 40 (40%) 44 (44%) 100 5
Tanzania Tanzania € 65 (31.4%) 35 (25%) 1
Central Africa
Cameroon Cameroonian 35 (2.8%) 59 (4.7%) 1265 4
Western Africa
Gambia Gambian € 68 (20.2%) 121 (37.1%) 6
Ivory Coast Ivorian 19 (14.3%) 48 (36.1%) 44 (33.1%) 133 7
Northern Africa
Egypt Egyptian 206 (55.5%) 109 (29.4%) 371 8; 9
Tunisia Tunisian 39 (21%) 118 (63.4%) 69 (37.1%) 186 10
Europe
Austria Austrian 19 (11.1%) 98 (57.3%) 30 (17.5%) 171 11
Czech Republic Czech € 445 (52.2%) 141 (16%) 12
Denmark Danish 105 (52.5%) 28 (14%) 200 5
France French 37 (66.1%) 14 (25%) 56 13
Germany German 1846 (52.5%) 621 (17.7%) 3513 14
Greece Greek 148 (59.9%) 107 (43.3%) 247 15
Italy Italian 59 (49.2%) 34 (28.3%) 120 4
Netherlands Dutch 733 (53.1%) 499 (36.2%) 1380 16
Turkey Turkish 269 (54.8%) 103 (21%) 491 27; 28
Spain Spainish 1637 (53.4%) 645 (21%) 3066 17; 4; 18
Asia
China Chinese 952 (54.6%) 755 (43.3%) 1743 19; 20
India Indian 300 (30%) 178 (17.8%) 999 21; 22
Japan Japanese € 1110 (50.1%) 753 (49.6%) 23
Korea Korean € 1952 (52.7%) 1853 (50.9%) 23
Mongolia Mongolian 25 (12.1%) 96 (46.4%) 53 (25.6%) 207 3
Taiwan Taiwanese 322 (56.1%) 287 (50%) 574 24
Middle East
Bahrain Bahraini 24 (14.4%) 83 (49.7%) 48 (28.7%) 167 10
Iran Iranian 142 (37.4%) 73 (19.2%) 380 25
Lebanon Lebanonese 23 (16.3%) 74 (52.5%) 53 (37.6%) 141 10
Saudi Arabia Saudi Arabian 158 (22.7%) 371 (53.4%) 271 (39%) 695 26
North America
Greenland Greenlander 47 (47%) 46 (46%) 100 5
America  Caucasian American 991 (52.5%) 309 (16.4%) 1886 29; 30; 31
America African-American 215 (28.6%) 145 (19.3%) 753 29; 30; 31
Canadia Canadian Caucasian 269 (56.5%) 75 (15.8%) 476 32
Mexico Mexican 143 (37.4%) 58 (15.2%) 382 33
South America
Brazil Brazilian 137 (31.5%) 128 (29.4%) 436 34; 35
Paraguay Paraguayian 24 (35.8%) 12 (17.9%) 67 36
¥ For population name and ethnicity refer to table 1.
[1] symbolises a population from other studies. These populations are similar to those collected for this study therefore the same popultation code has been used
€ Null mutations were either typed individually or samples typed differed for each mutation, therefore the total sample size has not been displayed.
₭ Reference numbers - references can be found in accompanying reference table
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Table F continued - references to GSTM1*0 and GSTT1*0 comparative data 
 
  
Reference number Reference
1 Dandara et al., 2002
2 Adams et al., 2003
3 Fujihara et al., 2009
4 Piacentini et al., 2011
5 Buchard et al., 2007
6 Wild et al., 2000
7 Santovito et al., 2010
8 Amer et al., 2011
9 Abdel-Rahman et al., 2012
10 Abdel-Halim et al., 2011
11 Gundacker et al., 2007
12 Sarmanova et al., 2001
13 Iarmarcovai et al., 2006
14 Rudolph et al., 2012
15 Agorastos et al., 2007
16 Van Der Hel et al., 2005
17 Cantor et al., 2010
18 Lopez-Cima et al., 2012
19 Wang et al., 2003
20 Liu et al., 2009
21 Kiran et al., 2008
22 Wang et al., 2011
23 Kurose et al., 2012
24 Tsai et al., 2006
25 Rafiee et al., 2010
26 Al-Dayel et al., 2008
27 Aydin-Sayitoglu et al., 2006
28 Yalin et al., 2007
29 Olshan et al., 2000 
30 Millikan et al., 2000
31 Van Emburgh et al., 2008
32 Fischer et al., 2012
33 Martínez-Ramírez et al., 2012
34 Gatta´s et al., 2004
35 Magno et al., 2009
36 Gaspar et al., 2002
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G) Comparative data - GSTP1-Ile105Val and GSTP1-Ala114Val allele frequencies  
  
Wild type Mutant Wild type Mutant
Southern Africa
South Africa South African Bantu-speakers 48 (47%) 54 (53%) — — Adams et al., 2003 
South Africa South African Bantu-speakers 203 (62.1%) 124 (37.9%) 283 (86.5%) 44 (13.5%) Li et al., 2010
South Africa South African Bantu-speakers 77 (87.9%) 11 (12.1%) — — Masimirembwa et al., 1998
South Africa South African Bantu-speakers 378 (47.2%) 422 (52.8%) — — Matejcic et al., 2012
South Africa South African Coloured 116 (60.5%) 76 (39.5%) 170 (89%) 21 (11%) Li et al., 2010
South Africa South African Coloured 366 (55.6%) 292 (44.4%) — — Matejcic et al., 2012
    
Eastern Africa     
Zimbabwe Zimbabwean 74 (75.8%) 24 (24.2%) — — Masimirembwa et al., 1998
Tanzania Tanzanian 86 (84.3%) 16 (15.7%) — — Dandara et al., 2002
    
Western Africa     
Ghana Ghanaian 420 (50.2%) 417 (49.8%) — — Yen-Revollo et al., 2009
Nigeria Yoruba 56 (62.2%) 34 (37.8%) — — International HapMap 3 Consortium, 2010
    
Northern Africa     
Tunisia Tunisian 513 (61.7%) 319 (38.3%) 352 (100%) 0 (0%) Lakhdar et al., 2010
    
Europe     
Czech Republic Slavic 36 (69.2%) 16 (30.8%) 53 (91.6%) 5 (8.4%) Gemignani et al., 2007
Czech Republic Slavic 456 (67.8%) 217 (32.2%) — — Šarmanová et al., 2001
Denmark Danish 563 (65.9%) 292 (34.1%) 864 (90.3%) 93 (9.7%) Schwartzbaum et al., 2007
Finland Finnish 199 (67.3%) 97 (32.7%) 305 (90.3%) 33 (9.7%) Schwartzbaum et al., 2007
Hungary Hungarian 74 (68.9%) 33 (31.1%) 106 (91%) 11 (9%) Gemignani et al., 2007
Italy Italian 178 (71%) 73 (29%) 237 (94.6%) 14 (5.4%) Ballerini et al., 2003
Italy Italian 527 (69.4%) 233 (30.6%) — — Canova et al., 2010
Netherlands Dutch 643 (63.5%) 370 (36.5%) 918 (91.4%) 87 (8.6%) Dura et al., 2013
Netherlands Dutch 66 (65.5%) 35 (34.5%) 95 (94.5%) 6 (5.5%) Ketelslegers et al., 2006
Poland Polish 130 (68.9%) 59 (31.1%) 189 (91.2%) 18 (8.8%) Gemignani et al., 2007
Romania Romanian 59 (69%) 27 (31%) 86 (91.3%) 8 (8.7%) Gemignani et al., 2007
Russia Russian 46 (68.9%) 21 (31.1%) 67 (91%) 7 (9%) Gemignani et al., 2007
Slovakia Slovakians 39 (68.8%) 18 (31.2%) 56 (90.9%) 6 (9.1%) Gemignani et al., 2007
Spain Spanish 434 (69.4%) 191 (30.6%) 650 (94.8%) 36 (5.2%) Landi et al., 2005
Spain Spanish 1035 (65.6%) 542 (34.4%) — — Lopez-Cima et al., 2012
Sweden Swedish 582 (65.9%) 302 (34.1%) 893 (90.3%) 96 (9.7%) Schwartzbaum et al., 2007
Turkey Turkish 189 (71.9%) 74 (28.1%) — — Altayli et al., 2009
Turkey Turkish 299 (75.9%) 95 (24.1%) 361 (91.6%) 33 (8.4%) Vural et al., 2012
United Kingdom English 588 (65.9%) 304 (34.1%) 902 (90.3%) 97 (9.7%) Schwartzbaum et al., 2007
    
Asia     
China Chinese 363 (82%) 80 (18%) — — Chen et al., 2007
China Chinese 190 (82.3%) 41 (17.7%) — — Wang et al., 2003
India Indian 187 (69.8%) 81 (30.2%) — — Mittal et al., 2005
India Indian 393 (78.6%) 107 (21.4%) — — Parveen et al., 2010
India Indian 628 (70.1%) 268 (29.9%) 837 (93.5%) 59 (6.5%) Wang et al., 2011
Japan Japanese 714 (84.9%) 127 (15.1%) — — Kiyohara et al., 2012
Taiwan Taiwanese 1077 (82.2%) 233 (17.8%) — — Su et al., 2011
Thailand Thai 777 (73.5%) 280 (26.5%) — — Sangrajrang et al., 2010
    
Middle East     
Iran Iranian 390 (68.2%) 182 (31.8%) — — Hashemi et al., 2012
    
North America     
United States of America African-American 51 (57.4%) 38 (42.6%) — — Olshan et al., 2000
United States of America African-American 80 (58%) 58 (42%) 109 (97.3%) 3 (2.7%) Watson et al., 1998
United States of America Caucasian American 179 (64.6%) 98 (35.4%) — — Olshan et al., 2000
United States of America Caucasian American 193 (67.1%) 95 (32.9%) 103 (91.2%) 10 (8.8%) Watson et al., 1998
Mexico Mexican 198 (51.8%) 184 (48.2%) — — Martínez-Ramírez et al., 2012
    
South America     
Argentina Argentinian 66 (64.7%) 36 (35.3%) — — Galvan et al., 2011
Brazil Brazilian 269 (63.2%) 157 (36.8%) — — Coutino et al., 2010
Brazil Brazilian 112 (73.7%) 40 (26.3%) — — Da Silva et al., 2008
    
Region &                                     
country of sample Population name
GSTP1*Ile105Val                       
rs1695A>G
GSTP1*Ala114Val                       
rs1138272G>A Reference
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H) Comparative data - NAT2*14A allele frequencies  
 
Wild type Mutant
Southern Africa
South Africa South African Bantu-speakers 234 (97.5%) 6 (2.5%) Adams et al., 2003 
South Africa South African Bantu-speakers 171 (89.1%) 21 (10.9%) Dandara et al., 2003
South Africa South African Coloured 162 (95.3%) 8 (4.7%) Adams et al., 2003 
   
Eastern Africa   
Zimbabwe Zimbabwean 281 (86.2%) 45 (13.8%) Dandara et al., 2003
Tanzania Tanzanian 207 (88.5%) 27 (11.5%) Dandara et al., 2003
Tanzania Tanzanian 121 (85.5%) 21 (14.5%) Hodel et al., 2012
Kenya Luhya 163 (91.6%) 15 (8.4%) International HapMap 3 Consortium, 2010
Kenya Maasai 275 (96.2%) 11 (3.8%) International HapMap 3 Consortium, 2010
Ethiopia Ethiopian 54 (100%) 0 (0%) Luca et al., 2008
Somalia Somali 100 (100%) 0 (0%) Bayoumi et al., 1997
Somalia Somali 47 (97.9%) 1 (2.1%) Upton et al., 2001
Sudan Sudanese 264 (97.1%) 8 (2.9%) Bayoumi et al., 1997
   
Central Africa   
Cameroon Baka Pygmies 58 (96.7%) 2 (3.3%) Patin et al., 2006a
Cameroon Bakola Pygmies 76 (95%) 4 (5%) Patin et al., 2006a
Cameroon Bedzan Pygmies 61 (95.3%) 3 (4.7%) Patin et al., 2006b
Cameroon Ngumba Bantus 27 (84.4%) 5 (15.6%) Patin et al., 2006b
Central African Republic Biaka Pygmies 43 (89.6%) 5 (10.4%) Patin et al., 2006b
Democratic Republic of Congo Mbuti Pygmies 37 (77.1%) 11 (22.9%) Patin et al., 2006b
Gabon Gabonese 95 (91.3%) 9 (8.7%) Deloménie  et al., 1996
   
Western Africa   
Ghana Ghanaian 718 (89.8%) 82 (10.3%) Yen-Revollo et al., 2009
Mali Dogons 123 (94.6%) 7 (5.4%) Deloménie  et al., 1996
Nigeria Yoruba 82 (91.1%) 8 (8.9%) International HapMap 3 Consortium, 2010
Senegal Senegalese 95 (90%) 11 (10%) Toure et al., 2012
   
Northern Africa   
Morocco Moroccan 88 (100%) 0 (0%) Upton et al., 2001
   
Europe   
Czech Republic Slavic 2173 (99.9%) 3 (0.1%) Cascorbi et al., 1999
Finland Finnish 96 (100%) 0 (0%) Patin et al., 2006a
France French 120 (100%) 0 (0%) Deloménie et al., 1996
Italy Italian 167 (99.4%) 1 (0.6%) International HapMap 3 Consortium, 2010
Poland Polish 496 (100%) 0 (0%) Mrozikiewicz et al., 1996
Russia Russian 580 (100%) 0 (0%) Gaikovitch et al., 2003
Sardinia Sardinian 98 (100%) 0 (0%) Upton et al., 2001
Siberia Siberian 72 (100%) 0 (0%) Fuselli et al., 2007
Spain Spanish 679 (99.9%) 1 (0.1%) Landi et al., 2005
Sweden Swedish 100 (100%) 0 (0%) Upton et al., 2001
Turkey Turkish 606 (100%) 0 (0%) Aynacioglu et al., 1997
United Kingdom English 224 (100%) 0 (0%) Hein et al., 2002
   
Asia   
Cambodia Cambodian 118 (97.5%) 3 (2.5%) Hodel et al., 2012
China Chinese 424 (100%) 0 (0%) Song et al., 2009
India Indian 122 (100%) 0 (0%) Lin et al., 1994
Indonesia Indonesian 424 (100%) 0 (0%) Yuliwulandari et al., 2007
Japan Japanese 158 (100%) 0 (0%) Lin et al., 1994
Korea Korean 576 (100%) 0 (0%) Lee et al., 2003
Taiwan Taiwanese 200 (100%) 0 (0%) Lin et al., 1994
Thailand Thai 88 (100%) 0 (0%) Patin et al., 2006a
Vietnam Vietnamese 144 (100%) 0 (0%) Cavaco et al., 2007
Republic of the Philippines Filipinos 200 (100%) 0 (0%) Lin et al., 1994
   
Middle East   
Iran Iranian 458 (100%) 0 (0%) Torkaman-Boutorabi 2007
Oman Omani 352 (100%) 0 (0%) Al-Moundhri et al., 2007
Saudi Arabia Saudi Arabian 974 (100%) 0 (0%) Bu et al., 2004
   
North America   
Canada Canadian Caucasian 1815 (99.8%) 3 (0.2%) Anderson et al., 2012
Canada Canadian Indian 962 (100%) 0 (0%) Hegele et al., 2000
United States of America African-American 330 (92.1%) 28 (7.9%) Lin et al., 1994
United States of America Caucasian American 196 (100%) 0 (0%) Lin et al., 1994
Mexico Mexican 32 (100%) 0 (0%) Fuselli et al., 2007
Nicaragua Nicaraguans 273 (99.6%) 1 (0.4%) Martinez et al., 1998
   
South America   
Brazil Brazilian 775 (95.9%) 33 (4.1%) Teixeira et al., 2007
Colombia Colombian 51 (98.1%) 1 (1.9%) Fuselli et al., 2007
Ecuador Ecuadorian 30 (100%) 0 (0%) Fuselli et al., 2007
Peru Peruvian 300 (100%) 0 (0%) Fuselli et al., 2007
Region &                                     
country of sample Population name
NAT2*14A                   
rs1801279G>A Reference
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Appendix C: SNP Marker regions with DNA Sequence, PCR primer and SBE primer sequence 
• PCR fragment sequences: 
- β-Globin 
5’- gaagagccaaggacaggtacGGCTGTCATCACTTAGACCTCACCCTGTGGAGCCACACCCTAGGGTTGGCCAATCTACTCCCAG 
GAGCAGGGAGGGCAGGAGCCAGGGCTGGGCATAAAAGTCAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTGACACAAC
TGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCA
Aggtgaacgtggatgaagtt -3’ 
SBE – POLYGACT + tggtgcatctgactcctgag  
Presence of G allele (CONTROL BAND) 
 
       -     GSTP1 — codon 105 polymorphism (Ile105Val / A to G) 
5’-accccagggctctatgggaaGGACCAGCAGGAGGCAGCCCTGGTGGACATGGTGAATGACGGCGTGGAGGACCTCCGCTGCAA 
ATACGTCTCCCTCATCTACACCAACTATGTGAGCATCTGCACCAGGGTTGGGCACTGGGGGCTGAACAAAGAaaggggcttcttgt
gccctca-3’ 
SBE – POLYGACT + aggacctccgctgcaaatac  
Presence of G allele (mutant) 
                          Presence of A allele (wild-type) 
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       -     GSTP1 — codon 114 polymorphism (Ala114Val / C to T) 
5’-gttgtggggagcaagcagaggAGAATCTGGGACTCTGGTGTCTGGCCTGGGGCAGACGGGGGTGTCTCAGGGGCTGGGAGGGA 
TGAGAGTAGGATGATACATGGTGGTGTCTGGCAGGAGGCGGGCAAGGATGACTATGTGAAGGCACTGCCCGGGCAACTGA
AGCCTTTTGAGACCCTGCTGTCCCAGAACCAgggaggcaagaccttcattgtg-3’ 
SBE (3’ end) – POLYGACT + cttcacatagtcatccttgccc  
Presence of A allele (mutant) 
                                      Presence of G allele (wild-type)  
 
       -     CYP1A1*2A (3’-flanking region) — T to C 
5’-cagtgaagaggtgtagccgcTGCACTTAAGCAGTCTGTTTGAGGGACAAGACTCTATTTTTTGAGACAGGGTCCCCAGGTCATCC 
AGGCTGGAGTGCACTGGTACCATTTTGTTTCACTGTAACCTCCACCTCCTGGGCCCACACGATTCTCCCACCTCAGCCTCTGAG 
TAGTTGGGGCCGCAGGCACACGCCACCACAGCTTTTTTTTTTTTTTTTTTTTTTTTTTGTAGAGATGGGGTTTCACCATGTTGCC
CAGGCTGGTCTCAAACTCGCTCAAGTGATCCACCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAggcatgagacaagactccta-3’ 
SBE – POLYGACT + tgtttcactgtaacctccacctcc  
Presence of C/ A allele (mutant)  
                                      Presence of T allele (wild-type 
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       -     CYP1A1*2C in exon 7 —  A to G 
5’- cagctgtctccctctggttaCAGGAAGCTATGGGTCAACCCATCTGAGTTCCTACCTGAACGGTTTCTCACCCCTGATGGTGCTAT 
CGACAAGGTGTTAAGTGAGAAGGTGATTATCTTTGGCATGGGCAAGCGGAAGTGTATCGGTGAGACCATTGCCCGCTGGga 
ggtctttctcttcctggc -3 
SBE – POLYGACT + ggaagtgtatcggtgagacc 
Presence of G allele (mutant) 
                                      Presence of A allele (wild-type) 
 
     -     CYP1A2*1C site in the 5’ flanking region — G to A 
5’- gctacacatgatcgagctatacATGACATATGCACTTTTCCATTTATTTATTTATTTTTGAGACAGAATCTTGCTCTGTCACCCAGG 
CTGGAGTGCAGTGGTGCGATCTTGGCTCACCGCAACCTCCGCCTCTCAgattcaagcaattgtcatgc-3’ 
SBE – POLYGACT + ccgcaacctccgcctctc  
Presence of A allele (mutant) 
                          Presence of G allele (wild-type) 
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     -     CYP1A2*1F site in intron 1 — C to A 
5’- gatgatgtgtggaggagagaGCCAGCGTTCATGTTGGGAATCTTGAGGCTCCTTTCCAGCTCTCAGATTCTGTGATGCTCAAAG 
GGTGAGCTCTGTGGGCACAGGACGCATGGTAGATGGAGCTTAGTCTTTCTGGTATCCAGCTGGGAGCCAAGCACAGAACAC
GCATCAGTGTTTATCAAATGACTGAGGAAATGAATGAATGaatgtctccatctcaaccct-3’ 
SBE – POLYGACT + aaagggtgagctctgtgggc  
Presence of C allele (wild-type)  
                                      Presence of A allele (mutant) 
 
- CYP2A6*7 (in green) and CYP2A6*8 (in purple) in 3’ flanking region  
5’- ctcaagtcctcccagtcaccTAAGGACACTGACGTGTCCCCCAAACACGTGGGCTTTGCCACGATCCCATAAACTACACCATG 
AGCTTCCTGCCCCGCTGAGCGAGGGCTGTGCCGGTGCAGGTCTGGTGGGCGGGGCCAGGGAAAGGGCAGGGCCAAGACCG
GGCTTGGGAGAGGGGCGCAGCTAAGACTGGGGGCAGGATGGCGGAAAGGAAGGGGCGtggtggctagagggaagaga-3’  
CYP2A6*7 
SBE (3’ end) – POLYGACT + acgtgtttgggggacacgtca 
Presence of A allele (wild-type) 
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                                      Presence of G allele (mutant)  
CYP2A6*8 
SBE (3’ end) – POLYGACT + ggcaggaagctcatggtgtagttt 
Presence of C allele (wild-type) 
                                      Presence of A allele (mutant)  
 
     -   CYP2D6*3A (1bp del (A) in position 2549)  
5’- taggtgctgaatgctgtccCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTCCTACGCTTCCAAAAGGCTTTCCTGACCCA 
GCTGGATGAGCTGCTAACTGAGCACAGGATGACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGgcag
agatggagaaggtgag -3’ 
SBE – POLYGACT + gatgagctgctaactgagcac 
Presence of A allele (wild-type) 
Presence of G allele (mutant) 
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-   CYP2D6*4A (1846G>A)   
5’- gtgggtgatgggcagaagGGCACAAAGCGGGAACTGGGAAGGCGGGGGACGGGGAAGGCGACCCCTTACCCGCATCTCCC 
ACCCCCAGGACGCCCCTTTCGCCCcaacggtctcttggacaaag-3’ 
SBE – POLYGACT + ccgcatctcccaccccca 
Presence of G allele (wild-type) 
Presence of A allele (mutant) 
      
- CYP2E1*5B(PstI) 
5’- cactggaaaggaaagagaggAGGAGGCGGCAGGCTAACCCACCCGTGAGCCAGTCGAGTCTACATTGTCAGTTCTCACCTCG 
AGGGGTGCCAAAAACCAGAGGGAAGCAAAGGCCCCTGAAGCCTCTGCCAGAGCCAACGCCCCTTCTTGGTTCAGGAGAGGT
GCAGTGTTAGGTGCAGCACAACcaatgacttgcttatgtggc-3’  
SBE – POLYGACT + cccttcttggttcaggagag  
Presence of G allele (wild-type) 
                                      Presence of C allele (mutant) 
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- CYP2E1*5B(RsaI) 
5’- aagtgatttggctggattgtAAATGACTTTTATTTTCTTCATTTCTCATCATATTTTCTATTATACATAAAGATTCATTGTTAATA 
TAAAAGTACAAAATTGCAACCTATGAATTAAGAACTTCTATATATTGCCAGTTAGAAGACAGAATGAAAAACATTCTCTTCAT
TCTAACCACACACACAAAAAAGCTCCACAAAATACCTATGGACTACCTtcatagaaggtggaagaggg– 3’ 
SBE (3’ end) – POLYGACT + gttcttaattcataggttgcaatttt 
Presence of G allele (wild-type) 
                                      Presence of A allele (mutant) 
 
- NAT2*14A (G to A transition at position 191)  
5’- ttaggggatcatggacattgAAGCATATTTTGAAAGAATTGGCTATAAGAACTCTAGGAACAAATTGGACTTGGAAACATTAAC 
TGACATTCTTGAGCACCAGATCCGGGCTGTTCCCTTTGAGAACCTTAACATGCATTGTGGGCAAGCCATGGAGTTGGGCTTA
GAGGCTATTTTTGATCACATTGTAAGAAGAAACCGGGGTGG gtggtgtctccaggtcaatc-3’ 
SBE – POLYGACT + tgatcacattgtaagaagaaacc 
Presence of G allele (wild-type) 
Presence of A allele (mutant) 
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Appendix D: Pair-wise genetic distance (Fst) for indigenous populations 
CAR_U CAR_P DAMA DRC HER HIM JU KHWE MOZ NAMA OVA SAC SEB UGA XUN ZAM
CAR_U 0.0000
CAR_P 0.0288 0.0000
DAMA 0.0294 0.1217 0.0000
DRC 0.0063 0.0537 0.0464 0.0000
HER 0.0134 0.0330 0.0276 0.0347 0.0000
HIM 0.0056 0.0530 0.0124 0.0234 0.0056 0.0000
JU 0.0630 0.0974 0.0878 0.0714 0.0313 0.0842 0.0000
KHWE 0.0119 0.0346 0.0236 0.0310 0.0000 0.0114 0.0165 0.0000
MOZ 0.0020 0.0499 0.0093 0.0195 0.0075 0.0000 0.0830 0.0109 0.0000
NAMA 0.0450 0.0736 0.0752 0.0693 0.0139 0.0501 0.0272 0.0164 0.0489 0.0000
OVA 0.0047 0.0426 0.0137 0.0259 0.0042 0.0000 0.0808 0.0087 0.0000 0.0431 0.0000
SAC 0.0111 0.0123 0.0543 0.0288 0.0069 0.0209 0.0424 0.0074 0.0173 0.0156 0.0159 0.0000
SEB 0.0109 0.0398 0.0204 0.0336 0.0000 0.0025 0.0369 0.0000 0.0034 0.0106 0.0009 0.0072 0.0000
UGA 0.0124 0.0736 0.0140 0.0311 0.0261 0.0018 0.1121 0.0313 0.0000 0.0573 0.0019 0.0337 0.0172 0.0000
XUN 0.0697 0.0980 0.0807 0.0799 0.0319 0.0774 0.0000 0.0182 0.0809 0.0502 0.0776 0.0555 0.0404 0.1177 0.0000
ZAM 0.0058 0.0297 0.0254 0.0246 0.0080 0.0000 0.0796 0.0114 0.0000 0.0539 0.0000 0.0176 0.0078 0.0125 0.0742 0.0000
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